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Aim: To establish an in vitro human corneal decompensation model and to use it for the 
evaluation of a cell-therapy approach for treating corneal endothelial (CE) disorders and to 
test the expression profile of positive regulatory domain proteins (PRDMs) as potential 
markers for corneal endothelial cells (CECs). 
Materials and Methods: Human cadaveric corneas were obtained from Bristol and 
Manchester Eye Banks, UK. A CE decompensation model was established by removal of 
the Descemet’s membrane (DM)/Endothelium complex from donor corneas and placing 
them in air-interface organ culture. The corneal thickness was used as a surrogate measure 
of CE function and was measured using Optical Coherence Tomography (OCT). 
Decompensated corneas were subjected to cultured endothelial cell therapy using 
immortalized HCEC -12 cells (group 1), primary human corneal endothelial cells (hCECs) 
at 0 passage (group 2) and hCECs at passage 2 (group 3) with defined seeding cell density. 
The effect on stromal de-swelling in cell therapy treated corneas was assessed 3, 7 and 10 
days post-transplantation followed by histological evaluation. In addition, expression of 
PRDM genes in the corneal endothelium was undertaken using reverse transcriptase 
polymerase chain reaction (RT-PCR), immunocytochemistry and immunohistochemistry. 
Results: Organ culture of human cadaveric corneas in air-interface following the selective 
removal of the DM/Endothelium complex resulted in stromal thickness of 903.6 ± 86.51 
μm, whereas normal corneas maintained a physiological thickness of 557.51 ± 72.64 μm. 
When transplanted directly onto the posterior corneal stroma the human CECs were able to 
attach and achieved physiological corneal thickness of 458.91 ± 90.07 μm, 489.65 ± 94.62 
μm and 613.7 ± 94.62 μm for cell therapy groups -1, -2 and -3 respectively. The study 
identified PRDMs 1, 2, 4, 5 and 10 in the human CE and revealed a differential expression 
between normal CE and cultured hCECs.  
Conclusion: Removal of the DM/Endothelium complex from cadaveric human corneas held 
in air interface organ culture resulted in corneal endothelial decompensation. Direct 
transplantation of cultured primary hCECs to bare posterior corneal stroma devoid of DM 
resulted in the formation of an endothelial monolayer and restoration of stromal hydration to 
physiological thickness, substantiating the role of cell therapy to treat corneal endothelial 
disorders. The identification of PRDM proteins in the human corneal endothelium paves the 
way for future studies to understand their role in hCEC proliferation control. 
Key words: Corneal endothelium – Human corneal endothelial cell culture – Corneal 
endothelial cell transplantation, PRDM proteins. 
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1. CHAPTER 1 – INTRODUCTION 
1.1. Chapter overview 
This chapter is an introduction to the corneal endothelium (CE), its function, 
pathological conditions that affect it, the current treatment methods used to manage 
such conditions, their limitations and research background of the development of a 
cell-therapy approach as a novel treatment method for corneal endothelial 
decompensation. It also includes current research advances in corneal endothelial 
cell culture and transplantation testing, and discusses some of the limiting factors in 
the development of a cell therapy approach. An outline of the aims of this study is 
presented at the end of this chapter. 
1.2. The human corneal endothelium 
The human cornea is the anterior-most part of the eye and being at the forefront of 
the visual apparatus, it is optically transparent and permeable to light. The cornea 
has five main layers: the epithelium, the Bowman’s layer, the corneal stroma, the 
Descemet’s membrane (DM) and the corneal endothelium (CE). The CE is a 
monolayer of cells located on the posterior side of the cornea, which separates the 
corneal stroma from the aqueous humour, and has a barrier and pump function, 
regulating stromal hydration (See Figure 1).  
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Figure 1 – The cornea is the front part of the eye and consists of five layers: (1) 
epithelium - the outer-most layer of the cornea that has a protective function; 
(2) Bowman’s layer - serves as a basement membrane or a scaffold for the 
corneal epithelium; (3) the stroma - the largest corneal layer, responsible for 
the mechanical robustness of the cornea; (4) the Descemet’s membrane (DM) - 
serves as a scaffold for the corneal endothelium; (5) the corneal endothelium 
(CE), which acts as a barrier and controls the fluid transport between the 
stroma and the aqueous humour, and keeps the cornea transparent by 
regulating the stromal hydration. 
1.2.1. Pre-natal and post-natal development of the human corneal endothelium 
and of the Descemet’s membrane 
During human embryonic development the CE originates from the neural crest, 
which itself is derived from the neural tube, mesoderm and surface ectoderm 
(Hayashi, et al., 1986). Prior to the 8th week of gestation mesenchymal cells are 
loosely arranged on the posterior surface of the cornea but by the end of the 8th week 
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they start forming a monolayer and the anterior banded layer of the DM is already in 
place, and by the 5th month of gestation it significantly increases in thickness and 
consists of multi-layered collagen lamellae, which by the 8th month of gestation 
become more compact (Wulle, 1972). The fluid transport mechanism of the CE also 
develops during the embryonic stage with gap junctions already in place by the 16th 
gestation week, and it becomes fully functional by the 20th gestation week (Wulle, 
1972). The DM is comprised of two layers: during its embryological development 
the CE secretes and deposits collagen type VIII on the posterior surface of the 
cornea and that forms the anterior banded layer, while the posterior non-banded 
layer starts to appear after birth and is composed of collagen type IV (Marshall, et 
al., 1993). The anterior banded layer could have up to 30-40 layers and has a 
thickness of about 3.5 μm at birth, but as the posterior non-banded layer appears and 
grows after birth, the DM size could reach about 12.5 μm by 60 years of age 
(Murphy et al., 1984b). Corneal endothelial cells (CECs) have the capacity to secrete 
collagen type IV (Kay, 1989) and the thickness increase of the posterior non-banded 
layer throughout the lifetime of the individual suggests that the CECs continuously 
secrete and deposit collagen type IV to form their basement membrane. 
The CECs have a hexagonal shape and the structural arrangement of the collagen 
type IV in the posterior non-banded layer of the Descemet’s membrane forms a 
hexagonal lattice (Jakus, 1956) [See Figure 2]. This hexagonal lattice acts as a 
scaffold for the corneal endothelial cells and plays a crucial role in the maintenance 
of corneal transparency (Hassell and Birk, 2010). There appears to be a strong 
correlation between the DM and the corneal endothelial cell morphology and they 
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seem to influence each other. For example, Park Kay, et al., (1985) showed that 
under the influence of polymorphonuclear leukocytes CECs change their 
morphology to a fibroblastic phenotype and start secreting collagen type I instead of 
collagen type IV which is responsible for abnormal collagen deposition on the DM 
(Kay, et al., 1982). On the other hand, it has been demonstrated that the presence of 
an intact DM supports CEC regeneration after wounding and stimulates the 
expression of a hexagonal morphology compared to when the DM has been peeled 
(Chen, et al., 2017a and Soh, et al., 2016, Bhogal, et al., 2017). Interestingly, 
Hanson, et al., (2017) found that the DM was able to support the differentiation of 
human embryonic stem cells into corneal endothelial-like cells in vitro that 
expressed Na+/K+ ATPase and ZO-1. Very new findings have revealed very 
interesting insights about the CEC morphology. It appears that the shape of the 
CECs is different on their apical side facing that aqueous humour in comparison 
with their basolateral side facing the DM. It has been demonstrated (Hirsch, et al., 
1977) and recently confirmed (Harrison, et al., 2016 and Chen, et al., 2017b) that the 
basolateral side facing the DM has an elaborate multipolar shape whereas the 
traditional hexagonal shape is only present on the apical surface facing the aqueous 
humour. These novel discoveries in the shape and morphology of the CE will give 
new insights in understanding how the CE performs its physiological function and 
how it interacts with the DM.  
All these findings taken together seem to point that the CECs are responsible for the 
secretion and deposition of the DM all the way from the embryonic development up 
to adulthood, but the DM is also influencing the CEC morphology, migration, 
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regenerative capacity and differentiation of the CECs. Ali, et al., (2016) described 
such a bidirectional relationship between the CECs and the DM and how they affect 
each other in health and disease. 
 
Figure 2 – Morphology of the human corneal endothelial cells [phase-contrast 
microscopy: x400] (A). The spatial arrangement of collagen type IV in the 
posterior non-banded layer of the Descemet’s membrane resembles a hexagonal 
lattice, which is secreted by the corneal endothelial cells after birth and serves 
as an anchorage substrate [Graphical representation] (B). 
The human corneal endothelial cells (hCECs) are hexagonal and have a cell density 
of 3,400 to 5,632 cells/mm2 in 6 days to 11 months old infants, 2,658 to 3,638 
cells/mm2 in 4-12 years old children, 1,962 cells/mm2 in a 31-year-old man and 
1,864 cells/mm2 in a 67-year old man (Sherrard, et al., 1987). Capella and Kaufman 
(1969) found that in infant (0-2.5 years), child (3-15 years), adult (15-65 years) and 
aged (65+) groups the surface area of the cornea and the cell area are increasing in 
children, suggesting that the endothelial cell count decrease during childhood is 
possibly due to the growth of the cornea. This notion has been confirmed in recent 
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years (Elbaz, et al., 2017). However, there is also some evidence that the CE cell 
number is decreasing with age from the embryonic stage throughout adulthood due 
to cell loss independently from the growth in size of the cornea (Murphy, et al, 
1984a). 
1.2.2. Corneal hydration control 
1.2.2.1.CE function: the pump-leak mechanism 
Theodor Leber in 1873 first demonstrated that the corneal endothelium controls the 
flow of fluid into the corneal stroma (Stocker and Reichle, 1974). Later studies on 
the corneal hydration control confirmed that the corneal endothelium plays the most 
significant role in the corneal swelling and the control of corneal hydration (Maurice 
and Giardini, 1951). It has been experimentally demonstrated that the CE resists the 
uptake of fluid into the stroma through an active-transport mechanism, which is 
highly dependent on the presence of oxygen (Davson, 1955). Mishima and Kudo, 
(1967) confirmed that the primary site of active transport is in the endothelium and 
later it was shown that it is capable of pumping fluid against a head of pressure 
(Maurice, 1972). In another study it was shown that corneal thickness could be 
reversed to normal in the presence of adenosine and glutathione and this was 
dependent on sodium, bicarbonate and oxygen, which suggests that the active pump 
function of the CE is performed by an adenosine triphosphatase (ATPase) (Dikstein 
and Maurice, 1972). A later study confirmed the importance of the Na+/K+ ATPase 
for the pump function in human corneas (Geroski, et al., 1984). It is now generally 
accepted that the CE has an active ion transport activity and regulates the fluid 
exchange between the corneal stroma and the aqueous humour, controlling the 
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stromal hydration and corneal transparency (Bourne, 2003). Under normal 
physiological conditions the human cornea is maintained in a dehydrated state and 
has a thickness of about 523 ± 39 μm (Martola and Baum, 1968). The pump and 
barrier function of the CE are highly dependent on the presence of calcium ions 
(Ca2+) and this barrier can be disrupted by perfusion with Ca2+- free medium, 
keeping the corneas completely immersed in medium (Eye Bank storage conditions) 
or perfusion of the cornea at a high pressure (Kaye, et al., 1968 and 1973). 
The mechanism of fluid transport regulation is termed the pump-leak mechanism. 
Ion transport exists both on the apical and on the basal side of the CE. The corneal 
endothelial cells express a number of voltage-gated ion channels, such as Na+ 
channels, K+ channels, Cl- channels and Ca2+ channels in addition to calcium-
permeable transient receptor potential channels (Mergler and Pleyer, 2007). They 
also express Cl-/HCO-3 exchangers, Na
+/H+ exchangers, Na+/K+/2Cl- co-transporters, 
Na+/K+ ATPase active pumps (Srinivas, 2010) and aquaporins (Bonanno, 2012). 
Through these ion transport proteins the CE is able to generate an ion flux that 
drives the fluid transport from the stroma towards the aqueous humour and nutrients 
from the aqueous humour to the stroma and epithelium. The Na+/K+ ATPase is 
responsible for the active ion exchange of 3Na+ outwards from the cells and 2K+ ions 
inwards and is crucial for normal CE function. It creates an ion flux, which 
facilitates water movement across the cell membrane through the CE (Bonanno, 
2012) and counterbalances the fluid leak, which occurs from the aqueous humour 
towards the stroma as a result of the stromal swelling pressure (Srinivas, 2010) (See 
Figure 3). 
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Figure 3 – The pump-leak mechanism of fluid transport through the corneal endothelium (CE): the swelling pressure of the 
stroma draws fluid from the aqueous humour into the stroma. The CE creates a flux of actively transported ions and the 
movement of fluid follows the flux of the actively transported ions (A), corneal endothelium ion channels, exchangers, co-
transporters and active ion pumps - basal (facing towards the stroma), facing towards the corneal stroma, and apical (facing 
towards the aqueous), facing towards the aqueous humor (B). 
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1.2.2.2.Stromal swelling pressure  
The stromal swelling pressure drives the fluid leak that occurs from the direction of 
the aqueous humour towards the stroma.  The stromal swelling pressure is the 
tendency of the stroma to swell as a result of its mechanical composition and is 
affected by the concentration of proteoglycans (Fischbarg and Maurice, 2004), 
which play an important role in corneal transparency (Massoudi, et al., 2016). 
Therefore, in the absence of a functional CE the stroma would swell as a result of 
the stromal swelling pressure, which equates to 60 mm Hg (Tuft and Coster, 1990). 
However, since the corneal stroma is sandwiched between the epithelium and 
endothelium, a negative fluid pressure is created through the active ion transport that 
counteracts the stromal swelling pressure and causes the corneal thickness to 
decrease (Dohlman, et al., 1962). 
1.2.2.3.Corneal endothelial permeability 
The corneal endothelial cells express a number of intercellular junctions, such as 
tight junctions, adherens junctions, gap junctions, ion transporter proteins and water 
channels (aquaporins) that enable them to perform their physiological fluid transport 
function. The intercellular junctions are responsible for mediating cell adhesion, 
cell-cell communication, and barrier function, and also have a role in the control of 
proliferation (Zhu, et al., 2008; Zhu, et al., 2012). 
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1.2.2.3.1.Tight junctions and adherens junctions 
Tight junctions (TJs) are connections between the corneal endothelial cells at the 
apical side and seal the spaces between each individual cell, thus blocking the free 
flow of fluid. This creates a barrier between the aqueous humour and the stroma and 
permits the CE to tightly control stromal hydration. The tight junctions are 
composed of zona occludens-1 (ZO-1), occludins and claudins (Anderson and Itallie, 
1995). ZO-1 is an intracellular protein that binds to actin and anchors the 
cytoplasmic components of the claudins and occludins to the cell cytoskeleton. The 
claudins and occludins have one cytoplasmic component, four trans-membrane 
domains and two extracellular loops. The extracellular loops form connections with 
the claudins and occludins of adjacent cells. Another type of intercellular junction 
that plays an important role in maintaining the physiological function of the CE is 
the adherens junction (AJs), which is composed of catenins and cadherins. 
Catenins and cadherins act in forming cell-cell adherens junctions by interacting 
with actin filaments. Cadherins are responsible for Ca2+ dependent cell adhesion and 
cell proliferation and come in several different types that are expressed by the 
human corneal endothelium in vivo, such as neuronal cadherins (N-cadherins), 
epithelial cadherins (E-cadherins), vascular endothelial cadherins (VE-cadherins), 
and placental cadherins (P-cadherins) [Zhu, et al., 2008]. Cadherins have a 
cytoplasmic component, a trans-membrane component and an extracellular 
component and in the presence of Ca2+ they bind to the extracellular component of 
the cadherins expressed by adjacent cells and form cell-cell connections. The human 
CE also expresses α-, β-, γ-, p120- and p190-catenins. α-Catenin is a cytoplasmic 
 11 
protein, which binds to actin and to β-catenin. β-Catenin and p120 bind to the 
cytoplasmic component of the cadherins. α- and p190-catenins have actin 
cytoskeleton remodeling function, β- and γ-catenin control Wnt signaling and p120-
catenin plays a role in cell-cell adhesion (Zhu, et al., 2008). 
1.2.2.3.2.Gap junctions 
Gap junctions are clusters of intercellular channels composed of connexin proteins 
that allow the direct connection of the cytoplasm of two cells, thus enabling cell-cell 
transfer of ions and small molecules, such as cyclic adenosine monophosphate 
(cAMP) and calcium (Ca2+) ions, between cells and participate in intercellular 
signaling (Keven Williams and Watsky, 2002). A type of transmembrane protein 
called connexin, which forms hexamers or connexons, forms the gap junctions. 
Two connexons assemble together to form an intercellular channel 
(Goodenough and Paul, 2009).  
1.3. Corneal endothelial disorders leading to corneal endothelial cell 
decompensation 
The corneal endothelium and its clinical implications have been of interest for a long 
time especially with regards to corneal endothelial degeneration that leads to corneal 
opacity (Stocker, 1953). The human corneal endothelial cells are generally 
considered post-mitotic and are not capable of replacing damaged or lost cells via 
mitosis. Normally humans have enough corneal endothelial cells to last for a lifetime 
but sometimes CE decompensation might arise due to some factors, such as: 
 12 
• Previous surgeries, such as cataract surgery that can lead to iatrogenic 
damage the CE. 
• Fuchs’ corneal endothelial dystrophy (FCED) and posterior polymorphous 
corneal dystrophy (PPCD), both of which can be inherited (Klintworth, 
2009). 
• Iridocorneal endothelial syndrome (ICE). 
• Viral infections, such as herpes simplex infections that affect the cornea. 
• Injury, such as mechanical injury to the cornea or to the endothelium. 
• Raised intraocular pressure as a result of glaucoma or other ocular disease. 
The progression of Fuchs’ dystrophy is characterized by the appearance of guttae on 
the posterior side of the Descemet’s membrane due to abnormal collagen deposition 
and by corneal endothelial cell degeneration resulting in loss of barrier and pump 
function and leading to corneal opacity and blindness. Abnormal collage deposition 
on the posterior side of the DM usually occurs post-grafting, post-disease or could 
be post traumatic (Sherrard and Rycroft, 1967a) and is very likely to occur if the 
corneal endothelium gets damaged (Sherrard and Rycroft, 1967b). In ICE and PPCD 
extensive damage to the corneal endothelial cells can be observed (Laganowski, et 
al., 1991). As a result of CE decompensation the cornea may become swollen and 
oedematous, which leads to corneal blindness. The barrier and pump function of the 
CE can still be maintained after some degree of cell loss by an increase in cell size 
(Zavala, et al., 2013). The critical cell density, below which the physiological 
function of the corneal endothelium starts to fail, is 300-500 cells/mm2, which 
results in corneal decompensation and corneal opacity (Tuft and Coster, 1990), 
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leading to corneal blindness. Corneal endothelial decompensation affects the corneal 
endothelial cell morphology and triggers abnormal changes in cell size and shape, 
such as pleomorphism (cell shape variation) and polymegethism (cell size variation). 
Loss of normal corneal endothelial cell function is usually preceded by abnormal 
morphological changes and a reduction in cell number in the CE monolayer. In 
addition to gradual corneal endothelial cell loss, DM thickening also occurs as a 
result of CE decompensation caused, for example, by Fuchs’ dystrophy. Corneal 
endothelial decompensation may arise from trauma or injury to the CE but also some 
genetic mutations have been associated with the development of Fuchs’ dystrophy, 
including mutations in genes such as SLC4A11 (Sodium-mediated transporter, 
Solute carrier family 4, sodium borate co-transporter, member 11), TGFBI 
(Transforming growth factor, beta-induced, 68kDa), and COL8A2 (Collagen, type 
VIII, alpha 2) (Iliff, et al., 2012; Gottsch, et al., 2005a and 2005b).  Thickening of 
the DM and guttae formation as a result of abnormal collagen deposition are caused 
by Fuchs’ dystrophy. However, an additional retrocorneal fibrous membrane 
(RCFM) on the posterior side of the DM may appear as a result of damage to the CE 
due to previous eye surgery (Jakobiec and Bhat 2010). In this case of abnormal 
collagen deposition, the DM itself seems to maintain normal integrity and normal 
thickness; however, a new collagenous layer, which closely resembles the corneal 
stroma in its structure but is much thicker than the DM, appears. Corneal endothelial 
cells that are isolated from RCFM and cultured in vitro have a spindle-shaped 
morphology and secrete collagen type I instead of collagen type IV (Kay, et al., 
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1982; Park Kay, et al., 1985; Kay, 1989). The secretion of collagen type I may cause 
the formation of a RCFM (Leung, et al., 2000). 
1.4. In vivo proliferative capacity of the human corneal endothelium 
The human CE is generally considered post-mitotic and unable to heal itself through 
proliferation. However, CE proliferation in vivo does not keep pace with cell loss 
even though growth factors are present in the aqueous humour and on the DM, such 
as fibroblast growth factor-2 (FGF-2), insulin-like growth factor (IGF), and 
hepatocyte growth factor (HGF) (Araki-Sasaki, et al., 1977; Joyce, 2003). This 
unresponsiveness of the CE to growth factors could be attributed to the effect of 
transforming growth factor-β2 (TGF-β2) present in the aqueous humour, which has 
been shown to suppress CE proliferation (Chen, et al., 1999) and also inhibits FGF-
2-induced corneal endothelial cell proliferation (Lu, et al., 2006). Wound repair in 
the CE occurs by cell enlargement and migration rather than cell proliferation. 
Hence treatment of corneal endothelial disorders relies on a corneal transplant. 
1.5. Current methods for treating corneal endothelial disorders 
The Australian Corneal Graft Registry Report 2015 shows that penetrating 
keratoplasty is the most common technique for treating corneal endothelial 
disorders, which also shows the highest success rate for transplant survival 
(Williams, et al., 2015). However, currently Descemet’s Stripping Automated 
Endothelial Keratoplasty (DSAEK) is the preferred method for treating corneal 
endothelial disorders since it is less invasive. Some other techniques have emerged 
such as as micro-thin DSAEK that allows the use of a thinner graft (Thomas, et al., 
2013; Melles, et al., 2002) and Descemet’s Membrane Endothelial Keratoplasty 
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(DMEK). These procedures are generally very efficient at restoring normal vision 
and show very good long-term results (Rajan, 2014). However, all these treatment 
methods are completely reliant on availability of donor tissue. Due to the donor 
shortage, which limits the treatment of corneal blindness especially in some parts of 
the world, a novel approach needs to be developed that could potentially eliminate 
the need for donor tissue. As a result a cell-based therapy approach has been actively 
researched as an alternative new treatment. Some non-transplant requiring treatment 
methods have emerged recently, such as the use of ROCK inhibitor eye drops 
(Okumura, et al., 2017). More recently, however, some researchers are challenging 
the notion about the in vivo capacity of the CE to regenerate itself and have proposed 
a non-transplant requiring treatment that only involves surgically removing the 
diseased central CE and DM and allowing the peripheral CE to renew and regenerate 
the central part that was removed (Van, et al., 2017). 
1.6. Cell-based therapy approach as a novel treatment for corneal 
endothelial disorders 
The use of cultured corneal endothelial cells for transplantation has been explored as 
early as the1970s and has been shown to be a promising method for restoring normal 
CE function (Jumblatt, et al., 1978; Gospodarowicz, et al., 1979 and Jumblatt, et al., 
1980). However, the clinical application of this technique is limited by the cell 
source and culture of the cells for provision of cells and the transplantation 
technique (Maurice, et al., 1981). A number of research groups in recent years have 
worked towards developing a cell-based treatment method that involves isolating 
and culturing hCECs in vitro and using them for cell transplantation and treatment of 
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CE disorders (Engelmann, et al., 1999 and Böhnke, et al., 1999, Aboalchamat, et al., 
1999, Chen, et al., 2001, Mimura, et al, 2004a, Sumide, et al, 2006, Koizumi, et al., 
2007, Patel, et al., 2009, Joyce, et al., 2012, Levis, et al, 2012, Ju, et al, 2012, Zhang, 
et al., 2014, Okumura, et al., 2014a, Bostan, et al., 2016, Yamaguchi, et al., 2016, 
Okumura, et al., 2016). This new treatment method has several advantages over the 
current treatment methods. For example, it is not limited by donor availability and 
could potentially be less invasive. 
There are a number of factors that are currently hindering the development of cell 
therapy, which include the lack of an established protocol for long-term in vitro 
culture and expansion of hCECs, and suitable experimental models for testing CE 
transplantation in human corneas. It has been shown that hCECs can enter the cell 
cycle when cultured in vitro using optimized culture environment consisting of 
culture media supplemented with growth promoting supplements, such as foetal 
bovine serum (FBS), and growth factors (Joyce, et al., 2003). The main aspects of 
cell therapy development that current research is mainly focused on include: 
• Testing and establishing a protocol for effective CE cultivation. 
• Establishing suitable experimental models for testing CE transplantation. 
• Optimizing CE transplantation techniques with translational value to future 
clinical trials. 
1.6.1. Human corneal endothelial cell culture as a source for cell-based 
therapy 
Isolation and culture of primary hCECs is considered to be the primary cell source 
for cell transplantation and cell therapy use, and therefore a lot of focus has been put 
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into developing an efficient method for successful hCEC isolation and culture in 
current literature.  
1.6.1.1.Human corneal endothelial cell isolation 
1.6.1.1.1.Enzymatic dissociation  
A number of different enzymes, such as trypsin/EDTA, dispase and collagenase 
(Engelmann, et al., 1988; Chen, et al., 2001; Ishino, et al., 2004; Li, et al., 2007; Peh, 
et al., 2011; Choi, et al., 2014), have been used by researchers and compared for 
their effectiveness in isolating hCECs from human corneas. And the authors have 
concluded that collagenase shows the best results followed by trypsin/EDTA, 
therefore these two will be considered as methods of choice for primary hCEC 
isolation in this study. 
1.6.1.1.1.1.From whole corneas without peeling the Descemet’s membrane 
Engelmann, et al. (1988) reported that the most effective way for isolating the 
corneal endothelial cells from whole corneas is by first exposing the cells to a high 
concentration of collagenase (0.5 %) for 90 min followed by exposure to a low 
collagenase concentration (0.04 %) for an additional 1020 min (17 hours) but this 
method seemed to produce contamination with other corneal cell types, such as 
stromal keratocytes. 
1.6.1.1.1.2.Peel-and-digest method  
More recently researchers have used the so called peel-and–digest method for hCEC 
isolation, which involves peeling the Descemet’s membrane/Endothelium complex 
first, then isolating the cells by enzymatic dissociation (Li, et al., 2007; Ishino, et al., 
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2004; Chen, et al., 2001; Peh, et al., 2011). Peh, et al. (2013) suggested that the 
initial seeding density is a very important factor for successful culture and sub-
culture of hCECs, and indicated that a seeding density of 10,000 cells/cm2 yields 
best results for initiating primary hCEC cultures when using the peel-and-digest 
method.  
1.6.1.1.2.Primary explant culture 
Primary explant culture has also been utilized for hCEC isolation and culture by 
Choi, et al. (2014) and Walshe and Harkin (2014) reported that serial explant culture 
might be a suitable method for isolating corneal endothelial progenitor cells, 
consequently it could be used for isolation of corneal endothelial progenitor cells. 
1.6.2. Proliferative capacity of cultured human corneal endothelial cells 
Corneal endothelial cells are arrested in Gap 1 (G1) phase of the cell cycle and, 
therefore, do not replicate in vivo (Joyce, et al., 1996). This is due to contact 
inhibition, lack of effective growth factor stimulation and TGF-β2 suppression of S-
phase entry (Joyce, 2012). Both TGF-β and contact inhibition mediate their effect 
through the action of cyclin-dependent kinase inhibitors p15, p16, p18, p19, p21 and 
p27 and lead to the degradation of cyclin D and cyclin E thus preventing the cell to 
progress to S phase of the cell cycle [See Figure 4].  
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Figure 4 – The human corneal endothelial cells are arrested in Gap 1 (G1) 
phase through the action of transforming growth factor-β (TGF-β) present in 
the aqueous humour and also as a result of cell-cell contact, which causes 
contact inhibition. TGF-β causes replicative senescence through cyclin-
dependent kinase inhibitors p16 and p21, which in turn inhibit cyclin 
dependent kinase 2 and 4 (CDK2 and 4) and trigger cyclin D and cyclin E 
degradation. Contact inhibition has a similar effect and causes CDK2 inhibition 
via p21 and p27 resulting in cyclin E degradation. This causes human corneal 
endothelial cells to be unable to complete the cell cycle and progress to the 
synthesis phase (S-phase) in which DNA is replicated.  
Joyce and Harris (2010) also demonstrated that p16 and p21 participate in the 
negative regulation of the cell cycle in cultured human corneal endothelial cells and 
cause senescence in culture. However, research shows that when using optimized 
culture conditions, corneal endothelial cells can be stimulated to proliferate in 
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culture to some extent (Joyce and Zhu, 2004). A number of growth factors and 
culture media supplements have been used for hCEC culture such as: 
• Fibroblast growth factor-2 (FGF-2) – 10, 12.5, 200 ng/ml (Rieck, et al., 
1995; Nayak and Binder, 1984; Senoo and Joyce, 2000a) 
• Epidermal growth factor (EGF) - 6.25 - 50 ng/ml (Nayak and Binder, 1984; 
Engelmann and Friedl, 1989; Senoo and Joyce, 2000a) 
• Endothelial cell growth supplement (ECGS) – 25 ng/ml, 12.5 μg/ml (Nayak 
and Binder, 1984; Engelmann and Friedl, 1989) 
• Transforming growth factor-β1 (TGF-β1) – 1 ng/ml (Rieck, et al., 1995) 
• TGF- β1 + FGF-2  (Rieck, et al, 1995) 
• Chondroitin sulfate (13.5 – 25 mg/ml) (Yue, et al., 1989) 
• Foetal bovine serum (FBS) (Engelmann and Friedl, 1989; Senoo and Joyce, 
2000a) 
• High-calcium (Li, et al., 2007) 
• L-Ascorbic acid 2-phosphate (Shima, et al., 2011) 
• Hepatocyte growth factor (HGF) (Shima, et al., 2011) 
• Laminin-5 (Yamaguchi, et al., 2011) 
Engelmann and Friedl (1989) performed clonal growth assays using cells (passages 
3 – 9) isolated from a 48-year-old donor cornea and (passages 6 – 10) from a 30-
year-old donor cornea. In the same study the researchers tested the effect of a 
number of culture medium supplements and mitogens on hCEC proliferation such 
as: FBS, human serum, platelet-derived growth factor (PDGF), epidermal growth 
factor (EGF), endothelial cell growth supplement (ECGS), nerve growth factor 
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(NGF), TGF-β and FGF-2. Out of all these they found that human serum and FBS 
gave the best results. Joyce and Zhu (2004) also reported that EGF had a stimulatory 
effect on hCEC proliferation, although NGF did not have any effect. Senoo and 
Joyce (2000a) reported that and ethylenediaminetetraacetic acid (EDTA) had a 
stimulatory effect on proliferation as well as FGF-2 (Joyce, 2003), however, FGF-2 
seems to be also capable of causing a morphological change to a spindle-shaped 
morphology in CECs (Gu, et al., 1996), whereas TGF-β had only a negative effect 
on proliferation (Chen, et al., 1999). Therefore, based on the above-mentioned 
studies FBS or human serum will be used as an essential culture medium supplement 
for hCEC culture based on availability. 
1.6.3. Human corneal endothelial cell culture conditions 
Optimized culture conditions are another very important aspect of primary hCEC 
culture. Basal culture media that are most commonly used include MEM (Blake, et 
al., 1997), DMEM (Ishino, et al., 2004), F99 (Ham’s F12/Medium 199 in a 1:1 ratio) 
(Engelmann and Friedl, 1989), Opti-MEM-I (Joyce and Zhu, 2004), SHEM (Li, et 
al., 2007), EGM-2 (Choi, et al., 2010) supplemented with foetal bovine serum, 
growth factors and various culture media supplements (See Table 1).  
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Table 1 - Media used for culture of corneal endothelial cells. 
Primary 
hCECs 
Cornea 
storage 
conditions 
Culture 
media 
Culture media supplements Substrate used Reference 
Human Not 
specified 
L-Valine 
free 
formulation 
of F99 
5% FBS, 20 μg/ml ascorbic acid, 20 μg/ml bovine 
insulin, 2.5 μg/ml transferrin, 0.6 ng/ml sodium 
selenite, 10 ng/ml bFGF 
0.5-1mg/ml 
collagen IV, 
10μg/ml laminin, 
15μg/ml 
fibronectin, 0.01% 
gelatin, 1% 
chondroitin sulfate 
Engelmann and 
Friedl, 1989; 
Engelmann, et al., 
1995 
Human Optisol GS DMEM 10% FBS, 2 ng/ml bFGF, 50 U/ml penicillin, 50 
μg/ml streptomycin 
Collagen IV Ishino, et al., 2004 
Human Optisol GS 
at 4oC 
Opti-
MEM-I 
8% FBS, 20 ng/ml NGF, ng/ml EGF, 20 μg/ml 
ascorbic acid, 200 mg/L calcium chloride, 100 
μg/ml pituitary extract, 50 μg/ml gentamicin, 1 x 
antibiotic/antimycotic , 0.08% chondroitin 
sulphate 
FNC coating mix Joyce and Zhu, 
2004 
Human Optisol at 
4oC 
SHEM 0.5 % DMSO, 2 ng/ml EGF, 5 μg/ml insulin, 5 
μg/ml transferrin, 5 μg/ml selenium, 0.5 μg/ml 
hydrocortisone, 1 nM cholera toxin, 50 μg/ml 
gentamicin, 1.25 μg/ml amphotericin B 
No coating Li, et al., 2007 
Human Optisol Opti-
MEM-I, 
ESC-CM 
25% ESC-CM, 8 % FBS, 40 ng/ml FGF, 5 ng/ml 
EGF, 20 ng/ml NGF, 20 μg/ml ascorbic acid, 
0.005% human lipids, 200 mg/L calcium chloride, 
0.08% chondroitin sulfate, 1% RPMI-1640 
multiple vitamin solution, 50 μg/ml gentamicin, 
and antibiotic/antimycotic solution (1:100) 
None Lu, et al., 2010 
Human Not 
specified 
DMEM 
(low 
glucose), 
DMEM 
1. 15% FBS, 2.5 mg/L amphotericin B, 2.5 
mg/L doxycycline, 2 ng/ml bFGF 
2. Serum free 
1. BCEC-ECM 
2. LM-5 
Yamaguchi, et al, 
2011 
Human 
(Fuchs’ 
dystrophy) 
Optisol-GS 
on ice 
OptiMEM-
I 
8% FBS, 5ng/ml EGF, 20ng/ml NGF, 20μg/ml 
ascorbic acid, 0.08% CS, 100 IU/ml penicillin. 
FNC coating mix Zaniolo, et al., 2012 
Human Not F99 5% Fetal calf serum (FCS), 100 μM sodium L- 5 mg/ml Sheerin, et al., 2012 
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specified ascorbate, 20 μg/ml bovine insulin, 2.5 μg/ml 
transferrin, 40 pΜ sodium selenite, 10 ng/ml 
bFGF 
chondroitin sulfate 
and 5 μg/ml mouse 
laminin 
Human Optisol-GS 
at 4oC 
F99 5 % FBS, 20 μg/ml ascorbic acid, 1x Insulin, 
transferrin, selenium, 1x anti-biotic/anti-mycotic 
and 10ng/ml bFGF 
FNC coating mix Peh, et al., 2013 
Human Optisol at 
4oC 
MSC-CM 8 % FBS, 5ng/ml EGF, 20 μg/ml ascorbic acid, 
200 mg/L calcium chloride, 0.08 % CS, 50 μg/ml 
gentamicin 
FNC coating mix Nakahara, et al., 
2013 
Human Not 
specified 
EGM-2, 
DMEM 
1. 10 % FBS, EGF, VEGF, FGF, IGF, 
hydrocortisone, gentamicin, amphotericin-B; 
2. 10 % FBS, FGF; 
Collagen type IV, 
Fibronectin, FNC 
coating mix 
Choi, et al., 2014 
Primate Not 
specified 
DMEM 10 % FBS, 50 U/ml penicillin, 50 μg/ml 
streptomycin, 2 ng/ml FGF-2 
FNC coating mix Okumura, et al., 
2013 
Bovine N/A (fresh 
corneas 
used) 
SHEM 5% FBS, 5 μg/ml insulin, 5 μg/ml transferrin, 5 
ng/ml selenium, 50 unit/ml penicillin, 50 μg/ml 
streptomycin, 250 ng/ml amphotericin B, 0.5% 
DMSO, 2 ng/ml (human epidermal growth factor) 
hEGF, 1nM cholera toxin 
No substrate used Chou, et al., 2014 
Note: Foetal bovine serum (FBS); Epidermal growth factor (EGF); Nerve growth factor (NGF), Chondroitin sulfate (CS); 
Dimethyl sulfoxide (DMSO); fibronectin-collagen coating mix (FNC); Mouse embryonic stem cell conditioned medium (ESC-
CM); bone marrow-derived mesenchymal stem cell conditioned medium (MSC-CM); Dulbecco’s modified Eagle’s medium 
(DMEM); Endothelial growth medium-2 (EGM-2); HEPES-buffered DMEM and Ham’s F12 in 1:1 ratio (SHEM); Mouse 
embryonic stem cell-conditioned medium (ESC-CM); Descemet’s membrane (DM); Bovine corneal endothelial cell-derived 
extracellular matrix (BCEC-ECM); Laminin-5 (LM5); basic fibroblast growth factor (bFGF). 
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1.6.3.1.Stem cell conditioned media 
Bone marrow-derived mesenchymal stem cell conditioned medium (MSC-CM) 
(Nakahara, et al., 2013) and mouse embryonic stem cell conditioned medium (ESC-
CM) (Lu, et al., 2010) have also been used in hCEC culture, showing very good 
results in stimulating proliferation. Cultured hCECs using MSC-CM maintain 
expression of CE functionality markers, Na+/K+ ATPase and ZO-1 suggesting that 
the cells still maintain normal corneal endothelial cell pump function. This culture 
medium was shown to mediate its positive effect on hCEC proliferation through the 
downstream activation of PI3K/Akt signaling that leads to p27 and p21 
degradation and cyclin D1 activation and cell cycle progression to S-phase. This 
signaling pathway has been shown to play a role in CEC proliferation in other 
studies as well (Lee and Kay, 2003). Therefore, MSC-CM was chosen for use in this 
study also because it seemed to yield better results for primary culture initiation 
compared to F99 with 10% FBS. However, research results are still inconclusive and 
currently the search for the best-optimized culture medium condition for hCEC 
culture is still ongoing. However, a new study more recently compared the effect of 
bone marrow-derived endothelial progenitor cell conditioned medium, bone 
marrow-derived mesenchymal stem cell conditioned medium (MSC-CM) and 
corneal stromal cell conditioned medium and found that the corneal stromal cell 
conditioned medium had the best effect on rat corneal endothelial cells (Zhu, et al., 
2016). It has also been revealed that the stromal keratocytes release a range of 
substances including growth factors/cytokines, extracellular matrix (ECM) 
components, and kinases, which support normal corneal development and 
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homeostasis (Zhang, et al., 2017). These are very important findings and suggest that 
the corneal stromal keratocytes play an extremely important role in supporting the 
CE and could give new insights for optimizing hCEC culture introducing stromal 
keratocyte conditioned medium or feeder layers. 
1.6.3.2.Substrates used in human corneal endothelial cell culture 
The extracellular matrix plays a very significant role in the cell shape and 
proliferation of different cell types including the corneal endothelium 
(Gospodarowicz, et al., 1978). Therefore, when endeavouring to optimize culture 
conditions for hCEC culture, many researchers have examined the effect of different 
extracellular matrices, substrates and culture dish coating substrates, including: 
• Different culture dish plastic (Li, et al., 2007; San Choi, et al., 2013; 
Yamaguchi, et al, 2011) 
• Bovine corneal endothelial cell-derived extracellular matrix (BCEC-ECM) 
(Engelmann and Friedl, 1989; Blake, et al., 1997) 
• Chondroitin sulfate (CS) (Engelmann and Friedl, 1989) 
• Laminin (LM) (Engelmann and Friedl, 1989; San Choi, et al., 2013) 
• CS/LM mix (Engelmann and Friedl, 1989) 
• Fibronectin (FN) (Engelmann and Friedl, 1989; San Choi, et al., 2013) 
• Gelatine (Engelmann and Friedl, 1989) 
• Collagen type IV (Engelmann and Friedl, 1989; San Choi, et al., 2013; 
Sumide, et al., 2006; Choi, et al., 2014) 
• Fibronectin-collagen (FNC) coating mix (Zhu and Joyce, 2004; Engler, et al., 
2009; San Choi, et al., 2013) 
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• Laminin-5 (Yamaguchi, et al., 2011) 
• Collagen type I (Engler, et al., 2009; San Choi, et al., 2013; Gruschwitz, et 
al., 2010) 
• Collagen type I/Fibronectin mixture (Engler, et al., 2009) 
A study by Engelmann, et al. (1988) compared the clonal growth of hCECs seeded 
on different substrates: plastic, laminin, laminin/chondroitin sulphate mix, 
chondroitin sulphate and gelatine. Laminin/chondroitin sulfate coating was reported 
to be yielding the highest clonal growth of the hCECs. Moreover, a later study by 
Engelmann and Friedl, 1989 demonstrated that BCEC-ECM greatly surpassed all 
other substrates tested in its effect on proliferation, including gelatine, chondroitin 
sulfate, laminin/chondroitin sulfate mix, fibronectin and collagen type IV in its 
stimulatory effect on proliferation. In addition, the proliferation effect on hCECs 
was very significantly enhanced when each substrate was used in combination with 
fibroblast growth factor (FGF) supplemented medium. Choi, et al. (2014) tested and 
compared the effect of collagen type IV, fibronectin and fibronectin-collagen mix 
(FNC) on the effective establishment of primary corneal endothelial cell cultures and 
reported that there was no statistically significant difference between them. 
However, the FNC mix showed an observable trend for the highest success rate in 
primary culture initiation. Numata, et al. (2014) demonstrated that collagen type IV, 
collagen type I, and fibronectin coating substrates did not have any significant 
growth-promoting effect on CECs. However, pericellular matrix prepared from 
human decidua-derived mesenchymal stem cells (PCM-DM) showed a significant 
effect. Based on the findings from the above-mentioned studies, BCEC-ECM and 
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PCM-DM seem to have the highest capacity to stimulate proliferation of CECs in 
culture. However, research results remain inconclusive and the search for the ideal 
substrate for use in hCEC culture is still ongoing. 
1.6.3.3.Rho-associated protein kinase inhibitor Y-27632 in human corneal 
endothelial cell culture 
Okumura, et al. (2009) were the first to use a ROCK inhibitor Y-27632 as a corneal 
endothelial cell survival and attachment enhancer. Rho-associated protein kinase 
signaling pathway is known to affect cell adhesion and plays a role in actin 
cytoskeleton remodeling and stress fiber formation and is involved in the cell cycle 
control. Signals from the extracellular matrix (ECM) and ligands activate the 
Rho kinase via integrins, receptor tyrosine kinases (RTKs), G-protein-coupled 
receptors (GPCRs) and downstream activation of guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs). The Rho kinase pathway 
regulates cell mobility, stress fiber formation and cell cycle progression 
(Schwartz, 2004). 
ROCK inhibitor Y-27632 has a positive effect on corneal endothelial cell yield in 
culture (Okumura, et al., 2014a) and facilitates transplantation (Okumura, et al., 
2012). Y-27632 mediates its effect through the PI3K and up-regulates cyclin D 
expression, in addition to up-regulation of cell division cycle 25A (CDC25A) 
enabling cyclin D/cyclin-dependent kinase 4 (CDK4) and cyclin E/cyclin-dependent 
kinase 2 (CDK2) complexes to inactivate retinoblastoma (Rb) and p27, thus 
activating E2F leading to progression to S phase of the cell cycle (Okumura, et al., 
2014a). This furthermore confirms the importance of PI3K signaling as an important 
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pathway that controls human corneal endothelial cell proliferation. In addition to its 
positive effect on cell proliferation Yamamoto, et al. (2012) found that it also 
protects the expression of normal CE morphology. Another study by Pipparelli, et al. 
(2013) demonstrated, however, that Y-27632 did not stimulate hCEC proliferation 
but could enhance cell attachment.  
1.6.3.4.Negative factors affecting human corneal endothelial cell 
proliferation 
1.6.3.4.1.Contact inhibition 
The corneal endothelial cells form a monolayer in which all cells are very closely 
packed together and retain close cell-cell contact, which induces contact inhibition 
and stops the corneal endothelial cells from proliferating (Joyce, et al., 2002; Joyce, 
2003). Disruption of cell-cell contact by EDTA has been shown to promote hCEC 
proliferation, especially from old donors (Senoo and Joyce, 2000b). Therefore, this 
suggests that using enzymatic dissociation as a method for corneal endothelial cell 
isolation may represent a suitable technique for breaking the cell-cell contacts. 
Releasing the cells from contact inhibition prior cell culture potentially makes them 
more susceptible to the effect of growth promoting molecules present in the culture 
medium. 
1.6.3.4.2.Transforming growth factor-β2  
Another factor that has experimentally been demonstrated to negatively affect 
corneal endothelial cell proliferation is TGF-β2 (Joyce, 2012). TGF-β signaling is a 
major pathway that controls corneal endothelial cell morphology and proliferation 
 29 
and mediates its effect through SMAD proteins. TGF-β or bone morphogenic 
proteins (BMPs) stimulation can activate a number of downstream signaling 
cascades including Rho signaling, phosphoinositide-3 kinase/Akt (PI3K/Akt) 
signaling and extracellular signal-regulated kinase 1/2 (Erk1/2) signaling all of 
which have been shown to play a significant role in the control of proliferation 
in human corneal endothelial cells. Joyce and Zieske (1997) demonstrated the 
expression of TGF-β receptor in human corneal endothelial cells. TGF-β2 was found 
to be a mitotic inhibitor for corneal endothelial cells (Chen, et al., 1999). In the 
aqueous humour the presence of TGF-β2 results in suppression of corneal 
endothelial cell proliferation and G1 phase arrest. Exogenous TGF-β2, when added 
to cultured corneal endothelial cells, has the ability to suppress their proliferation 
(Chen, et al., 1999). Zhu, et al. (2012) demonstrated that TGF-β1 could induce a 
morphological change in human corneal endothelial cells and cause them to acquire 
a spindle-shaped phenotype. Additionally, TGF-β1 stimulates the expression of α-
smooth muscle actin (α-SMA) by cultured hCECs, which is a differentiation marker 
of myofibroblasts (Zhu, et al., 2012). TGF-β is another potential target for further 
research on primary human corneal endothelial cell proliferation and some TGF-β 
receptor inhibitors seem to preserve the normal corneal endothelial cell morphology 
in culture (Okumura, et al., 2013). 
1.6.3.4.3.Age 
In a study using hCEC ex vivo culture, Choi, et al., (2014) indicated that age and 
hCECs isolation methodology most directly affect the quality of the cells grown. 
The results of this study further show that primary cells isolated from donors below 
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the age of 30 have the highest rate of culture success and the highest potential to 
reach confluence and be sub-cultured.  However, other studies, such as Zhu and 
Joyce (2004) successfully cultured human corneal endothelial cells isolated from 
both young and old donors on a 6-well plate pre-coated with undiluted FNC Coating 
Mix. Up to 4 passages were attained, using basal media OptiMEM-I supplemented 
with 8% FBS, EGF 5 ng/mL, NGF 20 ng/mL, pituitary extract 100 μg/mL, ascorbic 
acid 20 μg/mL, calcium chloride 200 mg/L, 0.08% chondroitin sulfate, gentamicin 
50 μg/mL, and antibiotic/antimycotic solution diluted 1:100 demonstrating that the 
current culture media confirmations do not allow continuous human corneal 
endothelial cell culture beyond several passages. This poses a limitation to the 
development of a cell-therapy approach for treating corneal endothelial disorders. In 
order to tackle this limitation of inadequate proliferative capacity of the human 
corneal endothelial cells some researchers have attempted to identify and isolate a 
human corneal endothelial progenitor cell with high proliferation potential. 
1.6.4. Human corneal endothelial progenitor cells 
The peripheral corneal endothelium has been the subject of much interest as 
potentially harbouring corneal endothelial progenitor cells that are capable of 
proliferation and renewal of the corneal endothelium. Such cells could prove to be 
very useful for culture and expansion due to their ability to proliferate, and could 
potentially be used to generate cells for transplantation and cell-based treatment of 
corneal endothelial disorders. 
Some studies have successfully demonstrated that the corneal endothelial cells from 
the periphery retain mitogenic activity, whereas the corneal endothelial cells from 
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the central cornea do not  (Bednarz, 1998). Konomi, et al. (2005) found that the cells 
from both these regions retain proliferative capacity. However, the peripheral region 
showed a higher capacity for proliferation. On the other hand, another study by 
Choi, et al. (2014) comparing the central and peripheral endothelium had a better 
success rate of primary cell culture initiation from the central region. Whikehart, et 
al. (2005) reported that in the periphery of the cornea, some cells that were 
undergoing mitosis, especially after wounding, migrated towards the wound site as 
demonstrated by 5-bromo-2-deoxyuridine (BrdU) incorporation. Some researchers 
have tried to locate a potential stem cell niche and found that stem cell markers, 
such as nestin, telomerase, octamer-binding transcription factor 3/4 (Oct 3/4), 
Wnt proto-oncogene family member 1 (Wnt-1), Paired box protein Pax-6 (Pax-
6), Sex determining region Y-box 2 (Sox-2), are expressed after wounding and 
removal of the central corneal endothelium within the regions of the Schlemm’s 
canal, trabecular meshwork, transition zone and peripheral endothelium, after 
wounding of organ cultured corneas (McGowan, et al., 2007). 
1.6.4.1.Isolation and culture of human corneal endothelial progenitor cells 
A number of research groups have reported successful isolation and cultivation of 
hCEC progenitor cells as a potential cell source that could be cultured more easily 
compared to normal mature hCECs. These cells have been isolated based on neural 
crest and stem cell marker expression, high proliferative capacity and sphere-
forming properties. 
Yokoo, et al. (2005) found that within the CE there are cells with sphere-forming 
capacity that express neural crest and mesenchymal markers - nestin and α-smooth 
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muscle actin (α-SMA) - and were able to isolate and culture them. In another study 
Hara, et al. (2014) isolated hCECs that expressed p75NTR (neurotrophin receptor), a 
neural crest marker, which had a higher proliferative capacity compared to other 
hCECs that did not express p75NTR (neurotrophin receptor). These cells were 
cultured as corneal endothelial progenitors, which could potentially be used for cell 
transplantation. Hirata-Tominaga, et al. (2013) reported that leucine-rich repeat-
containing G-protein coupled receptor 5 (LGR5), a stem cell marker, is exclusively 
expressed in the periphery of the CE. The LGR5-expressing cells had very high 
proliferative capacity and could be cultured in vitro more easily compared to hCECs, 
which did not express LGR5.  
Current research on identifying and culturing human corneal endothelial progenitor 
cells is still ongoing since there is a huge demand in the field for effective culture of 
primary human corneal endothelial cells. Positive regulatory domain zinc finger 
proteins (PRDMs) have been shown to regulate proliferation, differentiation and 
senescence of haematopoietic stem cells, embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPS) (Fog, et al., 2012; Zhang, et al., 2011; Kinameri, et al., 
2008) and their expression and role in the human cornea has not been well studied 
with the exception of PRDM5 that was reported to be involved in extracellular 
matrix development (Burkitt Wright, et al., 2011). Therefore, it would be of great 
interest to explore the role of these proteins in human corneal endothelial cell 
proliferation and stem cell properties. In this study a complete expression profile of 
PRDMs was generated and demonstrated that a number of PRDMs are expressed in 
human corneas and cultured human corneal endothelial cells. This unlocks 
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possibilities for future studies of the roles and function of these proteins in the 
control of proliferation and stem cell capacity in the human corneal endothelial cells 
and can potentially lead to finding new ways of enhancing corneal endothelial cell 
culture that can be used in cell-therapy approach for treating corneal endothelial 
disorders. 
1.7. Current methods used for testing corneal endothelial cell 
transplantation 
Human corneal endothelial cell transplantation involves isolating and culturing 
primary hCECs from human donor corneas and using them for transplantation. In 
the most current published literature the preferred isolation method of corneal 
endothelial cells is the peel-and-digest method where the Descemet’s 
membrane/Endothelium complex is peeled and the cells are enzymatically 
dissociated prior to primary culture initiation (Peh, et al., 2011 and 2015b; Okumura, 
et al., 2016). Basal culture media, such as DMEM (Okumura, et al., 2016), F99 
(Ham’s F12/Medium 199 in a 1:1 ratio) [Peh, et al., 2015b] and OptiMEM-I 
(Nakahara, et al., 2013) are currently being used for propagation of corneal 
endothelial cells in combination with FNC coating mix. ROCK inhibitor Y-27632 
has also been used and studied extensively in recent years and has shown some 
potential for enhancing corneal endothelial cell adhesion and culture (Okumura, et 
al., 2012; Okumura, et al., 2016; Pipparelli, et al., 2013 and Peh, et al., 2015b). The 
most commonly associated signaling pathway involved in inducing human corneal 
endothelial cell proliferation through growth factor and ROCK inhibitor stimulation 
is the PI3K signaling pathway with downstream activation of cyclin D and Erk 1/2 
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(Nakahara, et al., 2013; Okumura, et al., 2014a). Therefore, in this study F99 and 
Opti-MEM I (used as a basal medium for the preparation of MSC-CM), were used 
for culture of immortalized and primary hCECs and all primary hCECs were isolated 
using the peel-and-digest method. 
Two of the most common methods for hCEC transplantation include: 1) cell 
suspension transplantation, where a suspension of corneal endothelial cells is being 
injected into the anterior chamber of the eye and 2) carrier substrate transplantation, 
where the hCECs have been pre-cultured on a carrier substrate and are delivered to 
the anterior chamber of the eye via this carrier substrate. Human corneal endothelial 
cell transplantation has been the subject of investigation by many researchers in 
recent years using a number of in vivo and in vitro models.  
1.7.1. In vivo animal models for corneal endothelial cell transplantation 
In order to study and test the potential of cell-based therapy to restore corneal 
endothelial cell function, a suitable model is needed that allows the assessment of 
the post-cell therapy outcomes and determines the safety of the procedure. This 
would allow researchers to accurately compare the effects of cell therapy on the 
corneal thickness and corneal transparency to the effects of CE decompensation and 
enable them to test whether cell therapy is capable of restoring normal CE function 
and normal corneal thickness and transparency to corneas that have previously had 
CE decompensation. 
Han, et al. (2013) described a methodology for establishing an in vivo mouse model 
of corneal endothelial decompensation using cryoinjury. The researchers used the 
corneal thickness as a surrogate measure of corneal endothelial function and 
 35 
measured it using anterior segment optical coherence tomography (OCT) over a 21-
day period. Abnormally high corneal thickness in this case would testify for an 
abolished corneal endothelial cell function. This swollen phenotype can therefore 
easily be compared to cell-therapy treated animals. Comparison of the corneal 
thickness between the treated and non-treated eyes in this case would give evidence 
of restored corneal endothelial cell function.  
Most of the current research on corneal endothelial cell-therapy approach has been 
done using animal models (See Table 2). In experimental research the successful 
outcome of cell therapy could be evaluated based on several factors including:  
1) Morphology of the cultured corneal endothelial cells (CECs), observed by phase-
contrast microscopy prior to transplantation. 
2) CE functionality marker expression (Na+/K+ ATPase and ZO-1). 
3) Corneal transparency, observed by a slit lamp microscope post-transplantation. 
4) Central corneal thickness (CCT), measured by ultrasound pachymetry post-
transplantation. 
5) Cell morphology (hexagonal) relative to the normal in vivo CE morphology, 
observed in vivo by noncontact specular microscopy and electron microscopy 
post-transplantation. 
6) Histological observation of the CE post-transplantation. 
Therefore, a successful outcome of corneal endothelial cell transplantation could be 
determined by an effective recovery of normal corneal endothelial pump function 
evidenced by restoration of corneal transparency and normal corneal thickness. 
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Table 2 – In vivo animal models for corneal endothelial cell transplantation reported in literature. 
In vivo 
animal 
model 
Cells used for 
transplantation 
Substrate used as 
a carrier for cell 
transplantation 
Transplantation 
technique 
Outcome References 
Rabbit Rabbit corneal 
endothelial cells – 
2-5x103 cells/ml 
Rabbit corneal 
button with intact 
Descemet’s 
membrane (DM) 
Full-thickness corneal 
button graft 
19 clear grafts – 
maintained transparency 
up to 30 days. 
Jumblatt, et al., 
1978 
Rabbit Bovine corneal 
endothelial cells – 
1.5x106 cells 
Rabbit corneal 
button with intact 
DM 
Full-thickness corneal 
button graft 
Clear grafts for over 100 
days 
Gospodarowicz, 
et al, 1979 
Rabbit Human corneal 
endothelial cells 
(hCECs) - 6x103 
cells/mm2 
Denuded amniotic 
membrane (AM) 
was placed on 
rabbit corneal 
buttons - no DM 
Full-thickness corneal 
button/AM graft 
Transparent grafts with 
little oedema 4 days 
post-transplantation 
Ishino, et al, 
2004 
Rabbit hCEC cell sheet 
harvested from 
temperature-
responsive dishes – 
3x106 cells 
Rabbit central 
corneal button 
Corneal button/cell sheet 
graft 
Thin and clear corneas 
up to 7 days after 
transplantation 
Sumide, et al, 
2006 
Rabbit Rabbit corneal 
endothelial cells –
1x107 cells/ml 
No carrier substrate Cell seeding directly on 
native DM then 
encapsulated with self-
cross-linked composite 
hydrogel formed in situ 
Clear grafts up to 60 
days after 
transplantation 
Liang, et al, 
2011 
Rabbit CEC-like cells from 
ESC - 2x105 
cells/mm2 for 4h 
Posterior acellular 
porcine corneal 
matrix (PAPCM 
lamella) with DM 
CEC-like cells/PAPCM 
transplantation 
Corneal thinning up to 
28 days 
Zhang, et al., 
2014 
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Rabbit Rabbit corneal 
endothelial cells – 
2x105 cells in 200μl 
DMEM 
No carrier substrate Cell injection +/- 100 
μM Y-27632 ROCK 
inhibitor directly on 
native DM 
Cell injection with Y-
27632 produced corneal 
transpatency 
Okumura, et al., 
2012 
Rabbit hCECs – 1x 106 
cells in 300μl 
DMEM 
Collagen type I 
sheet coated with 
fibronectin 
Transplantation of 
collagen sheet 
Restored corneal 
transparency 
Mimura, et al., 
2004b 
Rabbit hCECs Collagen sheet with 
or without Viscoat® 
(seeded with 40,000 
cells/mm2 for 3 
weeks) 
DM removed. Collagen 
sheet transplantation 
Viscoat® improved cell 
viability of the 
transplanted hCECs 
Yamaguchi, et 
al., 2016 
Rabbit 
and 
Primate 
Corneal endothelial 
cell-like cells from 
skin-derived 
precursors and 
B4G12 - 2.0x105 or 
4.0x105 cells 
No carrier. The DM 
was left intact to 
serve as a substrate 
for the injected 
cells. 
Cell injection in 100 μl 
or 50 μl human 
endothelial serum-free 
medium supplemented 
with 3.2 μg or 1.6 μg of 
Y-27632 
Restored corneal 
transparency 
Shen, et al., 
2017 
Primate Monkey corneal 
endothelial cells 
Collagen type I - 5-
10x102 cells/mm2 
or 
No carrier 
substrate– 8x104 
cells in 50μl; 
Collagen carrier inserted 
and attached to DM by 
air injection or 
Cell suspension injection 
to native DM 
Collagen 
carrier/MCECs 
maintained corneal 
transparency up to 6 
months after surgery; 
Cell injection did not 
produce corneal 
transparency; 
Koizumi, et al, 
2007 
Primate Monkey corneal 
endothelial cells – 
2x105 cells in 200μl 
DMEM 
No carrier substrate Cell injection +/- 100μM 
Y-27632 ROCK 
inhibitor directly on 
native DM 
With or without Y-
27632 corneal 
transparency was 
achieved 
Okumura, et al., 
2012 
Primate Monkey corneal 
endothelial cells - 
5x105 cells in 200μl 
No carrier substrate Cell injection +/- 100μM 
Y-27632 ROCK 
inhibitor directly on 
The presence of ROCK 
inhibitor promoted 
corneal transparency 
Okumura, et al., 
2016 
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DMEM; 
hCECs - 5x105 cells 
in 200μl OptiMEM-
I; 
native DM 
Primate Monkey corneal 
endothelial cells 
Spherically curved 
gelatin hydrogel 
sheets (SCGSs) 
Transplantation of sheet 
(4mm of central DM 
removed) 
Restored corneal 
transparency 
Kimoto, et al., 
2014 
Feline Bovine corneal 
endothelial cells – 
1x105 cells/60μl 
Feline corneal 
button – no DM 
Full-thickness 
penetrating keratoplasty 
Thin and transparent 
grafts. Immune host 
response by 9th 
postoperative day 
Bahn, et al, 
1982 
Feline Feline corneal 
endothelial cells – 
250,000-285,000 
cells per cornea 
Devitalized human 
corneas – with DM 
Full-thickness corneal 
transplantation 
Thin and transparent 
grafts 7 days after 
grafting 
Proulx, et al, 
2009 
Feline Feline corneal 
endothelial cells – 
2x105 – 1x106 
No carrier used 
(cell transplantation 
directly on native 
DM) 
Cell injection with Y-
27632 ROCK inhibitor 
Incompletely functional 
CE 
Bostan, et al., 
2016 
Rat hCECs– 1x106 
cells/300μl DMEM 
Rat corneas with 
DM 
Full-thickness grafting Thin and transparent 
grafts for 1 month after 
transplantation 
Mimura, et al, 
2004a 
Rat Immortalized 
human corneal 
endothelial cells 
(B4G12) - 8.5x104 
cells or 3000 
cells/mm2 
No carrier used 
(cell transplantation 
directly on native 
DM) 
Cell injection Restored corneal 
transparency 
Ju, et al, 2012 
Note: Human corneal endothelial cells (hCECs); Acellular porcine corneal matrix (APCM); Descemet’s membrane (DM); 
Corneal endothelial cell-like cells from embryonic stem cells (CEC-like cells from ESC); Posterior acellular porcine corneal 
matrix (PAPCM); Descemet’s membrane endothelial keratoplasty (DMEK); Spherically curved gelatine hydrogel sheets 
(SCGSs); Monkey corneal endothelial cells (MCECs); Rho-associated protein kinase (ROCK); Dulbecco’s modified Eagle’s 
medium (DMEM). 
 39 
 
1.7.2. In vitro animal models for corneal endothelial cell transplantation 
 A number of studies have reported that in vitro cultured corneal endothelial cells 
can be successfully transplanted into various in vitro models and show positive 
effects on diminishing corneal oedema and restoring normal corneal thickness (See 
Table 3). 
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Table 3 – In vitro animal models for corneal endothelial cell transplantation reported in literature. 
In vitro corneal 
endothelial cell 
transplantation 
studies 
Cells used for 
transplantation 
Substrate used 
as a carrier for 
cell 
transplantation 
Transplantation 
technique 
Outcome References 
In vitro cultured 
porcine eyes 
Immortalized 
human corneal 
endothelial cells 
(B4G12) 
Plastic 
compressed 
collagen type I 
(RAFT) seeding 
density – 2000-
4000 cells/mm2 
for 4-14 days 
Pull-through/air-
bubble technique 
similar to DSAEK 
procedure 
The RAFT 
constructs 
successfully 
attached to the 
recipient ex vivo 
porcine eye. 
hCEC function 
was not reported. 
Levis, et al, 2012 
APCM lamellae 
with DM 
Immortalized 
human corneal 
endothelial cells 
(B4G12) 
No carrier Cell injection - 
Seeding density - 
1.5x105 cells/cm2 
for 4h 
APCM thickness 
decrease 
Ju, et al, 2012 
Note: Real architecture for 3D tissues (RAFT); human corneal endothelial cells (hCECs); acellular porcine corneal matrix 
(APCM); Descemet’s membrane (DM). 
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1.7.3. In vitro corneal endothelial cell transplantation in organ cultured 
human corneas 
Johnson and Tschumper (1987) previously described a method for in vitro culture of 
human cadaveric corneas, which involved culturing corneas in a moist chamber 
allowing the epithelial side of the cornea to maintain contact with the air while the 
endothelial side could be continuously perfused with culture medium. A 
modification of this model was used for corneal endothelial cell transplantation 
studies by Patel, et al. (2009) to test a technique using superparamagnetic 
microspheres (SPMs) incorporated hCECs and transplanting them to corneal stroma 
of cadaveric human corneas. Another type of set-up for air-interface organ culture of 
human corneas has previously been reported by Rajan, et al. (2005) that mimicked 
the normal corneal environment where the cornea keeps in contact with the air but 
without using continuous perfusion.  
In vitro organ cultured human donor corneas have also been used successfully in cell 
transplantation studies aiming to test the plausibility of a cell-therapy approach for 
treating corneal endothelial disorders (Engelmann, et al., 1993 and 1999; 
Aboalchamat, et al., 1999; Chen, et al., 2001; Patel, et al., 2009). They have had 
success in demonstrating efficient cell attachment, morphology and monolayer 
formation post-transplantation (Böhnke, et al., 1999) and restoring normal CE 
function based on the corneal de-swelling measured by ultrasound pachymetry 
(Aboalchamat, et al., 1999; Engelmann, et al., 1999), (See Table 4). 
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Table 4 - In vitro cultured human corneas used for corneal endothelial cell transplantation studies. 
hCEC 
transplantation 
model 
Descemet’s 
membrane 
Cells used for 
transplantation 
Substrate used 
as a carrier for 
cell 
transplantation 
Transplantation 
technique 
Outcome References 
Human donor 
corneas 
Intact Human corneal 
endothelial cells 
No Cell suspension 
transplantation 
on the DM 
Achieved a cell 
density of 1800 
cells/mm2. FGF 
improved 
monolayer 
formation. 
Function not 
assessed. 
Engelmann, 
et al., 1993 
Human donor 
corneas 
Intact Human corneal 
endothelial cells - 
150,000 – 700,000 
cells per cornea 
No Cell suspension 
transplantation 
on the DM 
1850 cells/mm2 
density. Stromal 
de-swelling 
reached 
physiological 
levels. 24 h 
perfusion 
experiment. 
Engelmann, 
et al., 1999 
and Böhnke, 
et al., 1999 
Human donor 
corneas 
Intact Immortalized 
human corneal 
endothelial cell 
line (HCEC-12) - 
50,000 or 200,000 
or 500,000 
cells/200μl 
No Cell suspension 
transplantation 
on the DM 
2086 - 2293 
cells/mm2 density. 
Corneal thickness 
measured by 
pachymetry 
showed normal 
corneal thickness 
within 
physiological 
Aboalchamat, 
et al., 1999 
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levels. 8-12 h 
perfusion 
experiments. 
Human donor 
corneas 
Intact Human corneal 
endothelial cells - 
5x105 cells/ml 
No Cell suspension 
transplantation 
on the DM 
Cells formed a 
monolayer and 
expressed ZO-1 
within 7 - 14 days 
after 
transplantation; 
Function not 
assessed. 
Chen, et al., 
2001 
Human donor 
corneas 
Removed Human corneal 
endothelial cells 
(SPMs 
incorporated) - 
300,000 – 
1,000,000 cells 
per cornea 
No Cell suspension 
transplantation 
directly on the 
stroma 
SPMs 
incorporated 
hCECs 
successfully 
attached and 
formed a 
monolayer on the 
corneal stroma; 
Function not 
assessed. 
Patel, et al., 
2009 
Human donor 
corneas 
Intact Human umbilical 
cord blood 
mesenchymal 
stem cells 
No Cell suspension 
transplantation 
on the DM 
Expressed ZO-1, 
N-cadherin and 
endothelial-like 
phenotype; 
Function not 
assessed. 
Joyce, et al., 
2012 
Note: corneal endothelial cells (CECs), acellular porcine corneal matrix (APCM), Descemet’s membrane (DM), corneal 
endothelial cell-like cells from embryonic stem cells (CEC-like cells from ESC), posterior acellular porcine corneal matrix 
(PAPCM), Descemet’s membrane endothelial keratoplasty (DMEK), mesenchymal stem cells (MSCs), superparamagmetic 
spheres (SPMs). 
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1.7.4. Limitations of using animal models for corneal endothelial cell 
transplantation testing 
The rabbit has been used the most in the research field as an animal model for cell 
therapy testing based on the largest number of articles reporting rabbit studies 
compared to any other animal model. Other animal models that have also been used 
include rat, feline and primate. However, the suitability of some of these models has 
been questioned because the CE of some species seems to possess proliferative 
capacity, therefore the results generated with these models might not be directly 
applicable to humans, whose CE is unable to regenerate itself by proliferation in 
vivo. Some species whose CE has been shown to possess proliferative capacity are 
rabbit (Van Horn, et al., 1977; Mimura, et al., 2005) and rat (Tuft, et al., 1986), 
which potentially makes these models unsuitable for cell therapy studies since their 
own regenerative capability might mask any effects from the cell transplantation 
treatment. Joyce, et al., (1996a) showed that cyclin E in rabbits was located in the 
cytoplasm of rabbit corneal endothelial cells but in humans it was found in the 
nucleus, which mediates its effect through protein kinase C (Graham, et al., 2000). 
This difference of cellular distribution of cyclin E is possibly the reason why rabbit 
corneal endothelial cells are able to overcome the G1-phase arrest and progress to 
the S-phase of the cell cycle. 
The CE of a number of other animal models, such as feline (Van Horn, et al., 1977) 
and primate (Van Horn and Hyndiuk 1975) seems to possess similar non-
proliferative characteristics as the human CE. This makes them a more suitable 
platform for cell therapy testing compared to rabbit and rat models. Some positive 
 45 
outcomes of hCEC transplantation to restore vision have been demonstrated in 
primates. In a primate model Koizumi, et al. (2007), after mechanically scraping the 
native corneal endothelium from four eyes of four different animals, transplanted 
collagen sheets with monkey corneal endothelial cells (MCECs) and used ultrasound 
pachymetry to measure corneal thickness over a period of 6 months. As a control 
they transplanted a collagen sheet without MCECs in one eye of another animal after 
corneal endothelial dysfunction by mechanically scraping the corneal endothelium. 
Their results showed that within 3 to 6 months after the transplantation the cell-
therapy treated eyes restored their transparency and returned to almost the same 
corneal thickness as before the experiment, whereas the control remained opaque, 
with corneal thickness larger than 1200 μm. The researchers pointed out a limitation 
of their corneal thickness measurement approach, stating that the pachymetry 
method used was not capable to detect any corneal thickness if the values were 
above 1200 μm. 
However, probably the biggest limitation of animal models remains the use of 
materials of animal origin making the generated data not directly relevant to 
humans. Therefore the development of a suitable human model for CE 
transplantation studies that can be directly applicable to humans is necessary. 
1.7.5. Limitations of using human donor corneas for cell transplantation 
studies 
The use of human donor corneas in research has several advantages over the use of 
various animal models. The translational value of results that could be extrapolated 
from laboratory studies to clinical studies is one of the prime benefits over animal 
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corneas or in vivo animal studies where proliferation potential is higher in certain 
species. However, there are also certain limitations of using human donor corneas 
such as: 
1) Availability. 
2) Lack of good quality of human cadaveric donor corneas. 
3) Advanced age of donor corneas available for research studies. 
4) Long post-mortem time intervals. 
5) Limitation of organ culture preservation. 
6) Lack of an intact closed anterior chamber. 
7) Poor understanding of stromal behavior in immersion and air-interface organ 
culture. 
Human donor corneas for research are available as excised tissue with a scleral rim 
and this forms one of the limitations because of the lack of an intact anterior 
chamber. In order to overcome this limitation several research studies have 
attempted to mount these human donor corneas in artificial anterior chambers with 
irrigation to mimic aqueous humour circulation. However, the transfer from 
immersion to air-interface organ culture is poorly qualified in relation to stromal 
behaviour seen in human corneas. We have attempted to overcome this knowledge 
gap by conducting specific experiments in this thesis to form a basis to undertake 
physiological assessment of human corneas with or without cell therapy.  
Despite these limitations we have attempted to use human donor corneas from eye 
banks for their translational value and to understand and to address the gap in 
knowledge regarding the stromal behaviour of human corneas in culture. By 
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carefully considering the limitations it is possible to form strategies using human 
donor corneas for cell therapy research, which could have the advantage of 
convincing ethical bodies when it comes to undertaking clinical experimentation in 
live humans. It is with this primary motive that we have undertaken all our 
experimentation using human donor corneas including ex vivo generated human 
corneal endothelial cell cultures.  
1.8. Summary of review of literature 
This literature review in relation to corneal endothelial cell cultures and their 
potential in cell therapy has identified a few areas that need to be addressed before 
human endothelial cell therapy can be used for treating corneal endothelial disorders 
in humans. They are as follows: 
 There is a lack of a well-documented and established in vitro human corneal 
model to test strategies for human corneal endothelial cell transplantation. 
 There is a lack of clarity related to methodology of cell therapy application 
and the requirement of the Descemet’s membrane for cell attachment. 
 Poor understanding and absence of a suitable methodology to test the 
physiological function of transplanted cultured endothelial cells. 
 There is a lack of understanding of the mechanisms that govern hCEC 
proliferation, differentiation and maintenance. 
1.9. Specific aims of this study 
In order to evaluate the plausibility of using cell therapy as a treatment for corneal 
endothelial (CE) disorders in humans and to address some of the limitations that are 
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currently hindering the clinical use of corneal endothelial cell therapy, this study 
aimed:  
• To set up and validate an in vitro human corneal model of CE 
decompensation. 
• To test the capacity of hCECs to attach, form a monolayer and restore normal 
corneal endothelial cell function after transplantation directly to posterior 
corneal stroma in the absence of a DM. 
• To study the expression profile of positive regulatory domain zinc finger 
proteins (PRDMs) in human corneas and cultured human corneal endothelial 
cells. 
1.10. Ethics approval 
The research project was granted ethics approval by the Faculty Research Ethics 
Panel (FREP), Faculty of Science and Technology, Anglia Ruskin University, 
Cambridge, UK in May 2011 for a period of 3 years. It was extended in June 2013 
and was further extended in February 2015 until 21st May 2017. Reference number: 
RESC080. A license was obtained from the Human Tissue Authority (HTA), UK for 
the handling of human tissue such as human cadaveric corneas.  
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2. CHAPTER 2 – ESTABLISHING AND VALIDATION OF 
AN IN VITRO HUMAN CORNEAL MODEL OF 
ENDOTHELIAL DECOMPENSATION 
2.1. Chapter overview 
In this chapter the use of cadaveric human donor corneas as an in vitro model of CE 
decompensation was tested. The thicknesses of normal and decompensated corneas 
were compared after incubation in air-interface organ culture for an incubation 
period of 12 hours and up to 14 days. The corneal thickness was used as a surrogate 
measure of CE function and was measured using Zeiss Visante OCT. It was 
confirmed experimentally that the absence of a Descemet’s membrane 
(DM)/Endothelium complex in the decompensated corneas resulted in an 
oedematous phenotype throughout the incubation period, whereas the presence of an 
intact DM/Endothelium complex in the normal corneas was sufficient to maintain 
normal physiological corneal thickness. The results from this chapter show that this 
in vitro model can be used for testing the presence or absence of a functional corneal 
endothelial cell monolayer, thus is a useful platform for cell-therapy evaluation in 
future studies. 
2.2. Brief introduction 
Cell-based approach for treating corneal endothelial decompensation has been 
investigated in animal models, such as rabbit (Jumblatt, et al., 1978; Gospodarowicz, 
et al., 1979), primate (Koizumi, et al., 2007; Okumura, et al., 2016), and feline 
(Bostan, et al., 2016). Important aspects of cell transplantation, such as the capacity 
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of the transplanted cells to proliferate, form attachment, maintain viability and 
restore a functional corneal endothelial monolayer need to be tested in order to 
confirm the feasibility and safety of such treatment before it can be applied to 
humans. In cell therapy research studies, several characteristics are regarded as 
determinants of a successful outcome after transplantation of cultured CECs, namely 
corneal endothelial cell attachment, morphology and monolayer formation, corneal 
transparency, and the ability to achieve physiological corneal thickness. Using a 
variety of animal models recent research studies have yielded very valuable insights 
and have confirmed the plausibility of using a cell-based therapy for treating corneal 
blindness by showing that after transplantation in vitro cultured CECs can attach and 
form a functional CE monolayer and restore corneal transparency and normal 
corneal thickness. However, using animal models for cell therapy studies has certain 
limitations due to the CE of some animals, such as rabbits possessing a high 
proliferative and self-regenerating capacity. Therefore, the research data obtained 
through animal models might not be directly applicable to humans. 
In order to address issues that are currently limiting cell therapy research studies 
with this study we established an in vitro human model of CE decompensation by 
surgically removing the DM/Endothelium complex from human donor corneas, 
which would allow cell therapy testing in a human model in the absence of a DM. It 
was hypothesized that after a period of time in air-interface organ culture corneas 
with intact DM/Endothelium would experience a reduction in thickness to a 
physiological level, whereas decompensated corneas (DM/Endothelium removed) 
would remain oedematous. The in vitro model was validated for future use in hCEC 
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transplantation studies by testing the effect of the presence or absence of the 
DM/Endothelium complex on the corneal thickness by measuring the corneal 
thickness using Zeiss Visante anterior segment OCT. The experiment results 
confirmed that this in vitro model could be used as a suitable platform for 
demonstrating the presence or absence of normal corneal endothelial function within 
12 hours and up to 14 days of air-interface corneal organ culture.  
2.3. Materials and methods 
2.3.1. List of materials 
Human corneas from deceased human donors were obtained from Bristol and 
Manchester Eye Banks, UK with consent for research studies; Foetal bovine serum 
(FBS) – (F0804-500ML), Sigma Aldrich; Trypsin/EDTA – (T3924), Sigma Aldrich; 
0.06% VisionBlue™ (trypan blue); Barron artificial anterior chamber – Barron 
Precision Instruments; BD Plastipak 10 ml syringes – (SYR188), Medisave; Zeiss 
Visante OCT. 
2.3.2. Cornea storage conditions 
In the eye bank and prior to experimentation all corneas were stored in immersion 
organ culture using Eagle’s Minimal Essential Medium (MEM) supplemented with 2 
% foetal bovine serum (FBS), at 37oC, 5 % CO2 in a humidified incubator (relative 
humidity – 95%.  
2.3.3. Cornea selection 
Corneas that were received from the eye bank were randomly allocated for 
DM/Endothelium removal in order to create a CE decompensation model. 
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2.3.4. Inducing corneal endothelial decompensation in human donor corneas 
An in vitro model of corneal endothelial decompensation was prepared by 
removing the native Descemet’s membrane/Endothelium complex as follows: 
1) The corneoscleral rim was placed with the endothelial side facing upwards 
on a trephine base and was stained for 30 sec with VisionBlue® (trypan blue) 
vital stain (See Figure 5). 
 
Figure 5 – A cornea placed endothelium side up on a trephine base. Corneal 
endothelial cell viability was tested using VisionBlue® (trypan blue) vital stain. 
2) After that the corneal endothelium was washed with un-supplemented basal 
culture medium F99 or OptiMEM-I. 
3) The corneal endothelium was maintained in a water bath to avoid drying.  
4) The corneoscleral rim was held in place using forceps. 
5)  The Descemet’s membrane was cut in a circular motion using a surgical 
knife up to the transition zone or Schawalbe’s line that separates the 
endothelium from the trabecular meshwork and was peeled from the stroma 
by using forceps. Care was taken not to disturb the underlying stroma whilst 
scoring the Descemet’s membrane. 
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6) The stroma was wiped with a sterile spear to ensure all remaining 
Descemet’s membrane was completely removed. 
Human corneas with intact DM/Endothelium complex were used as a positive 
control for normal CE function as part of the in vitro model validation process. 
Human donor corneas were dissected using a low magnification stereo zoom 
microscope (See Table 5). 
Table 5 – Leica S6E stereo zoom microscope specifications. 
Specifications 
Light Benchtop Stand and Simple light-
emitting diode (LED) Reflected Light 
Magnification Power 6.3x – 40x, continuous zoom 
Eyepiece 10X 
Maximum field of view 36.5 mm 
Product Type Microscope stereozoom 
 
• 0.06 % VisionBlue™ (trypan blue) vital staining was used to assess the CE 
viability (See Figure 6); 
• Corneas with low CE viability were excluded from the control group of 
normal CE function [See Figure 6 (D)]. 
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Figure 6 – Leica S6E stereo zoom microscope used for cornea dissection (A). A 
cornea is placed endothelial side up and is prepared for trypan blue cell 
viability assessment (No staining; x200) [B], cornea with high corneal 
endothelial cell viability [0.06 % VisionBlue® (trypan blue) staining for 30 sec; 
x200] [C], cornea with low corneal endothelial cell viability [0.06 % 
VisionBlue® (trypan blue) staining for 30 sec; x200] [D]. 
All corneas were kept in immersion organ culture except for when they were taken 
out for CE viability assessment and DM/Endothelium complex removal. After these 
processes were completed the corneas were transferred from immersion and into air-
interface organ culture as described below. 
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2.3.5. In vitro air-interface organ culture of normal and decompensated 
human corneas 
In vitro air-interface organ culture of human corneas is a technique, which allows the 
corneas to be cultured in conditions that mimic normal physiological conditions 
where the epithelial side of the cornea maintains contact with the air (air-liquid 
interface). A Barron artificial anterior chamber was used, which consists of three 
parts: a base, a tissue retainer and a locking ring. The base contains two port 
connectors with pinch clamps, allowing fluid injection using a syringe. The tissue 
retainer holds the cornea in place. The locking ring is used to lock the tissue retainer 
against the base. The anterior chamber can hold a donor cornea with a scleral rim 
diameter of 14-18 mm. The tissue retainer has a 12.5 mm opening, which allows air 
contact with the epithelial side of the cornea. Once the cornea is secured to the 
artificial chamber, culture medium can be injected through the port connectors. After 
the chamber is filled with medium the port connectors are closed using the pinch 
clamps. This model allows exchanging of the culture medium by injection of fresh 
medium through the port connectors when necessary and also allows controlled 
moisturizing of the epithelial side of the cornea. This in vitro system for air-interface 
organ culture of decompensated human corneas was used as an in vitro corneal 
model of CE decompensation and was incubated in an incubator at 37oC, 5% CO2 
and 95% relative humidity (See Figure 7). 
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Figure 7 – Eye bank human corneas were received in immersion organ culture 
storage conditions. Barron artificial anterior chamber consisting of a base (1), 
tissue retainer (2), a locking ring (3) and pinch clamps (4) for opening and 
closing the perfusion tubes (purchased from Barron Precision Instruments) 
with a 12.5 mm opening, which allows the epithelial side of the cornea to be in 
contact with the air during organ culture was used for air-interface organ 
culture of human donor corneas. The corneas were incubated in an incubator 
at 37oC, 5% CO2 and 95% relative humidity.  
Fresh pre-warmed culture medium F99 (37oC) was injected into the Barron artificial 
anterior chamber every 1 hour (12-hour experiment) and every 24 hours (14-day 
experiment) by releasing the pinch clamps on both port connectors while the base 
was kept in an upside-down position in order to avoid deflation of the cornea. The 
epithelial side of the corneas was moistened with 200 μl of medium every 1-hour 
(12-hour experiment) and every 24 hours (14-day experiment). The corneal 
thickness was measured using Zeiss Visante OCT every 1-hour (12-hour 
(2) 
(3) 
(1) 
(4) 
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experiment), and every 24 hours for 14 days (14-day experiment). The time periods 
for media exchange and moistening of the epithelial side of the cornea were based 
on observation of corneal capsizing occurring roughly every hour, therefore the 
media on the posterior side of the cornea was exchanged every hour followed by 
moistening of the epithelial side with fresh culture medium and this was kept 
consistent throughout the experiment. 
2.3.5.1.Air-interface organ culture: 14-day incubation 
2.3.5.1.1.Human donor corneas 
A total number of n=8 corneas were used for this experiment and were separated 
into groups: normal and decompensated. 
2.3.5.1.1.1.Normal and decompensated corneas 
Normal human donor corneas with an intact DM/Endothelium complex (n=4) were 
used as a normal CE function control. Human donor corneas that had their 
DM/Endothelium complex removed (n=4) were used as an in vitro model of CE 
decompensation  (See Table 6). 
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Table 6 – Corneal characteristics (14 days in air-interface organ culture). 
 Normal (n=4) Decompensated (n=4) 
DM/Endothelium complex Intact Removed 
ECD (cells/mm2) 1718 ± 306.31 (range 
– 1500-2172) 
1820.5 ± 433.81 (prior to 
DM removal) 
Age (years) 68.25 ± 3.30 (range – 
64-72) 
70.75 ± 5.3 (range – 64-
75) 
Period in storage prior to 
experiment (days) 
34.5 ± 6.45 (range – 
25-39) 
29.75 ± 10.11 (range – 21-
39 days) 
Note: There was no statistically significant difference between the normal and 
decompensated groups when ECD, age and period in storage were compared. 
Endothelial cell density (ECD); Descemet’s membrane (DM). Cornea donor 
information is available in APPENDIX 1- Table 18. 
2.3.5.2.Air-interface organ culture: 12-hour incubation 
2.3.5.2.1.Human donor corneas 
9 corneas were used in this experiment and were separated into groups. Two of the 
corneas were used once as part of the normal group with intact DM/Endothelium 
complex and then after DM/Endothelium removal they were used in the 
decompensated group, hence equating to 11 samples in total (See APPENDIX 1 
Table 16). 
2.3.5.2.1.1.Normal and decompensated corneas 
Normal human donor corneas (n=6) with intact DM/Endothelium complex were 
used as normal CE function control. Human donor corneas whose DM/Endothelium 
complex was removed (n=5) were used as an in vitro model of CE decompensation 
(See Table 7). 
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Table 7 – Corneal characteristics (12 hours in air-interface organ culture). 
 Normal (n=5) Decompensated (n=6) 
DM/Endothelium 
complex 
Intact Removed 
ECD (cells/mm2) 2002 ± 357.99 (range - 
1670-2500) 
N/A 
Age (years) 67.83 ± 20.52 (range - 
29-89) 
52.8 ± 22.18 (range – 
29-76) 
Period in storage prior 
to experiment (days) 
39.66 ± 13.6 (range - 29-
57) 
31.4 ± 3.28 (range - 29-
35) 
Note: There was no statistically significant difference between the normal and 
decompensated corneas when the age and period in storage were compared. The 
DM/Endothelium complex of the decompensated corneas was completely removed 
prior to the experiment. Endothelial cell density (ECD); Descemet’s membrane 
(DM). 
2.3.5.3.Optical Coherence Tomography assessment of corneal endothelial 
cell function 
The Zeiss Visante OCT is able to scan the entire surface of the cornea and to acquire 
a cross-section image at specific orientations, ranging between 0o-180o, 45o-225o, 
90o-270o and 135o-315o. It also has inbuilt software that allows corneal thickness 
measurements to be done at multiple locations, providing an accurate and precise 
method for assessment of whole corneal thickness without observer or selection bias 
(See Figure 8).  
 60 
 
Figure 8 – Zeiss Visante Optical Coherence Tomography (OCT). The thickness 
of each cornea was acquired and corneal cross-section images were generated 
at four different orientations – 0o-180o, 45o-225o, 90o-270o and 135o-315o (A and 
B), corneal cross-section image acquisition (C), a total of 28 measurements 
across a 6 millimeter diameter of the central cornea were done and the average 
value ± standard deviation (SD) was used as a representative of the corneal 
thickness (B and D). 
2.3.5.3.1.Initial corneal thickness measurement 
Before starting the experiment the human donor corneas were kept in immersion 
organ culture conditions as described in section 2.3.2. After the DM/Endothelium 
complex was removed to create a CE decompensation model both the normal and 
the decompensated corneas were transferred into air-interface organ culture as 
described in section 2.3.5. Immediately after the corneas were transferred from 
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immersion into air-interface organ culture an initial corneal thickness measurement 
was performed using Zeiss Visante OCT. Corneal cross-section images were 
acquired for each individual cornea at specific orientations or quadrants – 0o-180o, 
45o-225o, 90o-270o and 135o-315o. For each cornea 7 individual pinpoint 
measurements across a 6 mm diameter in each of the 4 quadrants were taken using 
the Zeiss Visante OCT analysis mode. Therefore, a total of 28 measurements were 
done at different locations for each cornea. The average value of the 28 
measurements was used to represent the corneal thickness of each cornea. Normal 
CE function could be demonstrated based on the amount of thickness de-swelling 
and physiological thickness level achieved after transfer into air-interface organ 
culture. 
2.3.5.3.2.Subsequent corneal thickness measurements 
Subsequent corneal thickness measurements were done at regular time intervals 
every 1-hour for the experiment lasting 12-hour incubation period and every 24 
hours for the 14-day incubation period experiment. 
2.3.6. Histology 
Histology was used to confirm the successful complete removal of the 
DM/Endothelium complex from human donor corneas used as a CE decompensation 
model. The corneas were fixed in 10% formalin for 10 min at room temperature and 
were stored at 4oC overnight. Paraffin embedding, haematoxylin and eosin (H&E) 
staining and sample analysis was done in Addenbrooke’s Hospital, Cambridge, UK. 
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2.3.7. Statistical analysis 
Single factor ANOVA test was used for statistical analysis to determine if there was 
a statistically significant difference between the normal and decompensated corneal 
groups after a period of air-interface organ culture. Confidence levels were set at 
95%. P<0.05 was considered statistically significant. Post hoc t tests (Bonferroni 
corrected) were used to compere the corneal thickness of the different groups of 
corneas at specific time points throughout the incubation period. The error bars in all 
graphs and bar charts represent the mean ± standard deviation (SD).  
2.4. Results 
2.4.1. Optical Coherence Tomography assessment of corneal endothelial cell 
function during air-interface organ culture: 14-day incubation 
There was no statistically significant difference in endothelial cell density (ECD) 
prior to DM/Endothelium complex removal, the age and the storage period prior to 
experimentation between the normal and decompensated corneas used in the 14-day 
incubation experiment. Both the normal and the decompensated corneas expressed 
oedematous phenotype at the start of the experiment as a result of being stored in 
immersion organ culture conditions before the experiment. The initial thicknesses at 
time point 0 of the normal and the decompensated corneas were 876.41 ± 88.62 μm 
and 918.68 ± 98.27 μm respectively. After 24 hours of in vitro air-interface organ 
culture the normal corneas showed a 33.32 ± 6.89 % decrease from the initial 
thickness reached a thickness of 582.59 ± 70.31 μm. This was statistically significant 
(p<0.001) compared to the decompensated corneas, which only showed a 4.21 ± 
6.62 % decrease and maintained an oedematous phenotype with 879.73 ± 109.58 μm 
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thickness over the same period. The normal corneas maintained a near-normal 
physiological thickness of 581.25 ± 7 μm between 24 hours and 4 days of 
incubation. Between the 4th and the 14th day the normal corneas maintained an 
average thickness of 666.87 ± 57.06 μm (23.01 ± 6.47 % decrease from their initial 
thickness). Between 24 hours and 14 days the decompensated corneas expressed a 
severe oedema and maintained an average thickness of 826.32 ± 23.46 μm (9.87 ± 
2.5 % decrease from their initial thickness). A single-factor ANOVA test showed 
that there was a statistically significant difference between the normal corneas and 
the decompensated corneas when the mean thicknesses (μm) and the mean 
percentage thickness decrease (%) were compared (See Figure 9 and Figure 10). 
The normal corneas showed a thickness decrease to normal physiological levels, 
which gradually started to increase after 72 hours of incubation, whereas the 
decompensated corneas had an oedematous phenotype throughout the entire 
incubation period (See Figure 11). All corneal thickness (μm) and percentage 
decrease (%) values are available in APPENDIX 1 - Table 19. 
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Figure 9 – Stromal de-swelling of in vitro organ cultured human corneas during 
a 14-day incubation period. Normal corneas with endothelial cell density of 
1718 ± 306.31 cells/mm2 (n=4) [] reached a normal physiological thickness 
level of 582.59 ± 70.31 μm and maintained a thickness of 666.87 ± 57.06 μm 
until the end of the 14-day incubation period. The endothelial cell density was 
not measured at the end of the experiment. The decompensated corneas showed 
signs of severe oedema with thickness of 826.32 ± 23.46 μm throughout the 
same period (n=4) []. A single-factor ANOVA test showed that there was a 
statistically significant difference between the means of the normal and 
decompensated corneas (p<0.05 was considered statistically significant). *Post 
hoc t test (Bonferroni correction) revealed statistically significant difference 
between all time points. 
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Figure 10 – Stromal de-swelling assessment of in vitro organ cultured human 
corneas during a 0-14 day incubation period. The normal corneas displayed an 
average 23.01 ± 6.47 % decrease, whereas the decompensated corneas only 
showed a 9.87 ± 2.5 % decrease. A single-factor ANOVA test revealed that 
there was a statistically significant difference between the normal and the 
decompensated corneas. *p=0.000003 (p<0.05 was considered statistically 
significant). 
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Figure 11 - Optical Coherence Tomography: images of normal (n=4) and decompensated (n=4) corneas cultured at air-
interface organ culture. The normal corneas show a reduction in thickness to normal physiological levels at 6, 24 and 72 
hours, however, an oedematous phenotype is observable after 7 and 14 days of air-interface organ culture. Corneal 
endothelial cell count was not done at the end of the experiment. The decompensated corneas displayed an oedematous 
phenotype throughout the entire experiment. 
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2.4.2. Optical Coherence Tomography assessment of corneal endothelial cell 
function during air-interface organ culture: 12-hour incubation 
There was no statistically significant difference between the age and the storage 
period prior to experimentation in the corneas used in the 12-hour incubation 
experiment. Both the normal and the decompensated corneas expressed oedematous 
phenotype at the start of the experiment as a result of being stored in immersion 
organ culture conditions prior to the experiment. The initial thickness at time 0 of 
the normal corneas (n=6) was 1092.74 ± 108.03 μm and 1128.51 ± 98.91 μm for the 
decompensated corneas (n=5). At 12 hours the normal corneas, placed into air-
interface organ culture, experienced a thickness decrease of 48.27 ± 9.78 % from its 
initial value and reached a normal physiological thickness of 557.51 ± 72.64 μm. 
While the thickness of the decompensated corneas decreased only by 19.27 ± 10.87 
% from their initial thickness, they maintained an oedematous phenotype with 
thickness of 903.6 ± 86.51 μm throughout the entire incubation period. A single-
factor ANOVA test showed that there was a statistically significant difference 
between these two groups (See Figure 12 and Figure 13). All corneal thickness 
values and % decrease values are available in APPENDIX 1 Table 17. 
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Figure 12 – Stromal de-swelling of in vitro organ cultured human corneas. 
Normal corneas (n=6) [] showed a more significant thickness decrease 
compared to decompensated corneas (n=5) [] and were able to reach a near-
physiological thickness of 557.51 ± 72.64 μm by the end of the 12-hour 
incubation period. The decompensated corneas maintained an edematous 
phenotype with thickness of 903.6 ± 86.51 μm. A single-factor ANOVA test 
showed that there was a statistically significant difference between the mean 
thicknesses of the normal and the decompensated corneas (p<0.05 was 
considered statistically significant). *Post hoc t test (Bonferroni correction) 
revealed statistically significant difference between all time points except point 
0 hours. 
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Figure 13 – Stromal de-swelling during a 12-hour incubation period. Normal 
corneas with endothelial cell density (ECD) 2002 ± 357.99 cells/mm2 were used 
as a positive control for normal corneal endothelial cell function (the normal 
endothelial cell density for an elderly cornea is between 2200 and 2800 
cells/mm2). The percentage reduction of corneal thickness in the normal 
corneas was 48.27 ± 9.78 % after 12 hours of incubation and 19.27 ± 10.87 % 
for the decompensated corneas. A single-factor ANOVA test revealed that there 
was a statistically significant difference between the normal and the 
decompensated corneas. *p=0000004 (p<0.05 was considered statistically 
significant).  
By the end of the experiment the normal corneas were significantly thinner (p<0.05) 
compared to the decompensated corneas and did not show any signs of posterior 
stromal folds. However, posterior stromal folds were observable in the 
decompensated corneas (See Figure 14). 
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Figure 14 – Optical Coherence Tomography: high-resolution quadrant images of normal (n=6) and decompensated 
(n=5) corneas. The normal corneas have reached normal physiological thickness after 12 hours of air-interface 
organ culture, whereas the decompensated corneas remain oedematous. 
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2.4.3. Histology 
Histological assessment with haematoxylin and eosin (H&E) staining of a 
decompensated cornea confirmed that the DM/Endothelium complex was 
completely removed and that a decompensation model was successfully created 
without disturbance to the posterior stromal collagen (See Figure 15).  
 
Figure 15 – Histological examination revealed the complete removal of the 
Descemet’s membrane/Endothelium complex with no disturbance to the 
posterior stroma of cadaveric human donor corneas, confirming that an in vitro 
human corneal endothelial decompensation model was successfully induced 
[Haematoxylin and eosin (H&E) staining; x100].  
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2.5. Discussion 
The human corneal endothelial cells form a monolayer at the posterior part of the 
cornea, which has a highly specialized function to maintain the corneal stroma in a 
controlled dehydrated state. This accounts for corneal transparency and is very 
important for normal vision. Damage or loss of the corneal endothelial monolayer 
leads to stromal oedema and loss of optical transparency of the cornea. Injury or 
damage to the corneal endothelium can be caused by dystrophies, such as Fuchs’ 
dystrophy or trauma, which leads to corneal blindness. The human corneal 
endothelial cells are generally considered post-mitotic and have poor proliferative 
and self-renewal capacity in vivo and in vitro (Joyce, et al., 1996a and 1996b; Chen, 
et al., 1999). Human corneal endothelial disorders are currently treated using partial 
thickness transplantation techniques, such as DSAEK, DMEK and micro-thin 
DSAEK (Rajan, 2014). These treatments all rely on a partial-thickness graft 
harvested from a donor cornea, which is a major limiting factor due to lack of donor 
tissue availability in some parts of the world. Therefore, current research is focused 
on developing novel strategies for generating hCECs for therapeutic purposes. Cell-
therapy would allow the use of a single donor cornea to produce a cell bank through 
isolation and in vitro culture of the corneal endothelial cells that could later be used 
for cell transplantation into patients. This treatment method has the potential to 
greatly reduce or even eliminate the need for donor material thus making this 
treatment available in countries where donor tissue is not readily available. In order 
to develop a cell-therapy treatment there is ongoing research for developing suitable 
in vivo or in vitro transplantation models and on optimizing primary hCEC isolation 
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and culture. In order to test this novel treatment method many groups have reported 
using a wide range of animal models including rabbit (Jumblatt, et al., 1978), rat 
(Mimura, et al, 2004a), cat (Proulx, et al, 2009) and primate (Koizumi, et al., 2007). 
However, certain limitations exist when using such models. For example, the rabbit 
and the rat have been documented as species whose corneal endothelium has the 
capacity to renew itself through proliferation (Van Horn, et al., 1977 and Tuft, et al., 
1986). Since the human corneal endothelium lacks proliferative capacity using 
animal models whose endothelium can proliferate makes the generated data not 
directly applicable to humans. Therefore, it would be more beneficial to have a 
model that is more similar to humans, which will make any data generated with it 
more clinically relevant. The primate model has recently gained a lot of eminence 
for being more similar to the human corneal endothelium in its lack of proliferative 
response. However, even though this primate model is considered adequate for 
testing the feasibility of corneal endothelial cell transplantation the use of it in the 
lab remains very challenging and expensive because it requires special facilities and 
maintenance techniques. Also in many countries the use of animal models especially 
primates is very strictly controlled because of ethical issues. Ideally a human model 
would provide a testing platform that would generate data that is clinically relevant.  
Therefore, in this study the aim was to establish an in vitro human corneal model of 
endothelial decompensation using cadaveric human corneas and to validate it for 
future use in testing the effectiveness of a cell-therapy treatment after transplanting 
cultured hCECs directly to the corneal stroma. Using an in vitro human model offers 
many advantages over animal models with the most important benefit being that it is 
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of human origin and also donor corneas are much easier and cost effective to 
maintain in the lab compared to animal models and allow for better control and 
reproducibility of the experiments. 
The data from this chapter shows that when human donor corneas with intact 
DM/Endothelium complex and adequate cell density are cultured using air-interface 
organ culture their thickness will reach normal physiological levels. Whereas, the 
corneas whose DM/Endothelium is removed would maintain a severely oedematous 
phenotype when cultured in the same conditions. The data clearly demonstrates that 
this method of air-interface organ culture can adequately be utilized to determine 
and test the presence or absence of a functional corneal endothelial cell monolayer 
by using the corneal thickness as a surrogate measure of corneal endothelial cell 
function. This is very important for cell-therapy evaluation because it will enable 
testing whether normal corneal endothelial cell function has been restored to 
decompensated corneas (DM/Endothelium removed) by measuring the corneal 
thickness using Zeiss Visante OCT after corneal endothelial cell transplantation. 
This method is very effective in accurately measuring corneal thickness because it is 
able to acquire a cross section image, which reveals if posterior stromal folds are 
present (See Figure 16). It allows for thickness measurements to be taken at 
multiple locations of each cornea thus increasing the accuracy of the measurements 
as opposed to a single point measurement done by ultrasound pachymetry. In our 
experiments 28 measurements were taken at different locations for each cornea 
making the corneal thickness assessment very accurate (See Figure 8). 
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Figure 16 – Posterior stromal folds are visible on a corneal cross-section image 
acquired by optical coherence tomography. 
The method of air-interface organ culture is very useful because it allows the 
corneas to be maintained in an environment that more closely simulates the normal 
physiological environment of the human cornea where the epithelial side has contact 
with the air. In Eye Banks normally human corneas are stored in immersion organ 
culture. But when stored in immersion even corneas with intact DM/Endothelium 
complex would swell. The mechanism by which the cornea maintains its thickness is 
interplay between the stromal swelling pressure driving the fluid inwards to the 
stroma and the active pump of ions driving the fluid outwards from the stroma. The 
stromal swelling pressure is the tendency of the stroma to swell as a result of its 
mechanical composition and is affected by the concentration of proteoglycans 
(Fischbarg and Maurice, 2004). However, since the corneal stroma is compressed 
between the epithelium and endothelium, a negative fluid pressure is created through 
an active ion transport that counteracts the stromal swelling pressure and causes the 
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corneal thickness to decrease (Dohlman, et al., 1962). When a donor cornea is stored 
in immersion, the storage environment does not allow such negative fluid pressure to 
be created, therefore causing even corneas with intact DM/Endothelium complex to 
become swollen. After transfer from immersion into air-interface organ culture, the 
cornea is no longer completely submerged in medium, with the exception of its 
endothelial side, and is able to de-swell (Aboalchamat, et al., 1999). Since the air-
interface culture environment mimics more closely the natural conditions to which 
the cornea is normally subjected, these conditions allow the negative fluid pressure 
to be restored resulting in corneal de-swelling. 
In our air-interface organ culture experiments, during both the 12-hour and the 14-
day incubations, a slight thickness decrease in the decompensated corneas 
(DM/Endothelium removed) was observed, which was independent of CE pump 
function since these corneas were denuded of their native DM/Endothelium 
complex. This dehydration effect accounted for a total of 19.27 ± 4.86 % thickness 
decrease during the 12-hour incubation and a 9.83 ± 3.38 % decrease during the 14-
day incubation experiments. Since the decompensated corneas had their 
DM/Endothelium completely removed prior to the experiments this minor decrease 
in thickness was attributed to the change of environment conditions after transfer 
from immersion to air-interface organ culture. The decompensated corneas 
maintained an oedematous phenotype with corneal thickness ≥ 780.83 ± 54.81 μm, 
whereas the normal corneas were able to reach and maintain physiological thickness 
of 555.86 ± 33.35 μm. When using this in vitro corneal model it was challenging to 
provide adequate hydration of the epithelial side of the cornea and to keep it 
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sufficiently moist throughout the entire incubation period. A plastic ring was 
attached to the artificial anterior chamber in order to hold culture medium and keep 
the corneal surface moist during incubation (See Figure 17).  
 
Figure 17 – A plastic ring attached to the artificial anterior mounting chamber 
was used to hold medium and moisturize the epithelial side of the corneas 
during the incubation period. However, its use was discontinued due to medium 
leaking out for some of the corneas causing inconsistencies in the experimental 
results. 
However, that proved ineffective due to the medium leaking through the ring for 
some of the corneas, therefore the use of these plastic rings was discontinued. 
Additionally, due to the nature of the model it could only be filled with a limited 
amount of medium that was injected in the artificial anterior chamber. The medium 
was not constantly being perfused but was rather injected into the tubing of the 
model and was clamped in place. This resulted the corneas would start collapsing 
after some time in air-interface organ culture due to decreasing medium pressure 
inside the artificial anterior mounting chamber. The corneal surface was moisturized 
by pipetting 200 μl medium to the epithelial side every 24 hours and the culture 
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medium of the artificial anterior mounting chamber was exchanged every 24 hours, 
however, this was not sufficient to prevent the corneas from gradually collapsing 
when incubating overnight. This would cause an inconsistency to the experimental 
procedure. Therefore, the long-term incubation period of 14 days proved to be a 
limiting factor that caused inconsistency in the control of experimental conditions. 
When analyzing the results from the 14-day incubation experiment it was observed 
that by the end of the first 24 hours in air-interface organ culture the normal corneas 
(with intact DM/Endothelium complex) had already reached the maximum reduction 
in corneal thickness suggesting that when normal corneal endothelial cell function is 
present the corneal thickness is restored to normal within 24 hours for the air-
interface organ culture conditions that were used in this study. It was also observed 
that after the 4th day of incubation the corneal thickness of the normal corneas 
gradually started to increase until it almost reached the same level as the 
decompensated corneas by the end of the 14-day incubation period. This gradual 
thickness increase could be attributed to a reduction in corneal endothelial cell 
viability and inadequate hydration of the corneas that could not be consistently 
controlled throughout the entire incubation period. This makes the current model 
limited to about 7 days in terms of efficacy to maintain normal corneal endothelial 
cell pump function. In order to optimize the experiment and to increase the 
consistency and control of experimental conditions the incubation period of the 
corneas was reduced to 12 hours. This reduction in incubation period allowed the 
culture conditions of the corneas to be more easily controlled and maintained 
consistent for all corneas through the entire experiment. By moistening the epithelial 
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side of the corneas every hour and by maintenance of the artificial anterior chamber 
through irrigation every hour. Hence, future studies for optimizing this corneal organ 
culture model should include optimizing the hydration of the epithelial side of the 
cornea by using a spraying device that would enable 24-hour constant moisturizing 
of the cornea. In addition to that a perfusion system to allow constant medium 
exchange and maintenance of a constant pressure to keep the corneas from 
collapsing would enable long-term testing of the effects of cell therapy over periods 
longer than 12 hours. In the normal physiological state some rhythmical changes of 
the aqueous humour flow have been reported with rates of 3 μl/min in the morning, 
2.4 μl/min in the afternoon and 1.5 μl/min at night (Brubaker, 1989). Rhythmical 
changes of the intraocular pressure have also been observed with values reaching 
around 14 mmHg in the morning and around 11 mmHg in the afternoon (Sajja and 
Vemapti, et al., 2013). In our in vitro corneal model the endothelial side of the 
cornea was not continuously perfused but the medium was kept in place by pinch 
clamps on the tubing of the artificial anterior mounting chamber. As a result of that 
after about an hour of incubation a slight capsizing of the corneas would be observed 
caused by a pressure decrease. This effect seemed to be more pronounced on the 
corneas with intact CE function suggesting that normal CE function can affect the 
intraocular pressure. Therefore, in the 12-hour incubation experiment the culture 
medium was exchanged every 1-hour in order to restore the pressure in the in vitro 
model and to keep the corneas from capsizing. Albeit, the pressure levels in the 
artificial anterior chamber were not measured during any of the experiments. 
Designing an in vitro human corneal model with a normal aqueous human outflow 
  80 
and intraocular pressure would be very beneficial in keeping the CECs healthy for a 
longer period of time. Measuring the pressure levels continuously throughout the 
incubation would allow keeping the corneas from capsizing and that would possibly 
increase the CE vitality over a long-term incubation period. In addition, for 
optimizing the in vitro model it would be beneficial to mimic the culture conditions 
as closely as possible to the normal physiological conditions. For example, the 
ambient humidity is about 30%, however in our case the corneas were incubated in a 
humidified CO2 incubator with 95% humidity levels. Interestingly, it has been 
demonstrated that the pre-corneal humidity does not have any substantial effect on 
the corneal thickness and de-swelling (Cohen, et al., 1990), therefore culturing the 
corneas at 95% humidity would not be expected to cause any negative effect on the 
stromal hydration. Nevertheless, relative humidity has been shown to have an effect 
on the aqueous tear loss with significant increase of tear loss at 20-25% humidity 
(McCulley, et al., 2006). Another aspect that could affect the long-term efficiency 
for maintaining the CE healthy in the in vitro model would be dependent on the type 
of media used for continuous perfusion of the posterior side of the cornea. It has 
been demonstrated that the aqueous humour plays a role in the CE proliferation 
control via TGF-β, which helps keep the hCECs in G1 stage (Chen, et al., 1999). 
Ideally a fluid with similar composition as the aqueous humour might prove to 
prolong the viability of the CE. In our in vitro model we used culture medium to 
moisturize the epithelial side of the corneas in order to simulate a tear film, however 
its composition is different from the physiological tear film and might not be as 
efficient in keeping the epithelium nourished and protected. One of the 
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decompensated corneas (DM/Endothelium complex removed) underwent 
histological examination in order to confirm the complete removal of the 
DM/Endothelium (See Figure 15). It shows a cross-section of the cornea and its 
epithelium, which is normally multi-layered and therefore appears much thicker than 
the CE monolayer, seems to be similar in thickness with the CE. This is perhaps 
indicative of epithelial cell loss during air-interface organ culture and suggests that 
the culture medium used for moisturizing the epithelium was not very effective in 
preserving it. For future optimization of the in vitro model it would conceivably be 
more efficient to use an artificial tear solution which would mimic the normal 
physiological conditions of the eye more closely thus improving the health of the 
corneal epithelium. This would be an important step in improving the in vitro model 
because even though the majority of the corneal hydration control depends on the 
CE, the epithelium has also been shown to play a minor role in the stromal hydration 
(Maurice and Giardini, 1951). The cadaveric human corneas that were used in our 
study as an in vitro corneal model were cultured at a temperature of 37oC, which 
might not be optimal conditions since it has been shown that the temperature on the 
surface of the cornea is around 34oC (Dixon and Blackwood, 1991). Hence, altering 
the culture temperature might also improve the longevity of this corneal model. 
Donor cornea characteristics, such as initial corneal thickness, age, period in storage 
and ECD, were compared for sample-specific variation. In both the 12-hour and 14-
day incubation experiments all corneas did not have any significant difference in age 
and period in storage prior to experimentation (p>0.05), therefore, these factors were 
not considered to have a significant contribution to sample variation.  
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The overall results in this study demonstrated that the corneal thickness of the 
normal corneas decreased more significantly compared to the decompensated 
corneas when cultured using air-interface organ culture. This means that using this 
in vitro model the presence or absence of a functional corneal endothelial cell 
monolayer could successfully be demonstrated by measuring its effect on the corneal 
thickness of normal (intact DM/Endothelium complex) and decompensated 
(DM/Endothelium removed) corneas. Overall the results of this chapter show that 
this model can successfully be used for corneal endothelial cell transplantation 
testing. 
2.6. Conclusion 
Firstly, this study establishes the base line for stromal hydration behaviour of normal 
human corneas with adequate endothelial cell density in air-interface organ culture. 
Secondly, the oedematous phenotype of corneas denuded of their DM/Endothelium 
complex is demonstrated in comparison to normal control corneas with an intact 
DM/Endothelium complex. Thirdly, the in vitro system for human corneal organ 
culture used in this study can be successfully utilized for testing the efficiency of 
transplanted hCECs to decompensated human corneas, making it a valuable tool for 
cell-therapy evaluation in future studies. In addition, the above study identified that a 
12-hour period would be the most appropriate time window to undertake CE 
functional assessment given the limitations of this in vitro set-up. 
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3. CHAPTER 3 – CELL THERAPY EVALUATION USING 
AN IN VITRO HUMAN CORNEAL MODEL OF 
ENDOTHELIAL DECOMPENSATION 
3.1. Chapter overview 
In this chapter the in vitro human CE decompensation model, which was established 
in chapter 2, was used to test human corneal endothelial cell (hCEC) transplantation 
as a potential treatment of CE disorders in humans. It was found that primary 
(passage 0) and (passage 2) hCECs have the capacity to restore normal functional 
CE monolayer after transplantation to the corneal stroma in the absence of a DM. 
Immortalized HCEC-12 cells were also used as a model for testing hCEC function 
after transplantation due to their high proliferative capacity that enables them to be 
readily expanded in culture and allows the generation of sufficient cell quantities 
that could be used for cell transplantation studies. The corneal endothelial cell 
function was tested up to 10 days after hCECs were transplanted to the corneal 
stroma. The corneal thickness was used as a surrogate measure of CE function and 
was measured using Zeiss Visante OCT over a 12-hour incubation period. The data 
from this chapter shows that after hCEC transplantation to the corneal stroma a 
functional CE monolayer is regenerated demonstrating the plausibility of using a 
cell-therapy approach for treating CE disorders in humans. 
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3.2. Brief introduction 
Current treatments for corneal blindness rely on human cadaveric donor corneas for 
graft harvesting and transplantation. This limits treatment availability in countries 
where access to donor tissue is inadequate.  
Hence, this chapter aims to evaluate the attachment, monolayer formation and 
functional potential of cultured human corneal endothelial cells after cell suspension 
transplantation directly to the posterior corneal stroma using an in vitro human 
corneal decompensation model. It was hypothesized that direct cell transfer to the 
posterior corneal stroma would result in endothelial cell attachment and will recover 
normal CE function in decompensated human corneas. The effect of hCEC 
transplantation on the corneal thickness was tested. The stromal thickness was used 
as a surrogate measure of hCEC function. Corneal thickness measurements were 
taken every hour over a 12-hour incubation. The outcome of hCEC transplantation 
to human donor corneas was evaluated using Zeiss Visante OCT for corneal 
thickness measurement and by histological assessment of the hCEC monolayer post-
transplantation. Primary hCECs (passage 0) and hCECs (passage 2) were used for 
cell transplantation testing. Immortalized corneal endothelial cells (HCEC-12 cell 
line) were also used as a model for testing hCEC transplantation because they are 
readily available and due to their capacity to be easily expanded in cell culture. 
3.3. Materials and Methods 
3.3.1. List of materials used 
Human corneas were obtained from Bristol and Manchester Eye Banks, UK; HCEC-
12 – (ACC 646), Leibniz Institute DSMZ – German Collection of Microorganisms 
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and Cell Cultures; Human bone marrow-derived mesenchymal stem cells (BM-
MSCs) - (PCS-500-012), The European Collection of Cell Cultures (ECACC); 
Mesenchymal Stem Cell Basal Medium – (PCS-500-030), ATCC Primary Cell 
Solutions; OptiMEM – (51985-026), Invitrogen by Life Technologies; Foetal bovine 
serum (FBS) – (F0804-500ML), Sigma Aldrich; Epidermal growth factor (EGF) – 
(E9644), Sigma Aldrich; Calcium chloride – (21115), Sigma Aldrich; Gentamicin – 
(G1397), Sigma Aldrich; Trypsin/EDTA – (T3924), Sigma Aldrich; Phosphate 
buffered saline (PBS) – (P3813), Sigma Aldrich; 24-well plates – (CLS3527), Sigma 
Aldrich; 6-well plates – (CLS3516), Sigma Aldrich; 12-well plates – (CLS3513), 
Sigma Aldrich; T25 flasks – (12-565-351), Thermo Scientific; T75 flasks – (12-565-
350), Thermo Scientific; 15 ml centrifuge tubes – (14-955-160), Thermo Scientific; 
50 ml centrifuge tubes – (14-955-161), Thermo Scientific; 0.06% VisionBlue™ 
(trypan blue); Barron artificial anterior chamber – Barron Precision Instruments; 
TrytonX-100 – (T8787), Sigma Aldrich; Hoechst 33258 – (94403), Sigma Aldrich; 
DAKO fluorescent mounting medium – (S3023), Dako; Anti-Na+/K+ ATPase 
primary antibody (mouse monoclonal) - (ab7671), Abcam, Cambridge, UK; Anti-
ZO-1 primary antibody (rabbit polyclonal) - (ab59720), Abcam, Cambridge, UK. 
Goat anti-rabbit (goat polyclonal) IgG secondary antibody (Alexa Fluor 488) – 
(ab150077), Abcam, Cambridge, UK; Goat anti-mouse  (polyclonal) IgG secondary 
antibody (Alexa Fluor 488) – (ab150117), Abcam, Cambridge, UK; Multiwell 
Chambered Coverslips – (24779), Invitrogen; BD Plastipak 10 ml syringes – 
(SYR188), Medisave; Millex 0.22 um syringe filters – (F7648-50EA), Sigma 
Aldrich; Zeiss Visante OCT. 
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3.3.2. Primary hCEC culture 
Cornea donor information is available in APPENDIX 2 - Table 20. 
• Number of corneas – n=22. 
• CE viability was assessed using 0.06% VisionBlue™ (trypan blue) staining 
prior to primary cell isolation.  
• Donor age – 70 ± 13 years old (43-86 range). 
• Days in storage – 49.3 ± 21 days (21-88 range). 
3.3.2.1.Preparation of bone marrow-derived mesenchymal stem cell-
conditioned medium 
All primary hCEC cultures were done using mesenchymal stem cell-conditioned 
medium (MSC-CM), which was prepared according to published protocol by 
Nakahara, et al. (2013). Human bone marrow-derived mesenchymal stem cells (BM-
MSCs) were seeded at 1.3 x 104 cells/cm2 and were cultured for 1 day in DMEM, 
10% FBS, 1% penicillin/streptomycin. The cells were then washed with PBS. The 
medium was then replaced with Opti-MEM-I, 8% FBS, 5ng/ml EGF, 20μg/ml 
ascorbic acid, 200 mg/L calcium chloride, 0.08% chondroitin sulfate and 50 μg/ml 
gentamicin. The BM-MSCs were maintained for an additional 24 hours. The 
medium was then collected and centrifuged at 2000 rotations per minute (rpm) for 
10 min and the supernatant was then filtered through a 0.22μm syringe filter. The 
filtered medium was then used as mesenchymal stem cell conditioned medium 
(MSC-CM). All primary cultures were cultured at 37oC, 5% CO2, humidified 
incubator Heracell™ (relative humidity – 95%). BM-MSCs passages 2 – 6 were 
used for conditioning. 
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3.3.2.2.Isolation of primary human corneal endothelial cells 
Primary human corneal endothelial cells were isolated from human donor corneas as 
follows: 
1) The corneas were placed endothelial side-up in a trephine base.  
2) The endothelium was stained with 0.06% VisionBlue™ (trypan blue) vital 
stain for 30 sec in order to minimize the cell toxicity effect of the trypan blue 
vital stain. 
3) The Descemet’s membrane was then washed and covered with 
unsupplemented culture medium to avoid drying of the endothelium.  
4) Using a surgical knife the Descemet’s membrane was scored at its periphery 
without disturbing the underlying stroma.  
5) The DM/Endothelium complex was then peeled using forceps.  
6) The cells were then dissociated from the membranes using 1 ml 0.05 % 
Trypsin/EDTA for 10-15 min at 37oC.  
7) After all the cells were dissociated from the Descemet’s membrane MSC-
CM supplemented with 8 % foetal bovine serum (FBS) was added to stop the 
trypsin reaction. 
8)  The cells were centrifuged and the supernatant was removed.  
9) 1 ml fresh MSC-CM was then added to the cell pellet.  
10)  The cells were then transferred to a 24-well plate and were cultured in a 
humidified incubator at 37oC, 5 CO2 (relative humidity – 95%).  
11)  The cells were incubated until confluence was reached – between 7-21 days. 
The medium was replaced every 2 days.  
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3.3.3. HCEC-12 culture 
The immortalized human corneal endothelial cell line HCEC-12 was used for culture 
and cell therapy testing due to its high proliferative capacity, which allowed it to be 
easily expanded in culture. These cells are a useful experimental tool because they 
seem to retain some characteristics of the normal CE, such as expression of CE-like 
morphology at confluence and CE pump function (Aboalchamat, et al., 1999). The 
HCEC-12 cell line, established in 1996 from normal corneal endothelial cells of a 
91-year-old Caucasian woman transformed with the early region of the Simian virus 
40 (SV40) genome including genes encoding large T-antigen and small t-antigen, 
was obtained from the Leibniz Institute DSMZ (German collection of 
Microorganisms and Cell Cultures). HCEC-12 cells were cultured using F99 
(mixture of Ham’s F12 and Medium 199 in 1:1 ratio), 10% FBS in a humidified 
incubator with 5% CO2 at 37
oC (relative humidity – 95%). The medium was 
changed every 2 days. The cells were seeded out at 50 cells/mm2. Confluent cultures 
were split 1:2 to 1:4 every 4-5 days using 0.05% trypsin/EDTA.  
3.3.4. Immunocytochemistry 
Primary antibodies against human Na+/K+ ATPase (ab7671), zona occludens 1 (ZO-
1) (ab59720) and secondary anti-mouse and anti-rabbit antibodies were obtained 
from Abcam, Cambridge, UK. HCEC-12 and primary hCECs were cultured on a 
glass slide with 4 separate chambers and the cells within each chamber were stained 
with a different antibody. Cells were seeded at 1000 cells/mm2. HCEC-12 were 
cultured in F99 (Ham's F12/Medium 199 1:1 mixture), 8% FBS. Each chamber 
contained 1 ml final volume culture medium. Primary hCECs were cultured using 
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OptiMEM-I, 8 % FBS, 5 ng/ml epidermal growth factor (EGF), 20 μg/ml ascorbic 
acid, 200 mg/L calcium chloride, 0.08 % chondroitin sulfate, 50 μg/ml gentamycin. 
Both HCEC-12 and primary hCECs were incubated overnight at 37oC, 5 % CO2, 
95% humidity before staining with antibodies.  
A commonly used procedure for antibody staining was done as follows: the culture 
medium was aspirated from the glass slide. The glass slide was then washed in 
phosphate-buffered saline (PBS) 3 times. 10 % Paraformaldehyde (PFA) solution 
was used to fix the cells for 10 minutes at room temperature. After the PFA was 
removed the cell were washed with PBS 3 times. Blocking solution (10% FBS, 0.1% 
TritonX-100 in PBS) was added and the cells were incubated for 1 hour at room 
temperature. The primary antibodies for Na+/K+ ATPase and ZO-1 were diluted in 
blocking solution in a 1:100 dilution as per the manufacturer's protocols. The 
solution with each antibody was then added to the respective chamber on the glass 
slide. The cells were incubated with the primary antibodies overnight at 4oC. The 
next day the primary antibody solution was removed and the cells were washed 3x 
with PBS for 10 min. The secondary antibodies were diluted in blocking solution 
with Hoechst DNA stain. The slides were then wrapped in foil to protect the 
photosensitive fluorophores. The diluted secondary antibody/Hoechst mixture was 
then added and the cells were incubated for 1 hour at room temperature. After 1 hour 
the secondary antibody/Hoechst solution was removed and the cells were rinsed 3x 
with PBS for 10 minutes each. Before mounting the slides were quickly washed with 
H2O and were then dried off. DAKO mounting medium was used to mount a 
coverslip to the glass slide, which was then allowed to dry at room temperature for 4 
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hours wrapped in foil. They were then viewed using a Leica Microsystems CMS 
confocal microscope. 
3.3.5. Human donor corneas used for human corneal endothelial cell 
transplantation 
Human donor corneas (n=17) for this study were supplied by Bristol Eye Bank, 
Bristol, UK and Manchester Eye Bank, Manchester, UK in three separate batches 
during separate time intervals (cornea donor information is available in APPENDIX 
3 Table 21. The corneas were stored in Eagle’s Minimum Essential Medium (MEM) 
supplemented with 2 % foetal bovine serum (FBS) at 37oC. Transportation of the 
corneas was at 25oC. No dextran was added to the medium at any point during 
storage and culture. Corneas age ranged between 46 - 81 years. Each of the three 
batches of corneas underwent removal of the DM/Endothelium complex in order to 
establish the CE decompensation model. Group 1 (n=6) was seeded with HCEC-12 
cells, group 2 (n=5) was seeded with passage 0 primary hCECs and group 3 (n=6) 
was seeded with passage 2 cultured hCECs. 
3.3.6. Corneal endothelial cell transplantation in an in vitro human corneal 
model of endothelial decompensation 
All corneas had their DM/Endothelium complex removed as described in the 
methods section 2.3.4 and were divided into three groups. In group 1 was seeded 
with HCEC-12 cells via cell suspension in culture medium F99 (1:1 mixture of 
Ham’s F12 and Medium 199), supplemented with 10% foetal bovine serum (FBS), 
1% penicillin/streptomycin. In groups 2 and 3 primary cultured hCECs (passage 0 
and passage 2 respectively) were used for seeding via cell suspension in culture 
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medium OptiMEM-I, 8 % FBS, 5 ng/ml epidermal growth factor (EGF), 20 μg/ml 
ascorbic acid, 200 mg/L calcium chloride, 0.08 % chondroitin sulfate, 50 μg/ml 
gentamycin.  
3.3.6.1.Group-1 corneas 
Cell therapy group-1 (n=6) corneas were used test the capacity of immortalized 
HCEC-12 cells to attach and form a functional corneal endothelial cell monolayer 
after transplantation to the posterior corneal stroma. For that purpose HCEC-12 cells 
were cultured to confluence using F99 (mixture of Ham’s F12 and Medium 199 in 
1:1 ratio), 10% FBS. The medium was changed every 2 days. After reaching 
confluence the cells were harvested using 0.05% trypsin/EDTA and were 
centrifuged. A cell seeding density of 310,000 cells/200μl per cornea was used for 
transplantation. 
3.3.6.2.Group-2 corneas 
Cell therapy group-2 (n=5) corneas were used to test the capacity of normal primary 
hCECs to attach and form a functional corneal endothelial cell monolayer after 
transplantation to the posterior corneal stroma. For that purpose passage 0 primary 
human corneal endothelial cells were isolated from n=5 human donor corneas. These 
cells were then seeded to the posterior stroma of the same corneas at a cell seeding 
density of 260,000 cells/200μl per cornea.  
3.3.6.3.Group-3 corneas 
Cell therapy group-3 (n=6) corneas were used to test the potential of primary 
cultured hCECs to attach and form a functional corneal endothelial cell monolayer 
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after transplantation to the posterior corneal stroma. For that purpose, passage 2 
cultured primary human corneal endothelial cells were harvested from a tissue 
culture flask using 0.05 % trypsin/EDTA, followed by centrifugation in order to 
pellet the cells. The cell pellet was then diluted with fresh medium to a desired cell 
concentration. A seeding density of 155,000 cells/200μl per cornea was used for 
transplantation. All three groups are summarized in Table 8. There was no 
statistically significant difference between the three groups when age was compared. 
There was no statistically significant difference between groups 1 and 2 and 1 and 3 
when the period in storage was compared, however there was a statistically 
significant difference between groups 2 and 3 (p=0.001). There was statistically 
significant difference between the cell-seeding densities for the three groups; 
however, all three seeding densities were sufficient to restore normal corneal 
endothelial cell function. There was a statistically significant difference between the 
post-cell transplantation periods of incubation prior to functional evaluation but all 
three incubation periods (3, 7 and 10 days) were sufficient for the corneal 
endothelial cells to attach to the stroma and form a functional corneal endothelium. 
The primary cells used in groups 2 and 3 were allowed to incubate longer on the 
corneal stroma in order to ensure proper attachment and monolayer formation on the 
corneal stroma since the primary cells are more fragile compared to the 
immortalized cells. Cell seeding, allowing the cells to attach and form a monolayer 
and functional evaluation were done in three stages. 
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Table 8 – Summary of cell therapy cornea groups. 
 Group 1 (n=6) Group 2 (n=5) Group 3 (n=6) 
DM/Endothelium complex Removed Removed Removed 
Age (years) 60.5 ± 13.99 (range - 46-78) 66.4 ± 12.25 (range - 46-76) 74 ± 8.08 (range - 67-81) 
Period in storage prior to 
experiment (days) 
47.33 ± 13.6 (range - 30-60) 51.2 ± 7.01 (range - 44-60) 33.5 ± 0.57 (range - 33-34) 
Cells used for 
transplantation 
HCEC-12 Primary hCECs (passage 0) Cultured hCECs (passage 2) 
Cell seeding density per 
cornea 
310,000 cells/200μl  
(2070 cells/mm2) 
260,000 cells/200μl 
(1740 cells/mm2) 
155,000 cells/200μl 
(1036 cells/mm2) 
CE functional evaluation 
(days after cell 
transplantation) 
3 10 7 
Time period during which 
CE function was assessed 
(hours) 
12 12 12 
Note: Descemet’s membrane (DM). The corneas from each group were received in three separate batches. Each batch was 
processed individually and experiments were run separately for each batch.
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3.3.6.4.Corneal endothelial cell transplantation – Stage 1 – Cell seeding 
All human donor corneas in the three groups were held in inverted position with the 
endothelial side facing up (native DM/Endothelium removed) at the bottom of a 50ml 
centrifuge tube. Human corneal endothelial cells were transplanted by pipetting a cell 
suspension diluted in 200μl of culture medium to the posterior stroma. After cells were 
transferred to the posterior stroma of each cornea in 200μl culture medium they were 
allowed to settle onto the posterior stroma aided by gravity. The epithelial side of each 
cornea was maintained moist with 50μl culture medium. The corneas were then incubated 
at 37oC, 5 % CO2, 95% humidity. After 4 hours it was evident that both the immortalized 
(HCEC-12) and the primary hCECs were already staring to attach to the stroma but still 
appeared rounded, suggesting that attachment was still incomplete (See Figure 18).  
 
Figure 18 – Human corneal endothelial cell transplantation to ex vivo cultured 
human donor corneas. HCEC-12 (A) and primary human corneal endothelial cells 
(B) are attaching to the stroma 4 hours after transplantation but still appear 
rounded as a result of incomplete attachment evidencing an immature corneal 
endothelial cell monolayer [EB-2000xyz Eye Bank Specular Microscope: 450µm x 
500µm field of view]. 
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3.3.6.5.Corneal endothelial cell transplantation – Stage 2 – Cell attachment 
After the initial 4 hours incubation the centrifuge tubes were then topped up with 
additional 10-20 ml of culture medium and the corneas were left to incubate in immersion 
organ culture in order to allow the monolayer to mature, tight junctions to be formed and 
the cells to adopt normal physiological morphology. Based on the proliferative capacity 
of the HCEC-12 cells and the primary hCECs the incubation time in immersion culture 
was set at 3 days for group-1 corneas, which were seeded with the HCEC-12 cells, and 7-
10 days for groups 2 and 3, which were seeded with passage 0 and passage 2 primary 
hCECs. Previous studies have reported incubation periods of 7-14 days prior to 
morphological or functional evaluation (Aboalchamat, et al., 1999; Engelmann, et al., 
1999 and Chen, et al., 2001). The culture medium was changed every second day. The 
cell seeding densities varied between the three groups based on possible cell yield in 
culture. Immortalized HCEC-12 cells, due to their proliferative capacity, were more 
readily available for use in cell transplantation studies. However, passage 0 and passage 2 
primary hCECs were more scarce due to poor proliferation response in culture, hence, a 
lower cell seeding densities were used in groups 2 and 3. Albeit, all seeding densities 
were sufficient to produce a functional CE monolayer and were well above the critical 
CE density of 300-500 cells/mm2 below which normal CE function gets compromised 
(Tuft and Coster, 1990). 
3.3.6.6.Corneal endothelial cell transplantation – Stage 3 – Corneal endothelial 
functional assessment 
Following these incubation periods, single corneas were removed from immersion culture 
and were placed in air interface organ culture using the in vitro air interface organ culture 
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model described in section 2.3.5. At this point stromal thickness measurements were 
done every hour for up to 12 hours to evaluate the physiological response. Previous 
studies have reported successful functional evaluation for 8-hour, 12-hour and 24-hour 
incubation periods (Aboalchamat, et al., 1999; Engelmann, et al., 1999 and Chen, et al., 
2001). 
3.3.6.7.Positive and negative controls 
The behavior of the corneas with intact DM/Endothelium complex over a 12-hour 
incubation period was used as a positive control for the presence of normal corneal 
endothelial cell function, whereas corneas whose DM/Endothelium complex was 
removed served as a bullous keratopathy model (See 2.4.2) 
3.3.7. Corneal endothelial cell density calculation 
The area of a cornea was calculated using the formula for calculating the area of a dome: 
A = 2 π r h. Where ‘r’ is the radius of the cornea and ‘h’ is the anterior chamber depth or 
the distance between the corneal endothelium and the anterior surface of the intraocular 
lens. The average diameter of a human cornea was assumed to be about 11.7 ± 0.42 mm 
(Rüfer and Erb, 2005) and the average anterior chamber depth measured by Visante OCT 
(the same brand of instrument that was used in this study) was 2.98 ± 0.29 mm (Dinc, et 
al., 2010). Therefore, the approximate area of a human cornea was calculated to be equal 
to 149.51 mm2. Corneal endothelial cell density was calculated by dividing the cell 
seeding density by the area of the cornea. 
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3.3.8. Optical Coherence Tomography assessment of corneal endothelial cell 
function after cell transplantation 
Corneal thickness was measured as described in section 2.3.5.3. 
3.3.9. Histology 
Histology was used to assess the corneal endothelial cell monolayer after each 
experiment in order to confirm the post-transplantation effects, such as cell attachment, 
morphology and monolayer formation after transplantation directly to the stroma of the 
human corneas. After each experiment the human corneas were fixed in 10% formalin for 
10 min at room temperature and were stored at 4oC overnight. Histological processing, 
haematoxylin and eosin (H&E) staining and sample analysis was done in Addenbrooke’s 
Hospital, Cambridge, UK. 
3.3.10. Statistical analysis 
Single factor ANOVA test was used for statistical analysis to determine if there was a 
statistically significant difference between the three corneal groups after a period of air-
interface organ culture. Confidence levels were set at 95%. P<0.05 was considered 
statistically significant. Post hoc t tests with Bonferroni correction (p value divided by the 
number of tests) were used to compere the corneal thickness of the different groups of 
corneas at specific time points throughout the incubation period. The error bars in all 
graphs and bar charts represent the mean ± standard deviation (SD). 
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3.4. Results 
3.4.1. HCEC-12 culture 
After they became confluent the HCEC-12 cells had a cell density of 1800 ± 173 
cells/mm2, showed positive expression of Na+/K+ ATPase and ZO-1, which was also 
present throughout the cell membrane but had highest expression on the cell borders 
especially where the cells formed contact with each other (See Figure 19). These cells 
were used for transplantation into group-1 corneas. 
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Figure 19 - HCEC-12 cells. Endothelial cell density – 1800 ± 173 cells/mm2 [Phase-contrast; x40 (A), x100 (B), x400 
(C)]. Na+/K+ ATPase staining (D), zona occludens-1 staining (E) [Confocal microscopy; x100]. 
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3.4.2. Passage 0 primary human corneal endothelial cells 
Passage 0 primary hCECs were isolated from a DM and were used for 
transplantation into group-2 corneas (See Figure 20). 
 
Figure 20 – Primary hCECs (passage 0) were dissociated from the Descemet’s 
membranes of individual corneas and were used for transplantation into 
corresponding group-2 corneas. Endothelial cell density – 1900 cells/mm2 
[Phase-contrast; x400]. 
3.4.3. Primary human corneal endothelial cell culture 
Out of the 23 corneas used for primary hCECs isolation and culture 7 cultures were 
successfully initiated and were able to reach confluence (See Table 9). 
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Table 9 - Primary cultures that successfully reached confluence. 
Cornea number Seeding density Days to confluence Cell density at confluence ± SD Number of passages 
1 192 cells/mm2 15 - 1 
2 314 cells/mm2 10 366 ± 115 cells/mm2 2 
3 650 cells/mm2 18 733 ± 378 cells/mm2 0 
4 500 cells/mm2 26 400 ± 100 cells/mm2 0 
5 2200 cells/mm2 3 1966 ± 378 cells/mm2 1 
6 1000 cells/mm2 15 200 ± 100 cells/mm2 1 
7 1200 cells/mm2 26 766 ± 588 cells/mm2 2 
Note: Cornea donor information sheets are available in APPENDIX 2 Table 20.
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There was no statistically significant difference in age, period in eye bank storage 
and cell seeding density between those cultures that were successful and those that 
were not (See Table 10). Passage 2 primary cultures, which exhibited positive 
Na+/K+ ATPase and ZO-1 expression after sub-culture were used in transplantation 
into group-3 corneas (See Figure 21).
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Table 10 – Comparison of the characteristics of donor cornea used for primary cell culture initiation. 
Primary cultures Age (years) Period in eye bank storage 
(days) 
Seeding density (cells/mm2) 
Successful (n=7) 69.5 ± 4.46 45.16 ± 11.58 977 ± 681 
Unsuccessful (n=16) 70.4 ± 14.92 51.71 ± 22.78 498 ± 238 
P value Non-significant Non-significant Non-significant 
Note: P<0.05 was considered statistically significant. 
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Figure 21 – Passage 2 primary human corneal endothelial cells sub-cultured at a cell density of 60 cells/mm2 and 
reached confluence 9 days later. [Phase-contrast microscopy; x40 (A), x100 (B) and x200 (C)]. Na+/K+ ATPase 
staining (D), zona occludens-1 staining (E) [Confocal microscopy; x100]. 
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3.4.4. Assessment of corneal endothelial cell function up to 10 days after cell 
transplantation 
All cell therapy-treated corneas as well as the normal and decompensated corneas 
had an oedematous phenotype at the beginning of the experiment as a result of being 
stored in immersion organ culture conditions. The initial corneal thickness 
measurement at the start of the experiment for each group was: group 1 – 1218.02 ± 
153.65 μm, group 2 – 1100.86 ± 86.15 μm and group 3 - 1143.56 ± 69.23 μm. After 
transfer to air-interface organ culture conditions a gradual thickness decrease was 
observed in all corneas. At the end of the 12-hour incubation group 1 had a corneal 
thickness of 458.91 ± 90.07 μm (a 63.15 ± 6.14 % decrease from its initial 
thickness), group 2 had an average thickness of 489.65 ± 94.62 μm (a 55.61 ± 7.44 
% decrease from its initial thickness), and group 3 had a thickness of 613.7 ± 47.23 
μm (a 46.19 ± 4.61 % decrease). All three cell therapy-treated groups reached a near 
normal physiological thickness between 5 and 7 hours of incubation and maintained 
it till the end of the incubation period. Their phenotype and thickness were similar to 
the normal corneas (See section 2.4.2) and were significantly thinner compared to 
the decompensated corneas, which maintained a severely oedematous phenotype 
throughout the entire period of incubation (See section 2.4.2). There was no 
statistically significant difference between the mean corneal thicknesses (μm) of the 
normal corneas and the cell therapy-treated groups 1, 2 and 3 during the 0-12 hours 
incubation (p>0.05). There was a statistically significant difference, however, 
between the mean thicknesses (μm) of the decompensated corneas and the cell-
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therapy treated groups 1, 2 and 3 (p<0.05) [See Figure 22]. There was no 
statistically significant difference between the mean percentage corneal thickness 
decrease (%) of the normal corneas and the cell therapy-treated groups 1, 2 and 3 
(p>0.05). There was, however, a statistically significant difference between the % 
thickness decrease of the decompensated corneas compared to the cell therapy-
treated groups 1, 2 and 3 (p<0.05) [See Figure 23]. 
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Figure 22 – Corneal endothelial cell function was assessed 3 to 10 days after 
human corneal endothelial cell (hCEC) transplantation by subjecting the 
corneas to a 12-hour experiment in air-interface organ culture incubation using 
the in vitro corneal model. Normal corneas (n=6) [] and decompensated 
corneas (n=5) [] were used as controls for normal corneal endothelial cell 
function and bullous keratopathy respectively (A). Group 1 (n=6) [], group 2 
(n=5) [×], group 3 (n=6) [] decompensated corneas underwent cell therapy 
treatment (B). A single-factor ANOVA test showed that there was no 
statistically significant difference between the mean thicknesses of the normal 
corneas and groups 1, 2 and 3 but there was a statistically significant difference 
between the mean thicknesses of the decompensated corneas and groups 1, 2 
and 3. P<0.05 was considered statistically significant.  
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Figure 23 – The mean percentage (%) thickness decrease over 0-12 hours 
incubation was compared. The normal corneas showed an average 48.27 ± 9.78 
% thickness decrease, group 1 - 63.15 ± 6.14 %, group 2 - 55.61 ± 7.44 %, group 
3 - 46.19 ± 4.61 %, and the decompensated corneas - 19.27 ± 10.87 %. A single-
factor ANOVA test showed that there was no statistically significant difference 
between the normal corneas and the cell therapy groups 1, 2 and 3 but there 
was a statistically significant difference between the decompensated corneas 
and cell therapy groups 1, 2 and 3. *P<0.05 was considered statistically 
significant. 
At the end of the 12-hour experiment in air-interface organ culture incubation all 
three cell-therapy groups reached physiological thickness levels. Additionally, the 
posterior stromal folds that were visible at 0h were no longer present after the 12-
hour period (See Figure 24). 
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Figure 24 – Optical Coherence Tomography: high-resolution quadrant images 
of cell therapy treated corneas. All three cell-therapy groups are showing a 
significant reduction in thickness to normal physiological levels. 
3.4.5. Endothelial cell attachment and formation of cell monolayer following 
cell transplantation 
A corneal endothelial cell monolayer with a normal phenotype was observable in 
groups -1 and -2 attached to the corneal stroma 3 and 10 days after HCEC-12 and 
passage 0 primary hCECs transplantation respectively, however in group 3 the cells 
appeared multi-layered and spindle-shaped (See Figure 25).  
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Figure 25 - Histological sections of cell therapy treated corneas. In Group 1 (A 
and B) and in group 2 (C) a monolayer of cells is present 3 and 10 days after 
transplantation to the corneal stroma respectively. In Group 3 corneas a multi-
layer of cells was seen 7 days after transplantation possibly a result of using too 
high cell seeding density (D; Note: cell detachment from the stroma is an 
artifact of histological processing). Basement membrane secretion was not 
observed in any of the groups throughout the duration of the experiment 
[Haematoxylin and Eosin (H&E) staining; (A) x100; (B and C) x400; (D) x200]. 
3.5. Discussion 
Studying the potential of human corneal endothelial cell transplantation as a 
treatment of corneal decompensation has currently generated significant interest. 
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The development of this novel approach can significantly reduce or perhaps even 
eliminate the need for donor tissue. 
In this study hCECs were isolated and seeded at different seeding densities into 24-
well plates and primary cultures were successfully initiated from 7 human corneas. 
Microscopic observations seemed to indicate that at high seeding densities, as in the 
case of cornea 5 (see Table 9), the primary culture was able to reach confluence in a 
shorter period of time and achieved higher endothelial cell density compared to 
primary cultures that were initiated at lower seeding densities. The comparison of 
the seeding density between the successful and unsuccessful cultures appeared to be 
statistically non-significant (See Table 10), however, this could be due to limited 
sample size. Nevertheless, microscopic observation seemed to point otherwise and 
seemed to suggest that the seeding density is an important factor for successful 
primary cell culture initiation and high seeding density enabled the cultures to reach 
confluence more quickly. 
Many research studies have been published in recent years focused on developing a 
novel cell therapy approach for treating corneal blindness using a variety of animal 
transplantation models, however, there are a limited number of studies that have 
examined the plausibility of a cell-based therapy using human donor corneas as a 
transplantation model to restore a functional corneal endothelial cell monolayer 
(Engelmann, et al., 1993 and 1999; Böhnke, et al., 1999; Aboalchamat, et al., 1999; 
Chen, et al., 2001 and Joyce, et al., 2012). These studies that used human donor 
corneas with intact DMs for hCEC transplantation testing reported that at seeding 
densities of 50,000, 150,000 and 700,000 cells/cornea a density of 1800 – 2200 
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cells/mm2 was achieved. Additionally, 20 days after transplantation the corneas 
showed significant thickness decrease and reached physiological thickness after 
perfusion culture over an incubation period between 8 – 24 hours (Engelmann, et al., 
1993; Engelmann, et al., 1999; Aboalchamat, et al., 1999). In another study Chen, et 
al. (2001) tested hCEC transplantation using in vitro cultured human donor corneas 
denuded of their native endothelium, but still with intact DM. Their results 
corroborated previous studies by Engelmann, et al., (1993), Engelmann, et al., 
(1999) and Aboalchamat, et al., (1999) and reported that at seeding densities 
between 250,000 and 500,000 cells a post-transplantation average cell density of 
1895 ± 178 cells/mm2 was reached 7-14 days after transplantation. However, Chen 
et al., (2001) only assessed the cell attachment and morphology but not the corneal 
endothelial cell pump function, which still leaves the question whether seeding the 
hCECs directly to the corneal stroma would have a negative effect on their 
attachment and function. In all of these studies cell-therapy outcomes showed very 
encouraging results of significant corneal thickness decrease. A limitation of these 
human corneal models, however, is that in such an experimental set up, it might be 
very difficult to ascertain if there were any residual host endothelial cells that were 
left behind on the host DM as they might confound the observed results. 
Additionally, after the removal of the native corneal endothelium the Descemet’s 
membrane was left intact and was allowed to serve as a natural substrate for the 
newly transplanted cells. Since the DM is the natural substrate for the corneal 
endothelial cells it would enable and facilitate corneal endothelial cell attachment 
and monolayer formation. It has been shown that the presence of an intact DM 
  113 
promotes endothelial cell migration on human corneas (Soh, et al., 2016). It has also 
been shown that the DM stimulates CE regeneration in rabbits (Bhogal, et al., 2017; 
Chen, et al., 2017a). But in reality in some patients the DM has to be removed prior 
to transplantation due to fibrosis and the cell-therapy would have to be applied 
directly to the corneal stroma. Because the DM and the corneal stroma have different 
composition and structure this might affect corneal endothelial cell, attachment, 
morphology and function. This structural difference of the underlining substrate 
might affect cell attachment, morphology and function.  
There is very limited evidence for the cell fate of hCECs after transplantation to bare 
posterior human corneal stroma. Patel, et al. (2009), on the other hand, showed that a 
method using superparamagnetic microspheres (SPMs) incorporation into hCECs 
and an external magnet were capable of inducing hCEC attachment to the corneal 
stroma. The technique employs a method for co-culture of hCECs with magnetic 
microspheres, which allows the microspheres to be absorbed by the cells, and thus 
allowing the cells to be attracted towards a magnet. This study gave an important 
insight that hCECs attachment to the corneal stroma can be facilitated using SPMs. 
However, it is still questionable whether the cells have the ability to attach to the 
stroma unaided. The use of such method and equipment are not readily available in 
most hospitals and therefore could severely limit its clinical application. 
Additionally, the long-term effect of the magnetic spheres on the viability, 
morphology and function of hCECs after transplantation is not known. Another 
limitation of the study of Patel, et al., (2009) is that hCEC function was not tested 
after transplantation to the stroma. Therefore, the effect of the structure of the 
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underlining substrate on the corneal endothelial cell function after transplantation 
remains unknown. Choi, et al., (2010) used 120-200 μm slices of decellularized 
human corneal stroma for hCEC transplantation and showed that the seeded cells 
still retained expression of Na+/K+ ATPase and ZO-1. This positive expression of 
CE functionality markers suggested that the transplanted hCECs will still be 
functional but this was not experimentally demonstrated. Moreover, since this study 
used decellularized stroma it still remains unknown how the absence of the stromal 
keratocytes would affect the hCECs biology and physiological function over time.  
Therefore, in order to build on the limitations of previous published literature it was 
aimed in this study to test the plausibility of hCEC transplantation directly onto the 
corneal stroma, and to determine how this change of substrate affects their 
attachment, morphology and function combined with histological evaluation. 
Corneal de-swelling, measured by Zeiss Visante OCT, was used as a surrogate 
measure of corneal endothelial ion pump function. For that purpose, human donor 
corneas, denuded of their native DM/Endothelium complex were used to establish an 
in vitro human corneal model of endothelial decompensation suitable for hCEC 
transplantation testing. This model could be used to demonstrate the corneal de-
swelling in normal and decompensated corneas in vitro and to compare them with 
cell-therapy treated corneas. The results of this chapter clearly demonstrate that 
human corneal endothelial cells were able to attach to the stroma under the action of 
gravity, which facilitated cell sedimentation when the corneas were incubated with 
the endothelial side facing upwards. After transplantation directly to the posterior 
stroma the hCECs formed a endothelial cell monolayer as evidenced by histology 
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and were able to reduce the corneal thickness of the recipient corneas to normal 
physiological levels measured by Zeiss Visante OCT. These results are very 
significant because they show that in cases, where the DM has had to be removed 
due to fibrosis and scarring, cell-therapy could still be successfully applied as an 
effective treatment and could restore normal corneal endothelial cell function. In 
these experiments the cell suspension was sedimented and cell attachment was 
facilitated under the influence of gravity. Such attachment was histologically shown 
to be stable and firm forming a monolayer of normal-shaped cells with high viability 
3-10 days after transplantation. However, the minimum duration that is required for 
this gravity-induced attachment is not yet confirmed. In our study we demonstrated 
that after transplantation to the bare posterior corneal stroma the hCECs are able to 
function normally and to regulate stromal hydration and restore normal corneal 
thickness in decompensated human corneas.  
In this study cell densities of 260,000 cells/cornea and 155,000 cells/cornea 
respectively were used for transplantation, which yielded on average a cell density 
of 2000 ± 212 cells/mm2 after transplantation. The in vitro model for air-interface 
culture of human donor corneas was restricted to a 12-hour CE functionality testing 
experiment and CE function was tested between 3 to 10 days after transplantation.  
There are a number of limitations that restrict the use of this model and these include 
donor availability with signed research consent. For this study mainly elderly 
corneas were used and the scarcity of young cadaveric corneal donors for research is 
another issue. In this project gravity-aided cell settlement was used to achieve cell 
attachment to posterior cornea in our in vitro model. This might pose some 
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challenges when it comes to translating these results to clinical application. For 
example, after cell transplantation the patient would have to be kept in a facedown 
position for up to 4 hours to aid cell attachment. Also the effect of aqueous humour 
circulation on cell attachment is unknown. It may cause washing off of the 
transplanted cell suspension, which in turn might cause blockage in the trabecular 
meshwork and a raise in intraocular pressure. If the intraocular pressure increases 
too much this can cause other complications, such as glaucoma. Therefore, the cell 
transplantation technique, that is used to deliver cell-therapy to patients, needs to be 
re-assessed and modified so that it can be optimized for clinical use. In this study the 
human in vitro corneal model could only be used between 12-hour incubation 
experiments and up to 14 days, which did not allow for long-term assessment of cell 
transplantation outcomes, such as long-term effect on cell morphology, attachment, 
proliferation, cell survival, scar formation and fibrosis. The nature of the in vitro 
model posed a limitation to infection control since the corneas had to be exposed to 
the open air when corneal thickness measurements were performed using the Zeiss 
Visante OCT. Additionally, the model although portable, is still constraining to 
testing corneal transparency. Another limiting factor of using this model is that 
Human Tissue Act (HTA) regulations restricting only certain labs suitable to test 
these models using human tissue and there is a long period of time required in order 
to put in place the necessary licenses for any work to commence. Other limitations 
of the model and strategies for improving its longevity were discussed in the 
Discussion section of CHAPTER 2 – ESTABLISHING AND VALIDATION OF AN IN 
VITRO HUMAN CORNEAL MODEL OF ENDOTHELIAL DECOMPENSATION. 
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In this chapter a cell suspension in F99 or OptiMEM-I culture media was seeded 
onto human donor corneas. The anterior chamber of the eye has aqueous humour 
circulating inside and bathing the CE which has a different composition compared to 
culture medium. Also the lack of circulation in the in vitro model that was used in 
this chapter facilitated cell attachment after seeding because the cells could remain 
undisturbed where otherwise in an in vivo model they would probably be washed off 
to some degree by the circulating aqueous.  This could pose additional clinical 
complications in patients since the washed off cells might block the aqueous humour 
drainage system and possibly lead to increased intraocular pressure which in turn 
might lead to glaucoma. There is also a possibility that the washed off cells might 
reach other parts of the body via the circulation. This could pose serious 
consequences if the transplanted cells become spontaneously transformed and gain 
capacity to proliferate uncontrollably and form tumors and are able to spread to 
other parts of the body. Other research studies that have explore cell injection of a 
cell suspension in intraocular irrigating solution into an in vivo animal model found 
that this technique by itself is not effective in restoring a CE monolayer as compared 
to transplantation using a collagen sheet as a carrier (Koizumi, et al., 2007). Later 
studies found that the use of a Rho kinase inhibitor Y-27632 was able to improve 
cell attachment after injection of cells suspended in DMEM culture medium into the 
eye of primates and rendered this transplantation technique efficient in recovering a 
functional CE (Okumura, et al., 2016). Interestingly, in it appears that the use of 
culture medium for cell injection was an effective method for delivering viable cells 
to the eye of this primate model. Another study that used in vivo rabbit and primate 
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models also reported a successful outcome after injecting cells suspended in 
endothelial serum-free culture medium using Y-27632 inhibitor (Shen, et al., 2017). 
However, additional very extensive work is required before the cell-therapy 
evaluation can be used for clinical trial studies. For example, by improving the 
culture conditions and the in vitro proliferation of hCECs a cell bank can be 
established, which would greatly increase the cell-therapy availability. Studying the 
cell fate in culture and after transplantation, finding ways to inhibit proliferation 
once the cells have been transplanted, testing different methods for administering 
cell therapy and the use of substrates, testing for any possible side effects, such as 
migration of the cells to the anterior chamber and any possible carcinogenic 
potential are all aspects that need to be studied very carefully before cell therapy can 
be approved for clinical trials. Additionally, the rejection mechanisms mediated by 
the host immune system against these cultured cells should also be investigated. 
Other important factors to consider include the cell source, i.e. from a single donor 
or multiple donors, gender-specific effects and the ability of the cells to maintain 
normal shape and functional potential and not cause any fibrosis over the long term 
after transplantation. But probably the single greatest limiting factor of cell-therapy 
development is the difficulty of culturing primary human corneal endothelial cells.  
In this study the limited proliferative potential of the primary hCECs negatively 
affected the cell yield in culture, this resulted in obtaining limited number of cells, 
therefore a range of different seeding densities, 1036 cells/mm2 for passage 2 and 
1740 cells/mm2 – for passage 0 had to be used for hCEC transplantation testing. 
Therefore, the immortalized HCEC-12 cell line was added to the experimental 
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model for testing corneal endothelial cell transplantation since it has a high 
proliferative potential and could generate a high cell yield when cultured allowing 
cell seeding densities of up to 2070 cells/mm2 per cornea. However, since this is an 
immortalized cell line it is deemed unsuitable to be used for transplantation and 
treatment due to its potential carcinogenic and possible uncontrolled proliferative 
properties. The main challenges in human corneal endothelial cell culture, such as 
lack of proliferation, incapacity for long-term cultivation and in vitro expansion, and 
morphological transformation, hinder the establishment of a clinical-grade human 
corneal endothelial cell bank that could be used as a source of cell therapy for 
corneal endothelial disorders. With the existing culture protocols, hCECs can be 
cultured for several passages but eventually the cultures are lost to senescence. They 
might also undergo morphological transformation when cultured (Roy, et al., 2015). 
Typical in vivo characteristics of the hCECs with normal morphology include: 
polygonal-shaped cells that form a monolayer and are arrested in gap 1 (G1) 
phase of the cell cycle and expressing zona occludens-1 (ZO-1), Na+/K+ ATPase 
and N-cadherin. Spindle-shaped morphology in cultured human corneal 
endothelial cells (hCECs) can be triggered by a number of factors including 
transforming growth factor-β (TGF-β) (Chen, et al., 1999), interleukin-1β (IL-
1β) and fibroblast growth factor-2 (FGF-2) (Kay, et al., 1994) through NF-kB 
(Lee and Kay., 2012) and connexin43 (Cx43) also play a role in hCEC spindle-
shaped morphology (Nakano, et al., 2008). 
The results of this study when passage 0 primary cells and HCEC-12 cells were used 
for cell therapy corroborated previously reported results by Engelmann, et al., 
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(1993), Engelmann, et al., (1999), Aboalchamat, et al., (1999), Chen, et al., (2001) 
and Patel, et al., (2009) and demonstrated that after hCEC transplantation directly to 
the corneal stroma similar results were obtained in comparison with hCEC 
transplantation to the DM. Nevertheless, Engelmann, et al., (1993) stated that when 
morphologically altered hCECs to a spindle-shaped phenotype were used for 
transplantation on the DM of human corneas they formed multilayer of elongated 
cells which did not revert back to normal corneal endothelial phenotype for up to 
two weeks after transplantation and were unable to restore normal corneal thickness. 
In this chapter it was experimentally confirmed that when seeding passage 2 cultured 
hCECs (spindle-shaped) directly to the corneal stroma of human corneas after 
complete removal of the DM they did form a multilayer that did not revert back to 
normal CE morphology for up to 10 days of incubation, however, normal corneal 
thickness was restored in a similar manner as when passage 0 hCECs with normal 
CE morphology were used. These results are potentially very intriguing as they 
might be showing that spindle-shaped hCECs, which have a much higher 
proliferative potential compared to normal-shaped hCECs, might be a suitable 
source for cell therapy and treating corneal endothelial disorders. Yet further 
experimentation is required to confirm these results. 
Cultivation of hCECs remains a challenge and in order to improve and enhance in 
vitro human corneal endothelial cell culture it is necessary to identify new cell 
markers for corneal endothelial progenitor cells, which can be used to identify, 
isolate and culture hCECs with high proliferative potential. Positive regulatory 
domain zinc finger proteins (PRDMs) have been implicated in the control of cell 
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differentiation and maintenance of stem cell potential in a variety of tissues but their 
expression and role in corneal endothelial cell biology has not been studied yet, 
except for PRDM5, which has been shown to play a role in Brittle Cornea Syndrome 
(Burkitt Wright, et al 2011). There are 17 PRDMs in total, all of which with slightly 
different functions. Therefore, the focus of the next chapter of this study is to test the 
expression of PRDM proteins and to construct a full expression profile of all 
PRDMs in the corneal endothelium and cultured corneal endothelial cells. This 
could give important clues about the role of these proteins in cell fate determination 
and regulation of proliferation in hCECs.  
3.6. Conclusion 
The DM is not necessary for hCEC transplantation. Seeding hCECs directly to the 
corneal stroma is sufficient to regenerate the CE monolayer and to restore normal 
corneal thickness. The use of cultured human corneal endothelial cells as a cell-
therapy approach for treating corneal endothelial disorders was confirmed to be 
efficient using an in vitro human model. 
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4. CHAPTER 4 – POSITIVE REGULATORY DOMAIN 
ZINC FINGER PROTEIN EXPRESSION PROFILE IN 
HUMAN CORNEAS AND CULTURED HUMAN 
CORNEAL ENDOTHELIAL CELLS1 
4.1. Chapter overview 
This chapter explores the expression profile of positive regulatory domain zinc 
finger proteins (PRDMs) in the human corneal endothelium and cultured human 
corneal endothelial cells using reverse-transcriptase polymerase chain reaction (RT-
PCR), immunocytochemistry and immunohistochemistry. PRDM proteins have been 
linked to the control of stemness and differentiation and their role in the CE has not 
been studied yet. Only PRDM5 has been shown to control extracellular matrix 
formation and mutations in PRDM5 lead to Brittle Cornea Syndrome. And more 
recently it was found that PRDM4 deletion causes a gender-specific abnormal 
corneal morphology in mice (Phenotyping Centre - MRC Harwell web reference), 
therefore studying their expression in the CE and cultured hCECs might give some 
clues to their role in hCEC proliferation control and can potentially be used for 
enhancing hCEC culture.  
                                                        
1 Rolev, K., O'Donovan, D.G., Georgiou, C., Rajan, M.S. and Chittka, A., 2017. Identification of Prdm genes in 
human corneal endothelium. Experimental eye research, [e-journal] 10.1016/j.exer.2017.02.009. Available 
through: Primo. 
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4.2. Brief introduction 
The corneal endothelial cells are found on the posterior side of the human cornea 
and form a monolayer of cells that serves as a barrier between the aqueous humour 
and the stroma. After damage to the endothelium following a disease process, as a 
result of previous eye surgery or as a result of mechanical damage the CE can loose 
its function, which results in corneal swelling (Parekh et al. 2016). After any such 
damage the human corneal endothelial cells are unable to regenerate themselves due 
to having a low proliferative potential and due to being arrested in the G1 phase of 
the cell cycle (Joyce, et al., 1996b). Recently researchers have found some evidence 
suggesting that human corneal endothelial progenitor cells exist in the periphery of 
the endothelium and a number of markers, such as nestin, telomerase, Oct-3/4, Wnt-
1, SOX-2, PAX-6, p75 NTR and LGR5 have been used in order to identify these 
progenitors (Whikehart, et al., 2005; McGowan, et al., 2007; He, et al., 2012; Hara, 
et al., 2014 and Hirata-Tominaga, et al., 2013). It is of a great interest to understand 
the mechanisms that control hCEC proliferation and differentiation in order to 
successfully develop a cell-therapy approach for treating corneal endothelial 
disorders. 
Positive-regulatory domain (PRDM) proteins are a family of 17 proteins that are 
transcriptional regulators and chromatin modifiers and play an important role in 
stem cells and a variety of developmental processes (Hohenauer and Moore, 2012) 
(See Table 11). 
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Table 11 - The PRDM proteins mediate their function via recruiting histone deacetylases and play crucial role in regulation of 
proliferation, cell differentiation and maintenance of stem cells. 
 Function Reference 
PRDM1 Drives terminal B cell differentiation Fog, et al., 2012 
PRDM2 Tumour suppressor; Expressed in immature progenitor cells and mature monocytes 
and granulocytes 
Fog, et al., 2012  
PRDM3 (MDS-1) Essential during the early stages of haematopoiesis Fog, et al., 2012  
PRDM3 
(MECOM) 
Essential during the early stages of haematopoiesis and in myeloid leukaemia stem 
cells. 
Essential for long-term haematopoietic stem cell function 
Fog, et al., 2012  
Zhang, et al., 2011 
Eppert, at al., 2011 
PRDM4 Inhibits proliferation during neuronal differentiation; interacts with p75NTR and 
controls neural development 
Fog, et al., 2012 
Chittka and Chao, 1999 
PRDM5 Tumour suppressor through suppressing Wnt signaling; Regulates extracellular 
matrix development and maintenance in the cornea; 
Regulates haematopoiesis; 
Suppressor of Wnt/ß-catenin signaling; 
Regulates collagen type I gene transcription in developing bone 
Fog, et al., 2012  
Shu, et al., 2011 
Burkitt Wright, et al., 2011 
Duan, et al., 2007 
Meani, et al., 2009 
Galli, et al., 2012 
PRDM6 Regulates aortic smooth muscle cell differentiation and vascular differentiation Fog, et al., 2012 
Davis, et al., 2006 
PRDM8 Expressed in mouse embryo nervous system; Neuronal differentiation; Expressed in 
post-mitotic neurons 
Fog, et al., 2012 
Kinameri, et al., 2008 
Komai, et al., 2009 
PRDM10 Expressed in mouse embryo nervous system Fog, et al., 2012 
Park and Kim, 2010 
PRDM12 Potential tumor suppressor for chronic myeloid leukaemia  Reid and Nacheva, 2003 
PRDM14 Required for derivation of embryonic stem cells Hohenauer and Moore, 
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2012 
PRDM16 Regulates brown adipocyte differentiation; Expressed in neural stem/progenitor 
cells; Essential during the early stages of haematopoiesis; Neuronal differentiation 
Fog, et al., 2012 
Kinameri, et al., 2008 
Seale, et al., 2007 
Kajimura, et al., 2009 
Note: Research articles describing the roles of PRDMs 7, 9, 11, 13 and 15 in stem cells and cell proliferation control were not found in 
the published literature. 
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Of all the PRDMs only PRDM4 and 5 have been associated with the cornea. 
PRDM5 plays an important role in the extracellular matrix development and 
maintenance in the human cornea and mutations in the PRDM5 gene lead to the 
development of Brittle Cornea Syndrome (Burkitt Wright, et al., 2011). PRDM4 also 
seems to be having a role in the corneal biology as PRDM4 knockout mice show 
abnormal corneal phenotypes (Phenotyping Centre - MRC Harwell web reference). 
It has been demonstrated that PRDM4 interacts with p75NTR (Chittka, et al., 1999). 
Expression of p75NTR has been associated with high proliferative capacity in 
hCECs (Hara, et al., 2014). In addition, PRDM4 has been shown to control neural 
stem cell proliferation and differentiation (Chittka, et al., 2012) and since hCECs are 
derived from the neural crest it would be of interest to test the expression of PRDMs 
and PRDM4 in particular in hCECs. The expression and function of all other PRDM 
proteins and their role in corneal endothelial cell proliferation and progenitor cells 
have not been adequately explored and revealed yet. The purpose of this study was 
to demonstrate the PRDM protein expression profile in normal human corneas and 
cultured primary and immortalized human corneal endothelial cells, which will pave 
the way for further studying and understanding the role of PRDM proteins in the 
control of hCEC proliferation and differentiation. This will potentially enable the 
finding of new ways of optimizing hCEC culture for cell-therapy testing and future 
clinical use. 
4.3. Materials and methods 
4.3.1. List of materials used 
Cell culture plastic dishes, flasks, well plates, centrifuge tubes, pipette tips, 
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eppendorf tubes and other plastics were purchased from ThermoFisher Scientific. 
Foetal bovine serum (FBS) – (F0804-500ML), was purchased from Sigma Aldrich. 
OptiMEM – (51985-026), was purchased from Invitrogen. Medium 199 – 
(31150022) was purchased from ThermoFisher Scientific. Ham’s F12 – (11765054) 
was purchased from ThermoFisher Scientific. Trypsin/EDTA – (T3924), was 
purchased from Sigma Aldrich. Phosphate buffered saline (PBS) – (P3813) was 
purchased from Sigma Aldrich. Goat serum – (G9023) was purchased from Sigma 
Aldrich. Immortalized human corneal endothelial cell line HCEC-12 – (ACC 646), 
was purchased from Leibniz Institute DSMZ – German Collection of 
Microorganisms and Cell Cultures. CultureWell™ multiwell-chambered coverslips 
– (24779) were purchased from Invitrogen. Micro-prep RNA extraction Kit – 
(400805) obtained from Agilent Technologies. TRIzol® - (15596018) obtained from 
ThermoFisher Scientific. Chloroform – (C2432) was purchased from Sigma Aldrich. 
Isopropyl alcohol for molecular biology (I9516) was purchased from Sigma Aldrich. 
Ethanol for molecular biology (E7023) was purchased from Sigma Aldrich. 
SuperScript® II Reverse Transcriptase – (18064-014) obtained from Invitrogen. 
GoTaq® Flexi DNA polymerase – (M8305) obtained from Promega. Primary 
antibodies against human PRDM4 – (ab156867), PRDM5 – (ab79016), PRDM5 – 
(ab84572) were obtained from Abcam, Cambridge, UK. Goat anti-rabbit (goat 
polyclonal) IgG secondary antibody (Alexa Fluor 488) – (ab150077), was purchased 
from Abcam, Cambridge, UK; Goat anti-mouse  (polyclonal) IgG secondary 
antibody (Alexa Fluor 488) – (ab150117) was purchased from Abcam, Cambridge, 
UK. PRDM1-16 forward and reverse primers were obtained from OriGene. DAKO 
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fluorescent mounting medium – (S3023), was purchased from Dako. Hoechst 33258 
– (B2883) was purchased from Sigma Aldrich. 
4.3.2. Human corneal tissue preparation 
Human donor corneas were obtained from Bristol and Manchester Eye Banks, UK 
(See Table 12).
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Table 12 – Human donor cornea information sheet. 
Cornea Age (years) Gender Cause of death Time in storage ECD (cells/mm2) 
1 69 Male Ruptured aortic aneurysm 43 days 2300 
2 64 Female Pulmonary fibrosis 27 days 2800 
3 87 Male Unknown 69 days - 
Note: Endothelial cell density (ECD).
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4.3.3. Cell culture 
4.3.3.1.Primary human corneal endothelial cell isolation and culture 
Primary hCEC culture from peripheral DM (2 mm) was initiated via primary explant 
culture. It was cut into small pieces with fine scissors and placed in an uncoated T25 
(25 cm2) cell culture flask. Culture was done using 1ml basal medium OptiMEM-I 
supplemented with 8 % FBS, 1% L-Glutamine, 1 % penicillin/streptomycin. Small 
amount of medium was used in order to allow the pieces of the peripheral DM to 
come in contact with the bottom surface of the flask and to promote cell outgrowth 
into the flask. The culture medium was not exchanged until primary cell outgrowth 
occurred. After that the culture medium was exchanged every 2nd day until the 
culture reached confluence. After reaching confluence the primary culture was sub-
cultured using 0.05 % trypsin/EDTA. Passage number 2 cells were used for 
transplantation studies. Cell culture was done in a 37oC, 5% CO2, humidified 
incubator Heracell™ (relative humidity – 95%).  
4.3.3.2.HCEC-12 culture 
HCEC-12 cells were cultured using F99 (mixture of Ham’s F12 and Medium 199 in 
1:1 ratio), 10% FBS. The medium was changed every 2 days. The cells were seeded 
out at 50 cells/mm2. Confluent cultures were split 1:2 to 1:4 every 4-5 days using 
0.05% trypsin/EDTA. Cell culture was done in a 37oC, 5% CO2, humidified 
incubator Heracell™ (relative humidity – 95%). 
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4.3.4. Ribonucleic acid extraction 
Ribonucleic acid (RNA) was extracted from whole human donor corneas, 
Descemet’s membrane/Endothelium complex, primary cultured human corneal 
endothelial cells (hCECs) and from cultured HCEC-12 cells (See Table 13).
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Table 13 – Samples and methods used for RNA extraction. 
Sample used for RT-PCR Method of RNA extraction 
Cornea (9.5 mm diameter) Trizol® 
Descemet’s membrane/Endothelium complex (whole) Micro-prep RNA extraction Kit 
Primary cultured hCECs (passage 2) Micro-prep RNA extraction Kit 
HCEC-12 Micro-prep RNA extraction Kit 
Note: Reverse transcriptase polymerase chain reaction (RT-PCR), human corneal endothelial cells (hCECs).
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4.3.4.1.Trizol reagent 
For RNA extraction from 9.5 mm corneas TRIzol reagent (Invitrogen) was used 
according to manufacturer’s protocol. 
4.3.4.2.Agilent Technologies Microprep Kit 
RNA extractions were performed using the Micro-prep Kit (Cat No: 400805) 
obtained from Agilent Technologies. Total RNA from each sample was extracted 
according to the manufacturer’s protocol. 
4.3.4.2.1.Primary cultured human corneal endothelial cells 
Primary human corneal endothelial cells (hCECs) were kept in culture for 7 days. 
The cells were harvested using trypsin/EDTA and total RNA was extracted using the 
Agilent technologies Micro-prep Kit. 
4.3.4.2.2.HCEC-12 
HCEC-12 cells were kept in culture for 7 days. The cells were harvested using 
trypsin/EDTA and total RNA was extracted using the Agilent technologies Micro-
prep Kit. A cell number of 5 x 105 HCEC-12 cells, passage 6 were used for RNA 
extraction. 
4.3.4.3.RNA quantification 
The quality of the RNA was measured by NanoDrop spectrophotometer. 
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4.3.5. Complementary deoxyribonucleic acid synthesis 
Complementary deoxyribonucleic acid (cDNA) was synthesized from 1μg total 
RNA using the SuperScript@ II Reverse Transcriptase kit (Invitrogen, Cat No: 
18064-014) according to the manufacturer’s protocol. Briefly, all reactions were 
assembled on ice in eppendorf tubes: 1μg of total RNA sample, 1μl random 
hexamers, 1μl dNTPs (deoxynucleotide triphosphates) mix (10mM), 7.7μl Diethyl 
pyrocarbonate (DEPC)-water, total sample volume=13μl. The mixture was heated to 
65oC for 5 min followed by a quick chill on ice. The eppendorf tubes were then 
briefly centrifuged. To each sample was then added: 5 x First-strand buffer - 4μl, 0.1 
mole (M) dithiothreitol (DTT)-2μl. The samples were then mixed gently and were 
incubated at room temperature for 2 min. 1μl of reverse transcriptase was added in 
the +RT (plus reverse-transcriptase – the test sample) sample and 1μl of DEPC-
water to the -RT (minus reverse-transcriptase – the negative control) sample to keep 
the volumes the same. All samples were then incubated at room temperature for 10 
min followed by incubation at 42oC for 50 min. Finally the reaction was inactivated 
at 70oC for 15 min. 
4.3.6. Primers for reverse transcriptase polymerase chain reaction (RT-PCR) 
All primers that were used in this experiment are listed in Table 14.
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Table 14 – Primer sequences. 
Oligonucleotide  Sequence (5' → 3') Product size (bp) 
PRDM1 F CAGTTCCTAAGAACGCCAACAGG (23) 
122 
PRDM1 R GTGCTGGATTCACATAGCGCATC (23) 
PRDM2 F TTGGGCTTGCTCAGGAGAAGAG (22) 
140 
PRDM2 R GCTGCTATCTCAGGGTTGTCTTC (23) 
PRDM3 (MDS1) F CCTTATGTGGGAGAGCAGAGGT (22) 
131 
PRDM3 (MDS1) R GAAGGCTATTCCTACGTCTGAGC (23) 
PRDM3 (MECOM) F CCTGCTTCAGATGGTTCCTTGC (22) 
147 
PRDM3 (MECOM) R GGTGAAACAAGAATCCTGGAGAAG (24) 
PRDM4 F CCAAAGCAGCTTGTTCTCCGTC (22) 
95 
PRDM4 R TAGAGGTCCAAAGCAAGTCCGC (22) 
PRDM5 F ACTCTGAGGAGAGACCGTTCCA (22) 
144 
PRDM5 R AGCATCGCAGTGATGGCACTTG (22) 
PRDM6 F GTGAGGAACACGCAGCATCTCT (22) 
128 
PRDM6 R TTCTCCGCAGTGCCTTGCACAT (22) 
PRDM7 F AGACGAAGAGGCAGCCAACAGT (22) 
149 
PRDM7 R GCCACCAGGTTCTGCTCTTCAT (22) 
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PRDM8 F CTGTGTCCTGAGCCATACTTCC (22) 
125 
PRDM8 R CCTTCTGAGGAACCATTTGCTGC (23) 
PRDM9 F ACGAAGAGGCAGCCAACAATGG (22) 
147 
PRDM9 R GCCACCAGGTTCTGCTCTTCAT (22) 
PRDM10 F CCGCAAAGACTTCCTGTGTTCC (22) 
120 
PRDM10 R GCTGATGCGGTCGGCTTTCTTG (22) 
PRDM11 F CCAGGAAACCATTCACCGCAAC (22) 
93 
PRDM11 R CCTCAGGTCTTCTGGGTTATCC (22) 
PRDM12 F TGCACGTAACGAACAGGAGCAG (22) 
118 
PRDM12 R GTGAGTTTCCGTACCACACCAG (22) 
PRDM13 F CTAACTCCTTGGCTCAGTGGTTC (23) 
90 
PRDM13 R CAGTACCAGCAGATGTAGCGCT (22) 
PRDM14 F CCTTGTGTGGTATGGAGACTGC (22) 
125 
PRDM14 R CTTTCACATCTGTAGCCTTCTGC (23) 
PRDM15 F GGCACTTGTGAGAAGACCTTCC (22) 
119 
PRDM15 R GAGGTTGCTGTTGGTGGAGAAG (22) 
PRDM16 F CAGCCAATCTCACCAGACACCT (22) 
145 
PRDM16 R GTGGCACTTGAAAGGCTTCTCC (22) 
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4.3.7. Reverse transcriptase polymerase chain reaction 
4.3.7.1.Sample preparation 
Reagents for 1xPCR reaction – final volume 25μl: 5 x Flexi Buffer - 5μl, MgCl2 
(25mM) - 1.5μl, dNTP (10mM) - 1μl, forward primer - 1 μl, reverse primer - 1μl, Go 
Taq DNA polymerase - 0.25μl, cDNA - 1 μl, water - 15.25 μl. 
4.3.7.2.PCR program 
PCR program: 94oC for 2 min, 40 cycles (94oC for 30 sec, 59oC for 30 sec, 72oC for 
30 sec), 72oC for 5 min, final hold 4oC. 
4.3.8. Agarose gels electrophoresis 
The gels were run for 1 hour and 30 minutes at 85 volts (V). 
4.3.8.1.Gel preparation 
2% agarose gels were prepared with 2 x 16 wells per gel (two rows of 16 wells per 
gel) and with 2 x 28 wells per gel (two rows of 28 wells per gel). 
4.3.8.2.Loading the samples on the gel 
5μl of each sample was mixed with 5μl loading dye to a 9μl final volume. The 
samples loaded on the gel by careful pipetting. 
4.3.9. Immunofluorescence staining 
Multiwell-chambered coverslips were pre-coated with poly-d-lysine (PDL). In vitro 
cultured HCEC-12 and primary hCECs were tested for PRDM protein expression. 
HCEC-12 and primary hCECs were seeded at 5000 cells/cm2 on chambered 
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coverslips and were incubated for 24 hours at 37oC and 5% CO2. The cells were then 
fixed by 4% paraformaldehyde (PFA) for 10 minutes at room temperature. The cells 
were then washed with phosphate buffered saline (PBS) 3x for 15 minutes. Goat 
serum was used as a blocking solution for 1 hour at room temperature. Primary 
rabbit anti-PRDM4 antibody (ab156867), primary anti-PRDM5 antibody (ab79016) 
and primary anti-PRDM5 antibody (ab84572) were diluted to a 1:100 concentration 
and were added to the cells followed by overnight incubation at 4oC. The cells were 
then washed with PBS 3x for 15 minutes and secondary goat anti-rabbit antibody 
(1:100 dilution) was added to the cells with Hoechst DNA stain (1μg/ml) followed 
by 1-hour incubation at room temperature. The cells were then washed with PBS 3x 
for 15 minutes. DAKO mounting medium with was used to mount glass coverslips 
onto the slides. The slides were then wrapped in foil and were left to dry out at room 
temperature in the dark for 2 hours. They were then viewed using the Leica 
Microsystems CMS confocal microscope. 
4.3.10. Immunohistochemical labeling of human cornea 
Immunohistochemistry was performed in Addenbrooke’s hospital, Cambridge, UK. 
Cornea were fixed in formalin and embedded in paraffin for processing using 
LEICA BondTM automated system with LEICA Bond Polymer Refine Detection kit 
according to the manufacturer’s instruction. Bond Polymer Refine Detection kit is a 
biotin-free, polymeric horseradish peroxidase (HRP)-linker antibody conjugate 
system for the detection of tissue-bound mouse and rabbit IgG’s. All sections were 
subjected to antigen heat retrieval at 100oC for 20 minutes prior to staining 
procedure using either Epitope retrieval solution 1 (pH 6.0) for anti-PRDM4 
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antibodies or Epitope retrieval solution 2 (pH9.0) for anti-PRDM5 antibodies.  Both 
antibodies were used at 1:500 dilutions. The staining program used was as follows: 
1) peroxide block - 5min, 2) primary antibody was applied for 30 minutes, 3) 
polymer HRP was added for 8 minutes, 4) mixed 3,3’-diaminobenzidine (DAB) was 
added for 10 minutes.  Sections were counterstained with haematoxylin for 5 
minutes to visualize nuclei. 
4.4. Results 
4.4.1. Reverse transcriptase polymerase chain reaction detection of positive-
regulatory domain proteins gene expression 
Expression of PRDMs was detected: in the 9.5 mm human cornea - PRDMs 1, 2, 4, 
5 and 10, in the corneal endothelium alone - PRDMs 2, 4, 5 and 10, in cultured 
hCECs - PRDMs 1, 2, 4, 5, 8 and 10 and in HCEC-12 cells - PRDMs 1, 2, 3 
(MECOM), 4, 5, 6, 8, 10, 11 and 16 (See Figure 26 and Table 15). PRDMs 2, 4, 5 
and 10 were consistently expressed by all samples. The HCEC-12 cells expressed 
the largest number of PRDMs (10 PRDMs in total).  
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Figure 26 – Positive-regulatory domain (PRDM) protein gene expression profile 
in different samples. 
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Table 15 – PRDM gene expression. + denotes expression of mRNA.  
 Normal Cornea DM/CECs Primary hCECs Immortalised hCECs (HCEC-12) 
PRDM1 +  + + 
PRDM2 + + + + 
PRDM 3 (MDS1)     
PRDM3 (MECOM)    + 
PRDM4 + + + + 
PRDM5 + + + + 
PRDM6    + 
PRDM7     
PRDM8   + + 
PRDM9     
PRDM10 + + + + 
PRDM11  + (Weak)  + 
PRDM12     
PRDM13     
PRDM14     
PRDM15     
PRDM16    + 
Note: Descemet’s membrane (DM); corneal endothelial cells (CECs); human corneal endothelial cells (hCECs).
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4.4.2. Immunofluorescence detection of positive-regulatory domain proteins 4 
and 5 expression 
Protein expression of positive-regulatory domain (PRDM) proteins 4 and 5 was 
detected on HCEC-12 cells and passage 2 hCECs (See Figure 27 and Figure 28). 
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Figure 27 – Positive-regulatory domain zinc finger protein (PRDM) 4 and 
Na+/K+ ATPase expression by HCEC-12 cells (A and B) and by passage 2 
cultured human corneal endothelial cells (hCECs) [C]. 
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Figure 28 – Positive-regulatory domain zinc-finger protein 5 (PRDM5) 
expression by HCEC-12 cells (A) and PRDM5 and Na+/K+ ATPase expression 
by passage 2 cultured human corneal endothelial cells (hCECs). 
4.4.3. Immunohistochemistry 
Immunohistochemical analysis of human corneal cross-sections showed that there 
was no differential expression of PRDMs 4 and 5 within the center and the periphery 
of the cornea (See Figure 29). 
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Figure 29 – Uniform expression of positive-regulatory domain protein 4 
(PRDM4) throughout the entire corneal cross-section including central and 
peripheral corneal endothelium (x100) [A], positive-regulatory domain zinc-
finger protein 4 (PRDM4) expression throughout the central corneal 
endothelium (x400) [B], uniform expression of positive-regulatory domain zinc-
finger protein 5 (PRDM5) throughout the entire corneal cross-section including 
the central and the peripheral corneal endothelium. Positive expression is also 
visible throughout the corneal epithelium (x100) [C], PRDM5 expression is 
visible throughout the central corneal endothelium (x400) [D]. 
4.5. Discussion 
Human corneal endothelial cells are generally notorious for their deficient 
proliferative ability. There is a significant lack of understanding of the mechanisms 
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that regulate proliferation both in vivo and in vitro of this cell monolayer that is so 
crucial for normal vision. Understanding the mechanisms that control proliferation 
of these cells would help in improving the in vitro corneal endothelial cell culture 
and will open up the possibility to use cell therapy as a novel treatment method for 
corneal endothelial disorders. Therefore, studying the expression of PRDM proteins, 
which are known to control differentiation and reprogramming of a wide variety of 
cells (Fog, et al., 2012), in the human corneal endothelium can open new doors in 
better understanding the mechanisms that control hCEC proliferation and can lead to 
the development of new strategies for enhancing hCEC culture.  
So far the expression and role of PRDMs in the human cornea have not been studied. 
Only PRDM5 has been shown to play an important role in the development and 
maintenance of the extracellular matrix in the human cornea and mutations in 
PRDM5 lead to Brittle Cornea Syndrome (Burkitt Wright, et al., 2011). And a novel 
finding has shown that PRDM4 deletion causes a gender-specific abnormal corneal 
morphology (Phenotyping Centre - MRC Harwell web reference).   
Therefore, this chapter endeavored to study the expression of PRDM proteins in the 
human corneal endothelium and to allow for future studies on the role of PRDM 
proteins in proliferation and cell fate control in hCECs. This expression profile has 
not been shown previously. In this chapter it was found that PRDMs 1, 2, 4, 5 and 
10 were consistently expressed by the human corneal endothelium of whole corneas. 
In cultured passage 2 primary hCECs additionally expressed PRDM8. Intriguingly, 
cultured immortalized human corneal endothelial cell line HCEC-12 expressed 
PRDMs 3 (MECOM), 6, 8, 11 and 16 in addition to PRDMs 1, 2, 4, 5, 8 and 10. 
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These findings suggest that there might be interplay between different PRDM 
proteins in the control of human corneal endothelial cell proliferation since a larger 
number of PRDMs is expressed in HCEC-12 cells that have a very high proliferative 
capacity. Some PRDMs are involved in regulating TGF-β signaling, namely PRDM3 
and PRDM16 can bind to and repress Smads, and in regulating Notch signaling 
(Fog, et al., 2012). TGF-β signaling and Notch signaling have been shown to be very 
important in the proliferation, senescence and morphological transformation in 
primary hCECs (Chen, et al., 1999; Joyce, et al., 2002; Okumura, et al., 2013; Li, et 
al., 2013). 
PRDM1 drives terminal B cell differentiation (Fog, et al. 2012) and controls the 
germ cell lineage (Ohinata, et al., 2005). However, there is currently no information 
available on the role of PRDM1 in corneal development. PRDM2 has been shown to 
act as a tumor suppressor and to inactivate a number of tumors (Liu, et al., 2012; 
Tan, et al., 2014; Zhang, et al., 2015). Its role and function in the cornea has not yet 
been reported also. In this study PRDMs 4 and 5 were expressed by all samples that 
were tested. PRDM4 has been reported to interact with p75NTR and control neural 
development (Chittka and Chao, 1999). It acts as a transcriptional repressor (Chittka, 
et al., 2004), controls neural stem cell proliferation and differentiation (Chittka, et 
al., 2012) and its activity is regulated by epidermal growth factor (EGF) and nerve 
growth factor (NGF) (Chittka, 2013). It has been shown that there are human corneal 
endothelial cell populations, which express p75NTR, and which also possess very 
high proliferative capacity (Hara, et al., 2014). Therefore, knowing that progenitor 
hCECs express p75NTR it was of interest to explore the expression and role of 
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PRDM4 in the corneal endothelium and to see whether it is specifically expressed 
only in progenitor p75NTR expressing hCECs and whether it could be used as a 
progenitor cell marker of the corneal endothelial progenitor cells. Both PRDMs 4 
and 5 were consistently expressed in all samples that were tested including whole 
cornea and primary and immortalized cultures, however, there was no differential 
expression of these proteins between the central and peripheral endothelium 
suggesting that there was no difference in the expression of these proteins between 
hCEC progenitors and mature hCECs.  
HCEC-12 cells showed a very significant difference in their PRDM expression 
profile compared to the contact-inhibited CE of the normal cornea and compared to 
the primary cultured hCECs, which could be due to the SV40 immortalization. 
HCEC-12 expressed PRDM3 (MECOM isoform), which seems to control 
haematopoietic stem cell (HSC) quiescence has been associated with controlling the 
survival of the primary myeloid leukemia stem cells (Eppert, et al., 2011). Its 
expression in HCEC-12 cells could be due to their immortalization with the SV40 
virus as part of the re-programming of these cells. Davis, et al. (2006) demonstrated 
in their study that PRDM6 promotes proliferation in smooth muscle cells while 
PRDMs 8 and 10 have been shown to play an important role in the mouse 
embryonic development (Kinameri, et al., 2008; Park and Kim, 2010). Moreover, 
PRDM8 has been implicated in specific aspects of eye development and 
differentiation of specific cell types within the visual system in mice (Komai, et al., 
2009 and Jung, et al., 2015). However, its role in the corneal endothelium has not yet 
been elucidated and it is unclear whether it is expressed in cultured primary hCECs 
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as a result of re-programming occurring in the absence of contact inhibition during 
culture. PRDM16 plays an important role in controlling adipose, haematopoietic and 
cardiac tissue (Seale et al. 2007; Kajimura et al. 2009; Arndt et al. 2013; Chi and 
Cohen 2016) and regulates oxidative stress in haematopoietic and neural stem cells 
and is involved in haematological malignancies (Chi and Cohen, 2016). Hence, 
PRDM16 could be contributing to the re-programming of the HCEC-12 cells after 
their immortalization. The genes for PRDMs 1, 2, 3 and 16 each encode two 
different isoforms, whose biological roles in the control of proliferation are opposite 
(Zazzo, et al., 2013). Hence, it is of great importance to study the distribution of 
these different isoforms in the human corneal endothelium and in cultured human 
corneal endothelial cells in order to understand their role in the control of 
proliferation and differentiation.  
In this study it was observed that some alterations occurred in the PRDM expression 
profile following in vitro culture and as a result of immortalization of the hCECs. 
This is very interesting because it was experimentally demonstrated that the contact-
inhibited CE monolayer from a normal cornea expressed only PRDMs 1, 2, 4, 5 and 
10, whereas, primary cultured and immortalized corneal endothelial cells expressed 
more PRDMs in addition to these expressed by the contact-inhibited monolayer. 
Since in the primary cultured hCECs contact inhibition has been disrupted by trypsin 
dissociation the cells have been sensitized to the mitogenic effect of growth factors 
present in the culture medium and started proliferating, as evidenced by reaching 
confluence being passaged over 2 times. In addition, the immortalization of the 
HCEC-12 cells via transfection with the small t-antigen and large T-antigen of the 
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SV40 virus is known to produce high cell proliferation. Therefore, these results 
might seem to indicate that the increased proliferation capacity in human corneal 
endothelial cells is accompanied by expression of additional PRDM proteins. 
Although, currently there is no available information on the role of PRDM proteins 
in the human corneal endothelium except for PRDM4 and PRDM5. Therefore, a 
further characterization of protein expression in the human cornea of PRDMs 4 and 
5 was performed in this study in order to test their distribution within the corneal 
endothelial cell monolayer. And it was found that these two proteins were uniformly 
expressed throughout the central and peripheral corneal endothelium. 
In summary, PRDMs are known to regulate proliferation, differentiation and 
senescence of haematopoietic stem cells, embryonic stem cells and induced 
pluripotent stem cells and have been implicated in some leukaemias. Therefore, it is 
of great interest to study the expression of PRDM proteins in the human corneal 
endothelium and to further elucidate their role in this particular cell type and their 
co-expression with p75NTR. 
4.6. Conclusion 
A wide range of PRDM expression was detected in a human cornea and cultured 
primary and immortalized human corneal endothelial cells. PRDMs 1, 2, 4, 5 and 10 
were consistently detected in all samples tested in this study. However, primary 
cultured and immortalized human corneal endothelial cells expressed some 
additional PRDMs suggesting that in vitro culture, disruption of contact inhibition 
and increased proliferation might be accompanied by a difference in the PRDM 
expression profile, hence implying that PRDMs might have a role in the control of 
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hCEC proliferation and re-programming. No differential expression of PRDM 4 or 5 
was found between the central and the peripheral endothelium of normal human 
corneas.  Studying the expression of PRDM proteins in hCECs opens an interesting 
avenue for further exploration of their role in corneal endothelial cell development, 
proliferation and homeostasis and for helping the generation of hCECs for 
therapeutic purposes in future studies. 
5. CONCLUDING REMARKS 
Transplantation of corneal endothelial cells as a cell-therapy approach for treating 
corneal endothelial disorders has been the focus of many researchers in recent years. 
The human corneal endothelial cells are arrested in G1 phase of the cell cycle 
(Joyce, et al., 1996b; Chen, et al., 1999). This G1-phase arrest is mediated by TGF-β 
and contact inhibition (Joyce and Zeiske, 1997; Joyce, et al., 2002). Corneal 
endothelial cell culture plays a central role as a cell source for hCEC transplantation 
and therefore many studies have attempted to optimize the in vitro culture conditions 
so that sufficient numbers of cells can be generated and used for transplantation. 
Cells from both young and old donors seem to be able to proliferate in culture after 
stimulation with appropriate culture conditions in response to foetal bovine serum 
and FGF (Senoo and Joyce, 2000b; Zhu and Joyce, 2004). However, some age-
related differences that negatively affect the cell cycle progression exist, such as 
increased expression of p16 and p21 in cells from older donors (Joyce and Harris, 
2010; Enomoto, et al., 2006). Different methods of isolation, culture media, growth 
factors and substrates have been tested for optimal corneal endothelial cell culture 
(Engelmann, et al., 1988; Engelmann and Friedl, 1989; Rieck, et al., 1995; Peh, et 
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al., 2011; Okumura, et al., 2015; Peh, et al., 2015a and 2015b; Valtink, et al., 2016) 
including serum-free culture (Bednarz, et al., 2001; Møller-Pedersen, et al., 2001), 
which have yielded some degree of success but hCEC culture still remains a 
challenge. 
It has been speculated for quite some time that the peripheral areas of the corneal 
endothelial monolayer harbour progenitor cells with high proliferative potential, 
which could be used for propagation in culture and later used for transplantation. 
Some studies have shown that hCECs, isolated from both the centre and the 
peripheral endothelium, retain proliferative potential (Konomi, et al., 2005). 
However, the cells from the peripheral region seem to possess higher proliferative 
potential regardless of donor age (Mimura and Joyce, 2006). Moreover, in another 
study by Hirata-Tominaga, et al., (2013) it was shown that leucine-rich repeat-
containing G-protein coupled receptor 5 (LGR5) is uniquely expressed in the 
peripheral region of the endothelium and that the LGR5 expressing cells have some 
stem cell properties. Later on Okumura, et al., (2014b) showed that roof plate-
specific spondin 1 (R-spondin1), which is an LGR5 ligand significantly upregulated 
corneal endothelial cell proliferation. In addition, He, et al., (2012) showed that there 
are corneal endothelial cells that have high proliferative capacity and migrate 
towards the corneal center and as they migrate they fully differentiate and loose their 
proliferative capacity. A number of other studies have also identified the existence 
of human corneal endothelial cell progenitor cells (Whikehart, et al., 2005; 
McGowan, et al., 2007; Hara, et al., 2014; Walshe and Harkin, 2014). However, a 
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cell bank of clinically usable cells suitable for transplantation testing has not been 
established yet. 
The development of cell-based therapy technologies has been a major focus in the 
search of new treatments for corneal blindness. These have been classified in a 
number of different sub-groups based on the cell source and various methods for 
applying them to treat corneal blindness, which include somatic cells, immortalized 
cells, in vitro and in vivo gene modification using viral vectors, genome editing, 
stem cells, iPSCs and cell differentiation and three-dimensional technologies 
(Mount, et al., 2015). Stem cells and iPSCs have been widely researched and 
reviewed and have shown some promise for clinical application but there are still 
many challenges remaining before these novel treatment methods can be translated 
to clinical use (Yuan and Fan, 2015). One of the biggest challenges to be overcome 
is the establishing of a suitable cell source for hCECs. In this study we used primary 
and immortalized hCECs in order to demonstrate the plausibility for hCEC 
transplantation to human corneas. However, both of these have certain limitations. In 
the case of primary cells the lack of proliferative capacity severely limits the amount 
of cells that can be generated for cell transplantation. Whereas, in the case of the 
immortalized cells they can be easily cultured and large numbers of functional cells 
can be generated but their carcinogenic properties and uncontrolled proliferation can 
cause complications including tumor formation and possible increased intraocular 
pressure due to cell flaking and obstructing the trabecular drainage system. 
Interestingly, research has shown that different methods of immortalization may 
provide a means for enabling in vitro expansion of the cells while abolishing their 
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proliferative capacity when transplanted in vivo. Stevanato, et al., (2009) showed 
that the c-Myc transcription factor/mutant estrogen receptor (cMycERTAM) transgene 
immortalization is very suitable for clinical application because it is conditional and 
is based on the presence of 4-hydroxytamoxifen. Therefore, this enables the cell 
proliferation to be activated when the cells are cultured but after in vivo 
transplantation when 4-hydroxytamoxifen is no longer present this proliferative 
potential is lost. Further research into different cell immortalization techniques 
might hold a significant potential for the future development of a cell-therapy 
approach for treating corneal blindness but extensive testing both in in vitro and in 
vivo models is required before it can be translated to clinical application. 
Even though there have been significant advances in the in vitro culture of hCECs 
and in the identification and isolation of human corneal endothelial progenitor cells, 
which seem to possess higher proliferative capacity than the fully differentiated 
hCECs, a cell bank for clinical use in transplantation and treatment of patients has 
not yet been established. This study has provided a human model for hCEC 
transplantation testing that can be successfully used for cell-therapy evaluation 
studies and producing clinically relevant data. Additionally, using this model it was 
demonstrated that after seeding to the posterior corneal stroma hCECs are able to 
regenerate a fully functional CE monolayer and to restore normal corneal thickness, 
which is a very significant finding for cases when the DM has to be removed prior 
transplantation due to fibrosis or other types of damage to the DM. However, further 
testing and evaluation of cell morphology, potential abnormal collagen deposition 
and fibrosis, cell migration to other parts of the cornea, corneal endothelial cell 
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culture optimization and corneal endothelial marker expression profiling are 
required before this treatment can be taken to clinical trials. Moreover, this study 
demonstrated the differential expression of PRDM proteins in normal CE and 
cultured hCECs with variable proliferative capacity due to disruption of the contact 
inhibition following trypsin dissociation. Further understanding of the role of the 
PRDM proteins in the proliferation and differentiation of hCECs could opens novel 
avenues for enhancing corneal endothelial cell culture and is another stepping stone 
towards the development of a cell-therapy approach for treating corneal endothelial 
disorders. 
5.1. Final conclusions 
1) The study established an in vitro human corneal endothelial decompensation 
model with a detailed description of stromal behaviour of human corneas 
after transfer from immersion to air-interface organ culture. 
2) Demonstrated the potential of cultured hCECs to restore normal 
physiological stromal thickness after cell transplantation using an in vitro 
human model. 
3) It was experimentally shown that the posterior human corneal stroma is a 
suitable substrate for direct transplantation of cultured hCECs following the 
complete removal of the DM/Endothelium complex, which allows successful 
cell attachment, monolayer formation and restoration of normal CE function.  
4) The work has detailed a methodology for the assessment of the functional 
potential of cultured hCECs by using cadaveric human donor corneas an in 
vitro human corneal endothelial decompensation model. 
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5) The limitations related to the proliferative capacity of hCECs prompted the 
exploration of PRDM protein expression in hCECs. Positive expression of a 
number of PRDM proteins in the normal CE (contact inhibited) and in 
cultured hCECs (contact inhibition released via trypsin dissociation) was 
successfully demonstrated with an interesting observation of differential 
expression between the normal CE and cultured hCECs suggesting that 
PRDMs might play a role in the control of hCEC proliferation. 
5.2. Future work and limitations 
The two biggest limitations in the field of cell therapy research remain (1) the 
limited potential of hCECs for in vitro expansion due to poor proliferative 
capacity and (2) a suitable in vitro human model that will enable longer post-
transplantation study periods of 1 month or more follow-ups. Improvements on 
the first limitation are necessary and will enable researchers to generate 
enough clinical-grade hCEC cultures for hCEC transplantation studies. 
Improvements on the second limitation will enable long-term studies of hCEC 
behavior post-transplantation such as morphological changes, abnormal 
collagen secretion, proliferation, spontaneous transformation, carcinogenic 
properties and immune response. In order to address these the following future 
work is proposed: 
1) Optimize the in vitro human corneal model of endothelial decompensation 
possibly by using an irrigation system that allows constant perfusion of the 
corneas while maintaining constant pressure in addition to a spraying device 
that would allow moistening of the epithelial side of multiple corneas at the 
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same time. Employing this system will ensure the proper hydration of both 
the endothelial and the epithelial side of the cultured corneas and 
maintenance of constant intraocular pressure that will preserve the viability 
of the corneal endothelial cells for a longer incubation period longer than 14 
days. 
2) Establish in vitro models with a longer life span by using younger donor 
corneas. 
3) Further test the use of hCECs that have obtained a spindle-shaped 
morphology after in vitro culture as a potential source for cell therapy and 
test their capacity to revert back to normal phenotype after transplantation. 
4) Study cell fate of hCECs including morphological changes and proliferative 
potential following cell therapy. 
5) Test the long-term physiological effects on stromal hydration and corneal 
transparency following cell therapy over a period of at least 1 month. 
6) Safety studies on immune rejection and on the potential of uncontrolled 
proliferation and tumor formation following cell therapy. 
7) Further studies on the interaction of PRDM4 and p75NTR in hCECs and 
their role in cell development and proliferation. 
8) Develop cell culture strategies for enhancing hCEC culture for research and 
possible future use in cell therapy. 
9) Explore the possibility of using whole human eyes as a transplantation model 
rather than just a corneoscleral rim. 
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APPENDIX 1 
Table 16 - Donor cornea information sheet: 12-hour air-interface organ culture experiment.  
Cornea 
number 
Age 
(years) 
Gender Cause of death  Time of 
enucleation 
Period in 
Eye Bank 
storage  
Endothelial cell 
density (ECD) 
1 89  Female Not reported 28.02.2014 31 days 1670 cells/mm2 
2 76  Female Intracranial – 1a Acute Spontaneous 
CVA2 Hypertension  
11.10.2014 29 days 1840 cells/mm2 
3* 65  Female 1a Bowel infarction & Advanced 
polycystic Kidney and Liver Disease 
30.10.2014 29 days Not available 
4** 29  Female Hypoxic brain damage – all causes 06.11.2014 35 days Not available 
5 74  Male Not reported 18.05.2015 57 days 2200 cells/mm2 
6 74  Male Not reported 18.05.2015 57 days 2000 cells/mm2 
7 65  Female 1a Bowel infarction & Advanced 
polycystic Kidney and Liver Disease 
30.10.2014 29 days Not available 
8 29  Female Hypoxic brain damage – all causes 06.11.2014 35 days Not available 
9 76  Female Intracranial – 1a Acute Spontaneous 
CVA2 Hypertension  
11.10.2014 29 days Not available 
Note: Corneas 3 and 4 were first used in the normal group (intact Descemet’s membrane/Endothelium complex). After the OCT 
measurements were taken the Descemet’s membrane/Endothelium complex from both corneas was removed and the corneas were 
included in the decompensated group. 
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Table 17 - 12-hour air-interface organ culture experiment results: in vitro corneal model validation. 
In vitro air-
interface organ 
culture 
Normal corneas – ECD - 2002 ± 
357.99 cells/mm2 (n=6) 
Decompensated corneas (n=5) Post hoc t test (Bonferroni 
corrected) 
Time (hours) Corneal 
thickness (µm) 
± SD 
Percentage 
Corneal 
thickness 
decrease ± SD 
Corneal 
thickness (µm) 
± SD 
Percentage 
Corneal 
thickness 
decrease ± SD 
Corneal 
thickness 
comparison (P 
value) 
Percentage 
thickness 
decrease (%) 
comparison (P 
value) 
0 1092.74 ± 
108.03  
- 1128. 51 ± 
98.91  
- Non-significant - 
1 1020.16 ± 
111.46  
6.47 ± 6.67 % 1096.29 ± 
105.93  
2.78 ± 5.7 % *p<0.0001 *p<0.0001 
2 943.67 ± 106.99  13.4 ± 7.42 % 1054.54 ± 
121.46  
6.61 ± 6.53 % *p<0.0001 *p<0.0001 
3 786.39 ± 101.63  27.6 ± 9.48 % 965.15 ± 105.59  14.21 ± 8.45 % *p<0.0001 *p<0.0001 
4 721.13 ± 89.91  33.44 ± 9.73 % 927.54 ± 106.6  17.62 ± 7.9 % *p<0.0001 *p<0.0001 
5 636.44 ± 94.11  41.24 ± 9.75 % 929.42 ± 83.5  17.34 ± 6.86 % *p<0.0001 *p<0.0001 
6 594.31 ± 78.7  44.96 ± 9.7 % 934.7 ± 76.37  16.82 ± 6.93 % *p<0.0001 *p<0.0001 
7 560.35 ± 87.02  47.99 ± 10.75 % 934.3 ± 68.74  16.78 ± 7.24 % *p<0.0001 *p<0.0001 
8 555.86 ± 81.7  48.37 ± 10.63 % 942.62 ± 68.7  16 ± 7.77 % *p<0.0001 *p<0.0001 
9 566.33 ± 90.68  47.42 ± 11.14 % 945.85 ± 67  15.7 ± 7.84 % *p<0.0001 *p<0.0001 
10 559.13 ± 84.03  48.12 ± 10.48 % 941.04 ± 58.61  16.06 ± 8.04 % *p<0.0001 *p<0.0001 
11 558.68 ± 85.1  48.15 ± 10.57 % 911.07 ± 83.21  18.67 ± 10.02 % *p<0.0001 *p<0.0001 
12 557.51 ± 72.64  48.27 ± 9.78 % 903.6 ± 86.51  19.27 ± 10.87 % *p<0.0001 *p<0.0001 
Note: *p<0.0003 was considered statistically significant; endothelial cell density (ECD); standard deviation (SD). 
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Table 18 – Donor cornea information sheet: 14-day air-interface organ culture experiment. 
Cornea 
number 
Age (years) Gender Cause of death 
as specified on 
donor 
information 
sheet 
Time of 
enucleation 
(dd/mm/yyyy) 
Period in Eye 
Bank storage 
Endothelial cell 
density (ECD) 
1 68 Male 1a Acute MI 1B 
Coronary Artary 
Disease 2 Renal 
Failure & 
Diabetes 
30.10.2013 25 days 1600 cells/mm2 
2 72 Female Intracranial 
haemorrhage 
19.10.2013 36 days 1500 cells/mm2 
3 64 Male Myocardial 
infarction 
17.10.2013 38 days 1600 cells/mm2 
4 69  Female Lung cancer 16.12.2013 39 days 2172 cells/mm2 
5 75  Female Peritonitis  02.10.2013 21 days 1900 cells/mm2 
6 75  Male Prostate Cancer 02.10.2013 21 days 1975 cells/mm2 
7 64 Male Myocardial 
infarction 
17.10.2013 38 days 1200 cells/mm2 
8 69  Female Lung cancer 16.12.2013 39 days 2207 cells/mm2 
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Table 19 –14-day air-interface organ culture experiment results: in vitro corneal model validation. 
In vitro air-
interface 
organ culture 
Normal corneas – ECD – 1718 ± 
306.31 cells/mm2 (n=4) 
Decompensated corneas (n=4) Post hoc t test (Bonferroni 
corrected) 
Time (days) Corneal 
thickness (µm) 
± SD 
Percentage 
corneal thickness 
(%) decrease ± 
SD 
Corneal 
thickness (µm) ± 
SD 
Percentage 
corneal thickness 
(%) decrease ± 
SD 
Corneal 
thickness 
comparison 
(P value) 
% thickness 
decrease 
comparison (P 
value) 
0 876.41 ± 88.62  - 918.68 ± 98.27 - *p<0.0001 - 
1 582.59 ± 70.31 33.32 ± 6.89 879.73 ± 109.58 4.21 ± 6.62 *p<0.0001 *p<0.0001 
2 571.33 ± 113.51 33.98 ± 16.01 844.32 ± 99.93 7.89 ± 6.53 *p<0.0001 *p<0.0001 
3 587.77 ± 114.76 31.98 ± 16.79 837.72 ± 118.48 8.89 ± 7.58 *p<0.0001 *p<0.0001 
4 583.29 ± 110.75 32.90 ± 14.55 823.74 ± 95.56 10.14 ± 7.32 *p<0.0001 *p<0.0001 
5 610.04 ± 91.18 29.69 ± 12.93 817.02 ± 73.37 10.74 ± 5.86 *p<0.0001 *p<0.0001 
6 627.87 ± 100.48 27.44 ± 14.82 848.79 ± 87 7.30 ± 7.29 *p<0.0001 *p<0.0001 
7 657.12 ± 86.17 24.07 ± 13.3 780.83 ± 109.63 14.88 ± 9 *p<0.0001 *p<0.0001 
8 667.02 ± 105.57 22.66 ± 16.57 831.761 ± 102.31 9.43 ± 5.7 *p<0.0001 *p<0.0001 
9 633.35 ± 107.93 26.50 ± 16.67 821.11 ± 108.69 10.50 ± 8.53 *p<0.0001 *p<0.0001 
10 640.30 ± 104.62 25.77 ± 16.06 809.48 ± 89.43 11.54 ± 8.42 *p<0.0001 *p<0.0001 
11 729.63 ± 68.08 15.80 ± 12.2 828.89 ± 95.91 9.64 ± 6.25 *p<0.0001 *p<0.0001 
12 681.97 ± 91.76 21.22 ± 14.57 798.11 ± 90.92 12.72 ± 9.27 *p<0.0001 *p<0.0001 
13 758.68 ± 64.38 12.67 ± 10.75 820.20 ± 81.8 10.41 ± 6.51 *p<0.0001 *p<0.0001 
14 746.29 ± 104.34 14.39 ± 12.13 826.81 ± 96.29 9.83 ± 6.77 *p<0.0001 *p<0.0001 
Note: *p<0.002 was considered statistically significant; endothelial cell density (ECD); standard deviation (SD). 
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APPENDIX 2 
Table 20 - Donor information sheet for all corneas that were used for primary cultures. 
Cornea 
number 
Age 
(years) 
Gender  Cause of death Time of enucleation  Period in 
storage  
1 73 Female Pulmonary Fibrosis 09.02.2014 59 days 
2 73 Female Pulmonary Fibrosis 09.02.2014 59 days 
3 63  Female Infections – 1a Urinary Tract Infection  14.03.2014 39 days 
4 82  Female Cerebral Infarction 12.03.2014 34 days 
5 67  Male Cardiovascular 03.09.2014 34 days 
6 67  Male Cardiovascular 03.09.2014 34 days 
7 81  Female Renal failure 04.09.2014 33 days 
8 75 Male - 30.01.2014 69 days 
9 75 Male - 30.01.2014 69 days 
10 43 Male CVA 20.03.2014 21 days 
11 43 Male CVA 20.03.2014 21 days 
12 74  Female Metastatic Esophageal Cancer 28.02.2014 46 days 
13 80  Male Intracranial haemorrage 15.03.2014 31 days 
14 86  Female Mettastatic Carcinoma of the Breast 11.03.2014 35 days 
15 63  Male Intracranial haemorrage 29.03.2014 43 days 
16 - - - - - 
17 - - - - - 
18 81  Female Renal failure 04.09.2014 33 days 
19 45  Female Not specified 05.12.2014 88 days 
20 73  Female Not specified 19.12.2014 74 days 
21 73  Female Not specified 19.12.2014 74 days 
22 83 Female Pneumonia 20.10.2014 73 days 
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APPENDIX 3 
Table 21 – Donor cornea information sheet. All corneas had their DM/Endothelium complex removed and were used for 
hCEC transplantation testing. 
Cornea number Age (years) Gender Cause of death  Time of 
enucleation 
(dd/mm/yyyy) 
Period in Eye 
Bank storage  
1 46  Female Intracranial haemorrhage 06.06.2015 60 days 
2 57  Male Unknown 10.06.2015 56 days 
3 52  Female Cancer (other than brain tumour) 12.06.2015 54 days 
4 52  Female Cancer (other than brain tumour) 12.06.2015 54 days 
5 78  Male Cancer (other than brain tumour) 26.06.2015 30 days 
6 78  Male Cancer (other than brain tumour) 26.06.2015 30 days 
7 46  Female Intracranial haemorrhage 06.06.2015 60 days 
8 67  Female Hypoxic brain damage - all causes 12.06.2015 54 days 
9 67  Female Hypoxic brain damage - all causes 12.06.2015 54 days 
10 76  Female Septicaemia 22.06.2015 44 days 
11 76  Female Septicaemia 22.06.2015 44 days 
12 73 Male Unknown  21.08.2014 21 days 
13 73 Male Unknown  21.08.2014 21 days 
14 67  Male Cardiovascular 03.09.2014 34 days 
15 67  Male Cardiovascular 03.09.2014 34 days 
16 81  Female Renal failure  04.09.2014 33 days 
17 81  Female Renal failure  04.09.2014 33 days 
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Table 22 - hCEC transplantation experiment results: cell therapy evaluation during a 12-hour air-interface organ culture. 
In vitro air-
interface 
organ culture 
Group 1 (n=6) - seeded with 2070 
cells/mm2 [HCEC-12] 
Group 2 (n=5) - seeded with 
1740 cells/mm2 [passage 0 
primary hCECs] 
Group 3 (n=6) - seeded with 1036 
cells/mm2 [passage 2 primary 
hCECs]  
Time (hours) Corneal 
thickness (µm) ± 
SD 
Percentage 
corneal thickness 
decrease (%) ± 
SD 
Corneal 
thickness (µm) 
± SD 
Percentage 
corneal 
thickness 
decrease (%) ± 
SD 
Corneal 
thickness (µm) ± 
SD 
Percentage 
corneal 
thickness 
decrease (%) ± 
SD 
0 1218.02 ± 153.65  - 1100.86 ± 
86.15  
- 1143.56 ± 69.23  - 
1 1089.67 ± 122.48  10.06 ± 7.71 % 987.87 ± 
106.25  
10.32 ± 5.65 % 1051.45 ± 72.37  7.95 ± 5.26 % 
2 992.68 ± 101.48  17.72 ± 9.58 % 900.24 ± 98.98  18.33 ± 4.83 % 886.27 ± 83.81  22.5 ± 5.34 % 
3 878.41 ± 129.58  26.62 ± 14.65 % 767.1 ± 109.63  30.38 ± 7.71 % 781.06 ± 69.66  31.69 ± 4.5 % 
4 744.08 ± 121.94  38.06 ± 12.13 % 656.59 ± 97.96  40.47 ± 6.64 % 686.74 ± 76.12  39.89 ± 6.05 % 
5 656.55 ± 137.55  45.14 ± 13.67 % 560.77 ± 73.63  49.02 ± 5.81 % 598.67 ± 74.87  47.52 ± 6.75 % 
6 637.69 ± 138.96  46.79 ± 13.45 % 510.41 ± 86.31  53.67 ± 6.78 % 557.19 ± 66.51  51.21 ± 5.45 % 
7 569.64 ± 118.89  52.86 ± 10.01 % 474.24 ± 79.39  56.98 ± 5.99 % 553.47 ± 74.54  51.4 ± 7.35 % 
8 487.19 ± 122.93  59.75 ± 10.12% 461.39 ± 82.56  58.16 ± 6.36 % 583.11 ± 72.82  48.91 ± 6.44 % 
9 448.33 ± 85.45  62.95 ± 6.78 % 467.68 ± 92.64  57.63 ± 7.19 % 611.38 ± 84.27  46.42 ± 7.5 % 
10 457.91 ± 91.94  62.2 ± 7.48 % 474.9 ± 93.84  56.98 ± 7.24 % 612.2 ± 65.98  46.31 ± 6.3 % 
11 451.4 ± 91.86  63.76 ± 6.38 % 483.50 ± 95.77  56.14 ± 7.81 % 619.63 ± 60.97  45.67 ± 5.82 % 
12 458.91 ± 90  63.15 ± 6.14 % 489.65 ± 94.62  55.61 ± 7.44 % 613.7 ± 47.23  46.19 ± 4.61 % 
 
 
